A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Phase: PHASE1
Conditions: Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma
Sponsor: Halozyme Therapeutics

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
CLINICAL STUDY PROTOCOL 
Title: 
A Phase 1b, Randomized, Open-Label Study of PEGylated 
Recombinant Human Hyaluronidase (PEGPH20) in 
Combination With Cisplatin Plus Gemcitabine and 
PEGPH20 in Combination With Atezolizumab and 
Cisplatin Plus Gemcitabine Compared With Cisplatin Plus 
Gemcitabine in Subjects with Previously Untreated, 
Unresectable, Locally Advanced, or Metastatic 
Intrahepatic and Extrahepatic Cholangiocarcinoma and 
Gallbladder Adenocarcinoma 
Phase 
1b 
Protocol Number: 
HALO-110-101 
Original Protocol Date: 
07 March 2017 
Protocol Amendment 1 Date: 24 May 2017 
Protocol Amendment 2 Date: 12 April 2018 
Protocol Amendment 3 Date: 09 April 2019 
IND: 
102770 
Sponsor: 
Halozyme, Inc. 
11388 Sorrento Valley Road 
San Diego, CA 92121 
Office: 
 
Confidential: This document and the information it contains are the property of Halozyme, Inc. 
and are provided for the sole and exclusive use of Investigators in this clinical study. The 
information in this document may not be disclosed unless such disclosure is required by Federal 
or applicable State Law or Regulations, or unless there is prior written consent from Halozyme, 
Inc. Subject to the foregoing, this information may be disclosed only to those persons involved in 
the clinical investigation who need it, and who share the obligation not to disseminate this 
information further. 
NCT #: NCT03267940

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Placeholder for Approval Signatures 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
1. 
SYNOPSIS 
Sponsor/Company 
Halozyme, Inc.  
Protocol Number 
HALO-110-101 
Study Title 
A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase 
(PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With 
Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects 
With Previously Untreated, Unresectable, Locally Advanced or Metastatic Intrahepatic and Extrahepatic 
Cholangiocarcinoma and Gallbladder Cancers 
Study Objectives 
Note: The objectives described below will be evaluated in subjects with previously untreated 
unresectable, locally advanced, or metastatic intrahepatic and extrahepatic cholangiocarcinoma (ICC; 
ECC) and gallbladder adenocarcinoma. 
Run-in Portion 
Primary: 
• 
To assess the safety and tolerability of (1) PEGPH20 in combination with cisplatin (CIS) and 
gemcitabine (GEM) (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and 
atezolizumab (PEGCISGEMATEZO) 
Secondary: 
• 
To assess the pharmacokinetics (PK) of PEGPH20, CIS, GEM, and atezolizumab when given 
in combination 
• 
To obtain an early assessment of the antitumor activity of PEGCISGEM and 
PEGCISGEMATEZO, as assessed by objective response rate (ORR) based on Response 
Evaluation Criteria in Solid Tumors (RECIST) v1.1 
Exploratory: 
• 
To characterize changes in cancer antigen 19-9 (CA19-9) and carcinoembryonic antigen 
(CEA) from baseline 
• 
To obtain an early assessment of the antitumor activity of PEGCISGEMATEZO, as assessed 
by ORR based on Immune-Modified Response Evaluation Criteria (Immune-Modified 
RECIST) 
• 
To obtain an early assessment of the antitumor activity of PEGCISGEM and 
PEGCISGEMATEZO, as assessed by duration of response (DOR) and progression free 
survival (PFS) based on RECIST v1.1, and overall survival (OS) 
• 
To assess the treatment effect of PEGCISGEM and PEGCISGEMATEZO on plasma 
hyaluronan (HA) levels and potential biomarkers and correlate those effects with clinical 
outcome 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
• 
To assess the prognostic and/or predictive value of exploratory biomarkers 
Expansion Portion 
Primary: 
• 
To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by ORR based on RECIST v1.1 
Secondary: 
• 
To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by DOR, disease control rate (DCR; complete response [CR] + partial 
response [PR] + stable disease [SD]) and PFS based on RECIST v1.1 and OS 
• 
To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by ORR, DOR, PFS based on RECIST v1.1, and OS in subjects by 
programmed death-ligand 1 (PD-L1) expression levels 
• 
To characterize the PK of PEGPH20, CIS, GEM, and atezolizumab when given in 
combination 
• 
To characterize the PK of PEGPH20, CIS, and GEM when given in combination 
• 
To evaluate the safety and tolerability profile of PEGCISGEM and PEGCISGEMATEZO 
compared with CISGEM 
Exploratory: 
• 
To evaluate the efficacy of PEGCISGEMATEZO based on Immune-Modified RECIST, as 
assessed by ORR and DOR 
• 
To evaluate the efficacy of PEGCISGEMATEZO, as assessed by ORR and DOR based on 
Immune-Modified RECIST in subjects by PD-L1 expression levels 
• 
To evaluate the DCR of PEGCISGEMATEZO according to Immune-Modified RECIST 
• 
To assess the treatment effect of PEGCISGEM, PEGCISGEMATEZO and CISGEM on 
plasma HA levels and potential biomarkers and correlate those effects with clinical outcome 
• 
To assess the prognostic and/or predictive value of exploratory biomarkers  
• 
To characterize changes in CA19-9 and CEA from baseline 
Study Design 
This is a Phase 1b, multicenter, randomized, open-label, study of PEGCISGEM and 
PEGCISGEMATEZO treatments compared with CISGEM treatment in previously untreated subjects with 
unresectable, locally advanced or metastatic ICC, ECC, and gallbladder adenocarcinoma. 
The study design includes 2 portions: an initial Run-in portion, followed by an Expansion portion. 
The Run-in portion of this study will be used to evaluate the safety profile of the PEGCISGEM and 
PEGCISGEMATEZO treatments. The Expansion portion will evaluate the efficacy and safety of 
PEGCISGEM and PEGCISGEMATEZO treatments compared with CISGEM treatment. 
Effective with Protocol Amendment 2, all-comers (subjects unselected for tumor HA and PD-L1 
expression levels) will be enrolled in the study and subjects’ tumor samples will be tested retrospectively 
for HA and PD-L1 expression levels. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
In the Run-in portion, approximately 6 subjects will be enrolled in the PEGCISGEM arm and undergo at 
least 1 treatment cycle; thereafter, approximately 6 subjects will be enrolled in the PEGCISGEMATEZO 
arm. An additional 8 subjects may be enrolled in the Run-in portion to further assess the tolerability of 
PEGPH20 in either combination arm in order to establish an acceptable safety profile prior to the 
Expansion portion of the study. 
After the Run-in portion of the study, the Expansion portion will begin. A total of approximately 
65 subjects will be enrolled in the Expansion portion including approximately 50 subjects per Protocol 
Amendment 2 and approximately 15 additional subjects per Protocol Amendment 3. 
The treatment period will consist of 21-day cycles in both the Run-in and Expansion portions of the study. 
PEGPH20 will be administered at 3.0 μg/kg once weekly during Weeks 1-3 of all cycles in both portions 
of the study. An additional cohort of approximately 15 subjects will be enrolled in the Expansion portion 
under Protocol Amendment 3 who will receive PEGCISGEMATEZO, with PEGPH20 3.0 μg/kg 
administered twice weekly in Cycle 1 and once weekly in subsequent cycles (Table S-2), to evaluate the 
efficacy and safety of the PEGCISGEMATEZO combination treatment at a higher PEGPH20 dosing 
frequency. 
The dosing schedule for atezolizumab administration in the Run-in portion will be the same as for subjects 
in the Expansion portion with 1200 mg atezolizumab administered 1 to 3 hours after PEGPH20 on Day 1 
of each 21-day cycle for subjects receiving PEGCISGEMATEZO treatment. 
For subjects receiving PEGCISGEM and PEGCISGEMATEZO treatment (Run-in and Expansion), the 
dosing schedule for CIS and GEM is the same during both portions, with administration of 25 mg/m2 of 
CIS and 1000 mg/m2 of GEM on Day 2 and Day 9 of each cycle. 
In the CISGEM control arm (Expansion only), the dosing schedule for CIS and GEM administration will 
be 25 mg/m2 of CIS and 1000 mg/m2 of GEM on Day 1 and Day 8 of each cycle. 
Treatment in both portions of the study will continue until death, withdrawal of consent from the study, 
disease progression, or unacceptable toxicity (further details in Section 6.1.3). Radiographic disease 
response/progression will be evaluated using RECIST v1.1 (see Section 8.2.15 for details on 
imaging/radiologic evaluation and Appendix B for details on RECIST v1.1). In addition, radiographic 
disease response/progression for subjects receiving PEGCISGEMATEZO treatment will also be evaluated 
using Immune-Modified RECIST (refer to Appendix D for further details on Immune-Modified RECIST) 
due to the possibility of pseudoprogression (an initial increase in tumor burden caused by immune cell 
infiltration in the setting of a T-cell response with atezolizumab treatment). In the absence of unacceptable 
toxicity, subjects who meet criteria for disease progression per RECIST v1.1 while receiving 
atezolizumab will be permitted to continue treatment if they meet all of the following criteria: 
• 
Evidence of clinical benefit, as determined by the Investigator following a review of all 
available data 
• 
Absence of symptoms and signs (including laboratory values, such as new or worsening 
hypercalcemia) indicating unequivocal progression of disease 
• 
Absence of decline in Eastern Cooperative Oncology Group (ECOG) Performance Status that 
can be attributed to disease progression 
• 
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that 
cannot be managed by protocol-allowed medical interventions 
• 
Subject's written consent to acknowledge deferring other treatment options in favor of 
continuing study treatment at the time of initial disease progression 
Dose modifications for chemotherapy (CIS and GEM) are permitted in the Run-in and Expansion portions 
of the study. Dose interruptions are allowed for atezolizumab in both the Run-in and Expansion portions 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
of the study; however, dose modifications of atezolizumab are not allowed. PEGPH20 dose interruption 
and dose reductions are allowed in both portions of the study. Dose reduction of PEGPH20 to lower doses 
of 2.2 µg/kg and 1.6 µg/kg will be recommended if necessary based on toxicities in the Run-in portion and 
the Expansion portion. After dose reduction, the dose of PEGPH20 may be re-escalated to the prior dose 
utilized, at the Investigator's discretion, following a discussion with the Sponsor, provided there are no 
safety concerns. Dose modification guidelines are provided in Section 8.3 for PEGPH20, CIS and GEM. 
Guidance on atezolizumab dose interruption and discontinuation due to adverse events (AEs) are provided 
in the atezolizumab Investigator’s Brochure (IB). Guidance on the allowed dose reduction levels for 
PEGPH20 are provided in Section 8.3.1.3 , Table 9, and Table 10. Additional dose modification 
guidelines for CIS and GEM are provided in the Prescribing Information of these chemotherapeutic 
agents. 
In single-agent studies of PEGPH20 and in a Phase 1 combination study of PEGPH20 with GEM, the 
dose-limiting toxicities (DLTs) were musculoskeletal events (MSEs) myalgia and muscle cramping. In 
clinical studies HALO-109-102, HALO-109-201, and HALO-109-202, dexamethasone was administered 
per protocol to attenuate the severity of MSEs. Since this study (HALO-110-101) uses an 
immunotherapeutic agent (atezolizumab) and dexamethasone and other steroids may suppress an immune 
response, steroids should only be used to treat AEs in some exceptional circumstances or at the 
Investigator’s discretion as detailed in Section 10.12.3. 
PEGPH20 and atezolizumab administration must be held if steroids are administered to treat AEs and can 
only be restarted once the steroid is discontinued. The only exceptions are topical, inhaled, intranasal or 
intra-articular steroids, thyroid-replacement hormone, and mineralocorticoids, which are allowed as 
described in Section 7.2 and Section 10.12.3, and low-dose steroids as described in Section 10.12.3. 
In addition to study medication, all subjects in the PEGCISGEM and PEGCISGEMATEZO arms will also 
be administered piroxicam to reduce potential musculoskeletal symptoms often associated with PEGPH20 
administration. Piroxicam (20 mg) will be administered at least 1 hour prior to PEGPH20 administration 
on the day of dosing (timing will be at the Investigator’s discretion based on the piroxicam manufacturer’s 
Prescribing Information, institutional practices, and subject’s convenience) to minimize the severity of 
MSEs. A non-steroidal analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. Prophylactic use of a 
proton pump inhibitor is mandated for all subjects while receiving PEGPH20 (e.g., 20 mg omeprazole 
daily or over-the-counter [OTC] equivalent). Toradol may be given for severe pain as recommended in the 
Toradol Prescribing Information. Toradol should not be administered concurrently with piroxicam as per 
the Prescribing Information, as it is contraindicated to administer Toradol simultaneously with other 
nonsteroidal anti-inflammatory drugs (NSAIDs) because of the cumulative risk of inducing serious 
NSAID-related side effects. To help minimize MSEs, prescribed medication such as narcotics, muscle 
relaxants and other analgesics, OTC drugs, and physical therapy can also be used at the Investigator’s 
discretion.  
To decrease the risk of thromboembolic (TE) events, an identified risk of PEGPH20, and based on the 
incidence of TE events observed in this study to date, prophylactic enoxaparin will be administered 
subcutaneously at 1 mg/kg/day to all subjects receiving PEGPH20 including subjects in the PEGCISGEM 
and PEGCISGEMATEZO arms enrolled through Protocol Amendment 2 and the additional cohort of 
15 subjects enrolled under Protocol Amendment 3 receiving PEGCISGEMATEZO (details in 
Section 10.1.1). The dosage of enoxaparin of 1 mg/kg/day is the same as that administered in trials of 
PEGPH20 in combination with gemcitabine and nab-paclitaxel in pancreatic ductal adenocarcinoma 
(completed Study HALO-109-202 and ongoing Study HALO-109-301). 
If enoxaparin is discontinued for any reason in subjects receiving PEGPH20, PEGPH20 will also be 
discontinued. Treatment with other drugs, however, may continue at the Investigator’s discretion. 
Subjects who discontinue treatment with all study drugs (PEGCISGEM/PEGCISGEMATEZO/CISGEM) 
will have an End of Treatment Visit and enter long-term follow-up for survival. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Subjects will be assessed for AEs and clinical laboratory evaluations as graded by the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. 
An independent data monitoring committee (DMC) will periodically review safety data to protect subject 
welfare and identify potential safety signals in the Run-in and Expansion portions of the study. 
In both portions of the study, tumor response will be assessed by a local reviewer after every 3 cycles 
based on RECIST v1.1 criteria and Immune-Modified RECIST. Scans for RECIST v1.1 
and Immune-Modified RECIST may be obtained any time on or after Day 15 to allow enough time for the 
scan to be reviewed locally prior to the subject’s next scheduled dosing visit.  
A confirmatory scan is required in both portions of the study for subjects with CR or PR for confirmation 
of response. This confirmatory scan may be performed at the earliest 28 days after the date of the first 
documented response (per RECIST v1.1) (preferred) or at the next scheduled imaging timepoint, 
whichever is clinically indicated (details in Section 8.2.15).  
A confirmatory scan is also required for subjects receiving PEGCISGEMATEZO treatment to confirm 
radiological disease progression, per Immune-Modified RECIST. This confirmatory scan should be 
obtained no sooner than 28 days after the initial scan that showed progression (this can be the next 
scheduled tumor assessment scan). 
All scans for tumor assessments performed during the study should be archived in accordance with the 
standard local practice. The scans will be submitted to a central core imaging vendor selected by the 
Sponsor for potential central review at a later timepoint. 
After the End of Treatment Visit, subjects will enter long-term follow-up during which information on the 
subject’s survival and subsequent anticancer therapy will be obtained by the site every 12 weeks until the 
subject dies, is lost to follow-up, or withdraws consent. Subjects may be contacted more frequently to 
collect information on survival and subsequent anticancer therapy, as required, prior to important study 
timepoints, including DMC meetings and database locks. 
Run-in Portion 
In the Run-in portion, approximately 6 subjects will receive 3.0 µg/kg PEGPH20 on Day 1, Day 8, and 
Day 15 and 25 mg/m2 of CIS and 1000 mg/m2 of GEM administered on Day 2 and Day 9 of each 21-day 
cycle. 
After the 6 subjects are treated for at least 1 cycle without significant toxicities, the PEGCISGEMATEZO 
arm will open and subjects in this arm will receive 3.0 µg/kg PEGPH20 on Day 1, Day 8, and Day 15 in 
combination with 1200 mg atezolizumab on Day 1 and 25 mg/m2 of CIS and 1000 mg/m2 of GEM 
administered on Day 2 and Day 9 of each 21-day cycle.  
PEGPH20 dose reduction to a lower dose of 2.2 µg/kg or 1.6 µg/kg will be performed if necessary. 
An additional 8 subjects may be enrolled in the Run-in portion to further assess the tolerability of either 
combination arm with PEGPH20 in order to establish an acceptable safety profile prior to the Expansion 
portion of the study. 
The Sponsor in collaboration with the treating investigators will review all available safety data from all 
subjects in the Run-in portion, and the Sponsor will determine if the doses/tolerability profile is 
acceptable. 
DLT evaluation of PEGCISGEM or PEGCISGEMATEZO treatments at a given PEGPH20 dose level will 
be carried out during DLT evaluation period (i.e., Cycle 1) as follows: 
Initially 3 subjects will be enrolled: 
• 
If ≤1 subjects experiences a DLT then 3 additional subjects will be enrolled. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
− 
If ≤1 subject experiences a DLT among the 6 enrolled subjects then the combination 
evaluated (PEGCISGEM or PEGCISGEMATEZO) will be considered safe. 
− 
If ≥2 subjects experience DLTs then PEGPH20 dose will be de-escalated to the next 
lower dose level (see Table S-1) and additional subjects (up to a total of 6) will be 
enrolled and evaluated. 
• 
If ≥2 subjects experience a DLT, then PEGPH20 dose will be de-escalated to the next lower 
dose level and additional subjects (up to a total of 6) will be enrolled and evaluated. 
• 
If the combination of PEGCISGEM is found to be safe and tolerable, the 
PEGCISGEMATEZO arm will be opened at the same PEGPH20 dose level found to be safe 
and tolerable in the PEGCISGEM arm, and the tolerability of this combination will be 
evaluated following the steps outlined earlier. 
• 
The highest PEGPH20 dose level found to be safe and tolerable in PEGCISGEM arm of the 
Run-in portion will be utilized in the PEGCISGEM arm of the Dose Expansion portion. The 
highest PEGPH20 dose level found to be safe and tolerable in PEGCISGEMATEZO arm of 
the Run-in portion will be utilized in the PEGCISGEMATEZO arm of the Dose Expansion 
portion. 
• 
Subjects who drop out during the initial 21 days of treatment without experiencing a DLT will 
be replaced. 
• 
Safety evaluation will be initiated at PEGPH20 3.0 μg/kg dose level for the PEGCISGEM 
combination. 
• 
Subjects who experience DLTs during Cycle 1 will be permanently discontinued from all 
study treatments. 
Table S-1: Dose Allocation and Cohort Schedule - Run-in Portion (PEGCISGEM and 
PEGCISGEMATEZO treatments) 
Cohort 
PEGPH20 µg/kg 
CIS mg/m2 
GEM mg/m2 
Atezolizumab mg 
-2 
1.6 
25 
1000 
1200 
-1 
2.2 
25 
1000 
1200 
1 
3.0 
25 
1000 
1200 
Abbreviations: CIS = cisplatin; GEM = gemcitabine; PEGPH20 = PEGylated recombinant human hyaluronidase 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted (refer to Section 8.3 for 
further details). 
Definition of Dose-Limiting Toxicity: 
Treatment-related AEs that limit the dose of PEGPH20 or the combination 
(PEGCISGEM/PEGCISGEMATEZO) may be considered as DLTs. DLTs will be assessed for each 
subject during the 21 days following their first PEGPH20 dose and will be defined as: 
• 
Treatment-emergent Grade ≥3 toxicity that is considered related to either PEGPH20 or the 
combination (PEGCISGEM/PEGCISGEMATEZO)  
- 
MSEs, colitis, and immune-related toxicities, infections will be considered as DLTs only 
if they reach Grade ≥3 severity despite adequate supportive care measures. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
- 
Grade 3 nausea, vomiting, and diarrhea will be considered as DLTs if they persist for >72 
hours despite optimal supportive care.  
- 
Grade 4 nausea, vomiting, and diarrhea will be considered as DLTs if they reach Grade 4 
severity despite optimal supportive care, irrespective of duration. 
• 
Treatment-emergent Grade ≥3 symptomatic hepatic toxicity that is considered related to either 
PEGPH20 or the combination that does not resolve to Grade ≤2 within 48 hours or Grade ≥3 
asymptomatic hepatic toxicity that is considered related to either PEGPH20 or the 
combination that does not resolve to Grade ≤1 within 3 weeks of onset with the following 
exception: 
- 
For patients with Grade 2 alkaline phosphatase abnormality at baseline, an increase to 
>8 × the upper limit of normal (ULN) that does not resolve to Grade ≤2 within 48 hours 
(if symptomatic) or that does not resolve to Grade ≤1 within 3 weeks of onset (if 
asymptomatic) will be considered a DLT.  
• 
Grade 4 hepatic toxicity of any duration will be considered as a DLT. 
• 
Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: 
- 
Grade 3 immune-related AE that resolves to Grade ≤1 with immunosuppressant therapy 
within 3 weeks of its onset  
- 
Grade 3 autoimmune thyroiditis or other endocrine abnormality that can be managed by 
endocrine therapy or hormonal replacement 
• 
Grade 3 neutropenia (asymptomatic) will not be considered a DLT; however Grade 4 
neutropenia lasting 7 days or longer will be considered a DLT. 
• 
Febrile neutropenia (defined below) will be considered as a DLT. 
Febrile Neutropenia - Fever is present, defined as an oral temperature of at least 38.0°C on at 
least 2 occasions within 24 hours, or a single oral temperature of at least 38.3°C, in the 
presence of neutropenia, defined as an absolute neutrophil count (ANC) of less than  
 500 cells/μl. Fever may also be defined as a rectal temperature of 38.6°C on at least 2 
occasions within 24 hours, or a single rectal temperature of 39°C (FDA Guidance for 
Industry: Empiric Therapy of Febrile Neutropenia - Developing Antimicrobial Drugs for 
Treatment 1998). 
• 
Grade 3 MSEs are considered DLTs only if they do not reduce to Grade ≤2 within 48 hours 
despite therapeutic intervention. 
• 
Hypersensitivity/infusion reactions related to PEGPH20 or the combination dosing 
(PEGCISGEM/PEGCISGEMATEZO) will not be considered DLTs (hypersensitivity 
reactions are generally not related to the dose level of a drug since they can occur even upon a 
low level of exposure). 
To be considered evaluable for DLT assessment, subjects in the PEGCISGEM arm must receive 1 of the 3 
full planned doses of PEGPH20 and 1 complete dose each of CIS and GEM in Cycle 1.  
To be considered evaluable for DLT assessment, subjects in the PEGCISGEMATEZO arm must receive 1 
of the 3 full planned doses of PEGPH20 and 1 complete dose each of atezolizumab, CIS, and GEM in 
Cycle 1. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Subjects who experience a DLT within the first 21 days of treatment and withdraw from the study 
treatment will be considered evaluable for DLT and will not be replaced. Subjects who withdraw within 
the first 21 days for reasons other than a DLT will be considered not evaluable and will be replaced.  
Subjects who experience DLTs in the Run-in portion will be permanently discontinued from all study 
treatments. 
Expansion Portion 
Approximately 50 previously untreated subjects will be randomized in a 2:2:1 ratio into 1 of 3 treatment 
arms as follows: 
• 
PEGCISGEM arm: PEGPH20 (3.0 µg/kg) + CIS (25 mg/m2) + GEM (1000 mg/m2) 
• 
PEGCISGEMATEZO arm: PEGPH20 (3.0 µg/kg) + Atezolizumab (1200 mg) + CIS (25 
mg/m2) + GEM (1000 mg/m2) 
• 
CISGEM arm: CIS (25 mg/m2) + GEM (1000 mg/m2) 
Randomization will be stratified by geographical region (North America and Asia) and cancer type 
(cholangiocarcinoma [CCA] and gallbladder). 
An additional cohort of approximately 15 subjects will be enrolled in the Expansion portion under 
Protocol Amendment 3 and receive PEGCISGEMATEZO treatment: PEGPH20 (3.0 µg/kg) + 
Atezolizumab (1200 mg) + CIS (25 mg/m2) + GEM (1000 mg/m2). 
The study medication dosing and schedule is shown in Table S-2. 
Table S-2: 
Study Medication Dosing and Treatment Schedule  
Timepoint 
PEGCISGEM Treatment 
All Cycles (21-day cycles) 
Week 1 
Day 1 
PEGPH20  
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20)  
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Week 3 
Day 15 
PEGPH20 
 
 
Timepoint 
PEGCISGEMATEZO Treatment 
Cycle 1 (21-day cycles) 
Week 1 
Day 1 
PEGPH20 
Atezolizumab (1 to 3 hours after PEGPH20) 
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20) 
Day 4 a 
PEGPH20 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Day 11 a 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Day 18 a 
PEGPH20 
Cycle 2 and Beyond 
Week 1 
Day 1 
PEGPH20 
Atezolizumab (1 to 3 hours after PEGPH20) 
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Week 3 
Day 15 
PEGPH20 
 
Timepoint 
CISGEM Treatment 
All cycles (21-day cycles) 
Week 1 
Day 1 
CIS + GEM  
Week 2 
Day 8 
CIS + GEM  
Abbreviations: CIS = cisplatin; GEM = gemcitabine; PEGPH20 = PEGylated recombinant human hyaluronidase  
Note: Dose interruption and modifications are permitted (see Section 8.3 for further details). 
a This visit is applicable to the additional cohort of ~15 subjects enrolled under Protocol Amendment 3 only. 
Study Population 
Males and females aged 18 years and older with previously untreated, locally advanced or metastatic ICC, 
ECC and gallbladder adenocarcinoma who meet the inclusion/exclusion criteria.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Inclusion Criteria 
For both portions of the study, subjects must satisfy all of the following inclusion criteria to be enrolled in 
the study: 
1. Written Institutional Review Board/Ethics Committee-approved Informed Consent form, signed 
by subject or legally authorized representative. 
2. Subjects must be determined to have histologically confirmed unresectable, locally advanced or 
metastatic adenocarcinoma of the intra- and/or extra-hepatic bile ducts and/or gallbladder. Prior to 
enrollment, confirmation of shipment of tissue sample to the central laboratory must be obtained. 
Subjects must have sufficient tissue with architectural integrity, including tumor and associated 
stroma, available for retrospective PD-L1 and HA testing (details will be included in a separate 
Laboratory Manual). 
Note: Tumor biopsies must be collected on or after the date that locally advanced or metastatic 
disease is documented. 
3. One or more lesions measurable on computed tomography (CT) scan/ magnetic resonance 
imaging (MRI) scan per RECIST v1.1. 
4. Subjects having ECOG Performance Status of 0 to 1. 
5. Life expectancy ≥3 months. 
6. Males and females aged ≥18 years. 
7. Screening clinical laboratory values as follows: 
• 
Total bilirubin ≤1.5 × ULN, except for Gilbert’s syndrome 
• 
Aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN (<5 × ULN is allowed 
if liver metastases or liver involvement are present) 
• 
Serum creatinine ≤1.5 mg/dL 
• 
Serum albumin ≥2.5 g/dL 
• 
Hemoglobin ≥9 g/dL (transfusion and erythropoietic agents allowed) 
• 
Absolute neutrophil count ≥1500 cells/mm3 
• 
Platelet count ≥100,000/mm3 
8. Female participants of childbearing potential (WOCBP) must have a negative urine or serum 
pregnancy test within 7 days before Day 1 (first dose of study medication). 
9. For WOCBP and for men, agreement to use a highly effective contraceptive method from the time 
of screening throughout the study until 5 months (WOCBP) or 6 months (men) after 
administration of the last dose of any study medication. Highly effective contraceptive methods 
consist of prior sterilization, intrauterine device (IUD), intrauterine hormone releasing system 
(IUS), oral or injectable contraceptives, barrier methods, and/or true sexual abstinence.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Exclusion Criteria 
Subjects are ineligible for enrollment if they meet any of the following exclusion criteria: 
1. Clinical evidence of deep vein thrombosis or pulmonary embolism present during the screening 
period. 
• 
Subject with superficial vein thrombosis are eligible. 
• 
Subjects with visceral/splanchnic vein thrombosis, that in the opinion of the Principal 
Investigator are primarily associated with the anatomic location of the underlying disease of 
metastatic biliary tract cancer, are eligible. 
2. New York Heart Association Class III or IV (Appendix C) cardiac disease, atrial fibrillation, 
unstable angina, or myocardial infarction within the past 12 months before screening. 
3. Subjects with known brain metastases. 
4. History of cerebrovascular accident or transient ischemic attack. 
5. History of active bleeding within the last 3 months prior to screening requiring transfusion. 
6. Contraindication to heparin as per institutional guidelines. 
7. Subjects must have received no previous radiotherapy, surgery, chemotherapy or investigational 
therapy for treatment of metastatic or locally advanced disease. 
8. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 
(anti-PD-1), and anti-Programmed death-ligand 1 (anti-PD-L1) therapeutic antibodies. 
9. Prior treatment with 5-fluorouracil (FU) or GEM administered as a radiation sensitizer in the 
neoadjuvant and adjuvant settings surrounding surgery, during and up to 4 weeks after radiation 
therapy, is allowed if all toxicities have returned to baseline or ≤ Grade 1. 
10. If a subject received therapy in the adjuvant setting, tumor recurrence or disease progression must 
have occurred no sooner than 6 months after completing the last dose of the adjuvant therapy. 
11. Clinically significant pre-existing carotid artery disease. 
12. Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 
13. Known allergy to hyaluronidase. 
14. Intolerance to NSAIDs. 
15. Current use of megestrol acetate or megestrol acetate-containing drugs (within 10 days of Day 1). 
16. Women currently pregnant or breastfeeding. 
17. Positive human immunodeficiency virus (HIV) test. 
18. Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface antigen 
(HBsAg) test at screening. 
• 
Subjects with a past or resolved HBV infection, defined as having a negative HBsAg test and 
a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for the study 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
if active HBV infection is ruled out on the basis of HBV ribonucleic acid 
(RNA)/deoxyribonucleic acid (DNA) viral load per local guidelines. 
19. Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at 
screening. 
• 
Subjects who have a positive HCV antibody test are eligible for the study if a polymerase 
chain reaction assay is negative for HCV RNA. 
20. Active tuberculosis. 
21. History of: 
a. Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-
induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is 
permitted. 
b. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary sclerosing 
cholangitis, history of immune-mediated cholangitis);  
i. 
Subjects with cholangitis attributed to infectious etiology (e.g., ascending cholangitis, 
bacterial cholangitis) are eligible if the infection has been fully resolved prior to the 
screening visit.  
c. Or known cases of drug-induced hepatobiliary toxicities.  
22. Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, 
cirrhosis, fatty liver, and inherited liver disease. 
23. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells. 
24. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or 
humanized antibodies or fusion proteins. 
25. Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiation 
of study treatment. 
• 
Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic 
obstructive pulmonary disease exacerbation) are eligible for the study. 
26. Signs or symptoms of infection within 2 weeks prior to initiation of study treatment. 
27. Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study 
treatment, or anticipation of need for a major surgical procedure during the course of the study. 
• 
Placement of central venous access catheter(s) (e.g., port or similar) is not considered a major 
surgical procedure and is therefore permitted. 
28. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or 
anticipation of need for such a vaccine during the course of the study. 
• 
Influenza vaccination should be given during influenza season only (approximately October 
to March in the Northern Hemisphere and approximately April through September in the 
Southern Hemisphere). Subjects must agree not to receive live, attenuated influenza vaccine 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
(e.g., FluMist) within 28 days prior to the start of study treatment, during treatment, or 
within 5 months after the last dose of atezolizumab. 
29. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and 
interleukin-2) within 6 weeks or 5 half-lives of the drug, whichever is longer, prior to initiation of 
study treatment. 
30. Treatment with systemic immunosuppressive medication (including, but not limited to, 
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis 
factor alpha [anti-TNF-α] agents) within 2 weeks prior to initiation of study treatment, or 
anticipation of need for systemic immunosuppressive medication during the course of the study. 
• 
Subjects who have received acute, low-dose, systemic immunosuppressant medications (e.g., 
a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion 
with and approval by the Medical Monitor. 
• 
The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for subjects 
with orthostatic hypotension, chronic obstructive pulmonary disease, or adrenocortical 
insufficiency is allowed. 
• 
Subjects with a history of allergic reaction to IV contrast requiring steroid pre-treatment 
should have baseline and subsequent tumor assessments performed using MRI. 
31. Active or history of autoimmune disease, including, but not limited to, colitis, Crohn’s disease, 
myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid 
arthritis, inflammatory bowel disease, Wegener granulomatosis, Sjögren’s syndrome, 
Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.* 
• 
Subjects with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-
replacement hormone may be eligible for this study after discussion with and approval by the 
Medical Monitor. 
• 
Subjects with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible 
for this study after discussion with and approval by the Medical Monitor. 
32. Subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., subjects with psoriatic arthritis) are permitted provided that they meet 
the following conditions: 
• 
Subjects with psoriasis must have a baseline ophthalmologic exam to rule out ocular 
manifestations 
• 
Rash must cover less than 10% of body surface area (BSA) 
• 
Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., 
hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, 
alclometasone dipropionate 0.05%) 
• 
No acute exacerbations of underlying condition within the last 12 months (not requiring 
PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologic agents, oral 
calcineurin inhibitors, high potency or oral steroids) 
33. Uncontrolled tumor-related pain. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
• 
Subjects requiring narcotic pain medication must be on a stable regimen at study entry. 
• 
Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) 
amenable to palliative radiotherapy should be treated prior to start of study treatment. 
Subjects should be recovered from the effects of radiation. There is no required minimum 
recovery period. 
• 
Asymptomatic metastatic lesions whose further growth would likely cause functional deficits 
or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord 
compression) should be considered for loco-regional therapy if appropriate prior to the start of 
study treatment. 
34. Uncontrolled hypercalcemia (>1.5 mmol/L ionized calcium or calcium >12 mg/dL or corrected 
serum calcium >ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate 
therapy (unless bisphosphonate is used to prevent skeletal events). 
35. Prior allogeneic stem cell or solid organ transplantation. 
36. History of another primary cancer within the last 3 years that required treatment, with the 
exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical 
carcinoma in situ. 
37. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory 
finding that lead to reasonable suspicion of a disease or condition that contraindicates the use of 
an investigational drug, may affect the interpretation of the results, or may render the subject at 
high risk for treatment complications. 
38. Subject inability to comply with study and follow-up procedures, as judged by the Investigator. 
* Any relevant diseases that are not listed as examples of exclusionary diseases are to be discussed with 
the Sponsor.  
Study Medication 
For this study, study medication will include PEGPH20, CIS, GEM, and atezolizumab. 
PEGPH20: PEGPH20 drug product is supplied as an aqueous solution containing 0.30 mg/mL PEGPH20 
with 10 mM succinic acid, 130 mM NaCl and 10 mM L-methionine at pH 6.2. Each vial contains 1.0 mL 
(0.30 mg) of PEGPH20 drug product. PEGPH20 drug product is provided as a refrigerated formulation 
and should be stored at 2°C to 8°C before use. 
Instructions for PEGPH20 preparation will be provided to sites in the pharmacy binder.  
For subjects enrolled through Protocol Amendment 2, PEGPH20 (3.0 µg/kg) will be administered on 
Day 1, Day 8, and Day 15 of all cycles as an IV infusion over 10 minutes, approximately 1 mL/minute (a 
window of +2 minutes is allowed, i.e., infusion can be 10 to 12 minutes).  
For the cohort of approximately 15 subjects enrolled under Protocol Amendment 3, PEGPH20 (3.0 µg/kg) 
will be administered on Day 1, Day 4, Day 8, Day 11, Day 15, and Day 18 of Cycle 1 as an IV infusion 
over 10 minutes, approximately 1 mL/minute (a window of +2 minutes is allowed, i.e., infusion can be 
10 to 12 minutes); in Cycle 2 and beyond, PEGPH20 (3.0 µg/kg) will be administered on Day 1, Day 8 
and Day 15. 
Atezolizumab: Atezolizumab 1200 mg will be administered as an IV infusion over 60 minutes, 
1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle. Note that in Cycle 2 and beyond, 
atezolizumab may be administered as an IV infusion over 30 minutes instead of 60 minutes if the first 
infusion in Cycle 1 is tolerated. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Cisplatin: CIS, a chemotherapeutic drug, will be administered as an IV infusion at 25 mg/m2 over 1 hour 
with prior hydration and electrolyte supplementation with potassium and magnesium per individual 
institutional standard 24 ± 4 hours after a dose of PEGPH20 on Day 2 and Day 9 of each 21-day cycle to 
subjects receiving PEGCISGEM and PEGCISGEMATEZO. In the CISGEM arm, CIS will be 
administered on Day 1 and Day 8 of each 21-day cycle. Please refer to the current CIS package insert for 
the description and composition of this drug. 
Gemcitabine: GEM, a chemotherapeutic drug, will be administered as an IV infusion at 1000 mg/m2 over 
30 minutes per institutional standard on Day 2 and Day 9 of each 21-day cycle after CIS in the 
PEGCISGEM and PEGCISGEMATEZO arms 24 ± 4 hours after a dose of PEGPH20. In the CISGEM 
(Control arm), GEM will be administered after CIS on Day 1 and Day 8 of each 21-day cycle. Please refer 
to the current GEM Prescribing Information for the description and composition of this drug. 
Note: Premedication with antiemetics will be administered as standard-of-care to all subjects prior to CIS 
and GEM infusions. Steroids can only be administered if emesis is not controlled with other antiemetics. 
Study Duration 
The study will consist of a screening period of up to 28 days, a treatment period (21-day cycles), a 30-day 
post-treatment period (after last dose) for collection of AEs, and a long-term follow-up. Subjects will be 
allowed to continue treatment on study until radiologic disease progression or clinical progression or 
unacceptable toxicity is documented. Disease progression will be defined by the presence of the 
following, based on the Investigator’s radiology reviewer’s assessment: 
• 
Disease progression documented by CT scan/MRI scan based on RECIST v1.1 
• 
Disease progression for subjects treated with atezolizumab requires confirmation of progression 
with an additional scan obtained no sooner than 28 days after the initial scan that showed 
progression per Immune-Modified RECIST. 
Due to the possibility of “pseudoprogression” in immunotherapy trials, subjects who meet the criteria for 
disease progression, per RECIST v1.1, while receiving atezolizumab will be permitted to continue 
treatment if they meet all of the following criteria: 
• 
Evidence of clinical benefit, as determined by the investigator following a review of all 
available data 
• 
Absence of symptoms and signs (including laboratory values, such as new or worsening 
hypercalcemia) indicating unequivocal progression of disease 
• 
Absence of decline in ECOG Performance Status that can be attributed to disease progression 
• 
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that 
cannot be managed by protocol-allowed medical interventions 
• 
Subject's written consent to acknowledge deferring other treatment options in favor of 
continuing study treatment at the time of initial disease progression 
Investigators may also discontinue study treatment if it is no longer in the best interest of the subject, 
following a discussion with the Sponsor. 
Subjects who discontinue treatment with all study drugs will be followed every 12 weeks for survival until 
death, withdrawal of consent, or lost to follow-up. Subjects may be contacted more frequently to collect 
information on survival, as required, prior to important study timepoints, including DMC meetings and 
database locks. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Criteria for Evaluation 
Study Endpoints 
Run-in portion 
Primary:  
• 
Incidence of AEs, changes in clinical safety laboratory values, changes in cardiovascular 
parameters (electrocardiogram [ECG]), vital signs, and dose modifications (e.g., dose 
interruptions and delays) 
Secondary:  
• 
PK parameters of PEGPH20: maximum plasma concentration (Cmax), minimum plasma 
concentration (Cmin), elimination rate constant (kel), terminal elimination half-life (t1/2), 
clearance (CL), volume of distribution (Vd), and area-under-the-concentration time curve 
(AUC).  
• 
PK parameters of atezolizumab: Cmax, Cmin, t1/2, AUC, Vd, and CL when applicable 
• 
PK parameters for GEM: Cmax, t1/2, AUC, Vd, and CL when applicable 
• 
PK parameters for CIS (total and unbound): Cmax, t1/2, AUC, Vd, and CL when applicable 
• 
ORR based on RECIST v1.1 
Exploratory: 
• 
Change in CA19-9 from baseline 
• 
Change in CEA from baseline 
• 
ORR based on Immune-Modified RECIST 
• 
DOR and PFS based on RECIST v1.1 
• 
OS 
• 
Changes in plasma HA from baseline 
• 
Changes in tumor HA from baseline, when available 
• 
Explore co-variates of safety and efficacy parameters with drug exposure as measured by 
plasma HA levels 
• 
Explore co-variates of safety and efficacy parameters with exploratory biomarker responses 
Expansion portion 
Primary: 
• 
ORR based on RECIST v1.1 
Secondary:  
• 
DOR, PFS, and DCR based on RECIST v1.1, and OS 
• 
ORR, DOR, and PFS based on RECIST v1.1, and OS by PD-L1 expression levels 
• 
PK parameters of PEGPH20: Cmax, Cmin, kel, t1/2, CL, Vd, and AUC 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
• 
PK parameters of atezolizumab: Cmax, Cmin, t1/2, AUC, Vd, and CL when applicable 
• 
PK parameters of GEM and CIS (bound and free): Cmax, t1/2, AUC, Vd, and CL when 
applicable 
• 
Incidence of AEs, changes in clinical safety laboratory values, changes in cardiovascular 
parameters (ECG), vital signs, and dose modifications (e.g., dose interruptions and delays) 
Exploratory: 
• 
ORR and DOR based on Immune-Modified RECIST 
• 
ORR and DOR based on Immune-Modified RECIST by PD-L1 expression levels 
• 
DCR, as assessed by the Investigator according to Immune-Modified RECIST 
• 
Changes in plasma HA from baseline 
• 
Changes in tumor HA from baseline when available 
• 
Explore co-variates of safety and efficacy parameters with drug exposure as measured by 
plasma HA levels 
• 
Explore co-variates of safety and efficacy parameters with exploratory biomarker responses 
• 
Change in CA19-9 from baseline 
• 
Change in CEA from baseline 
Safety Assessments 
Safety will be assessed during the study by evaluation of AEs, dose modifications (e.g., interruptions and 
delays), clinical safety laboratory tests (hematology, blood chemistry, coagulation, urinalysis, viral 
serology, and PEGPH20 and atezolizumab immunogenicity), vital signs, 12-lead ECGs, and physical 
examinations. 
The severity of AEs will be graded by Investigators using the NCI CTCAE Version 4.03 (at time of study 
initiation). 
Efficacy Assessments 
In the Run-in portion of the study subjects will be evaluated for efficacy endpoint ORR per RECIST v1.1. 
In the Expansion portion of the study, subjects will be evaluated for efficacy endpoints ORR, DOR and 
PFS using RECIST v1.1 and OS. Subjects will also be evaluated for efficacy endpoint DCR using 
RECIST v1.1.  
Pharmacokinetic Assessments 
Plasma PEGPH20, GEM, CIS (bound and free), and serum atezolizumab concentrations will be measured 
as specified in the Study Schedule of Events. 
Exploratory Assessments 
In the Run-in portion, subjects may be evaluated for the efficacy endpoint ORR based on Immune-
Modified RECIST. DOR and PFS may be evaluated based on RECIST v1.1. OS may also be evaluated. 
In the Expansion portion efficacy endpoints ORR and DOR may be evaluated based on Immune-Modified 
RECIST. ORR and DOR may also be evaluated based on Immune-Modified RECIST by PD-L1 
expression levels. Subjects may be evaluated for DCR per Immune-Modified RECIST criteria, as assessed 
by the Investigator. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
In both portions of the study plasma and tumor samples will be collected from all subjects to assess tumor 
and blood biomarkers (such as circulating tumor DNA) as specified in the Study Schedule of Events. A 
whole blood sample will be collected from all subjects to correlate individual subject DNA sequence 
variation (e.g., exploratory single nucleotide polymorphism genotyping) with safety, tolerability, and 
potential clinical benefit. 
If deemed clinically feasible by the Investigator, a second tumor sample may be collected at the time of 
disease progression per RECIST v1.1 (in all arms), loss of clinical benefit as determined by the 
Investigator (in the PEGCISGEM and PEGCISGEMATEZO arms only), or unacceptable toxicity (all 
arms). The sample will be analyzed for tumor HA, PD-L1 expression, and other exploratory biomarkers in 
comparison with the pre-dose sample to evaluate PEGPH20 and/or chemotherapy effects and to 
potentially identify resistance mechanisms. 
Serum samples will be collected from all subjects to assess the effect of treatment on CA19-9 and CEA 
levels. 
The treatment effect of PEGCISGEM, PEGCISGEMATEZO and CISGEM (in Expansion only) may be 
evaluated based on HA levels and exploratory biomarker levels in plasma and/or tumor samples. 
Statistical Methods 
Planned Total Sample Size 
This study is planned to enroll approximately 77 to 85 subjects.  
In the Run-in portion, approximately 6 subjects will receive PEGPH20 plus CIS plus GEM, then a cohort 
of 6 subjects will receive PEGPH20, atezolizumab, CIS, and GEM when the PEGCISGEM cohort clears 
the safety evaluation. Additional dosing cohorts may be evaluated in the Run-in portion if the initial dose 
of PEGPH20 utilized in the combinations tested is deemed unsafe and/or intolerable. An additional 
8 subjects may be enrolled in the Run-in portion to further assess the tolerability of PEGPH20 in order to 
establish an acceptable safety profile prior to randomization in the Expansion Portion of the study. 
In the Expansion portion, approximately 50 subjects will be enrolled and randomized in a 2:2:1 ratio into 
PEGCISGEMATEZO, PEGCISGEM, and CISGEM treatment arms, stratified by geographical region 
(North America and Asia) and cancer type (CCA and gallbladder).  
For the approximately 50 subjects enrolled in the Expansion portion through Protocol Amendment 2, it is 
assumed that the addition of PEGPH20 and atezolizumab to CIS + GEM treatment increases ORR from 
26% to 66%. An ORR of 26% was observed in subjects treated with CIS + GEM combination treatment in 
the ABC-02 trial, a Phase 3 trial enrolling 410 patients with biliary tract cancers (Valle 2010). A total of 
50 subjects, 20 each in the PEGCISGEM and PEGCISGEMATEZO treatment arms and 10 in the 
CISGEM arm, are required to detect a treatment difference of 40% in ORR between the CISGEM and 
PEGCISGEMATEZO arms with a statistical power of approximately 80% at the one-sided alpha level of 
0.1.  
For the cohort of approximately 15 subjects enrolled in the Expansion portion under Protocol 
Amendment 3 receiving PEGCISGEMATEZO, assuming a more conservative ORR of 60% for the 
PEGCISGEMATEZO treatment is observed, the 80% confidence interval is 40%, 77%. The lower bound 
of 40% is higher than the ORR of 37% observed in a study of the immunotherapy agent nivolumab in 
combination with CIS and GEM in 30 subjects with advanced biliary tract carcinoma (Ikeda 2019). 
Analysis Populations 
Enrolled Population: All subjects enrolled in the Run-in portion and the Expansion portion of the study. 
The enrolled population will be used for the subject disposition, demographics, and baseline 
characteristics summaries. 
Treated Population: All subjects in the Run-in and the Expansion portion of the study who receive any 
study medication. The Treated Population will be used for efficacy and safety analyses. Subjects will be 
analyzed based on the treatment received. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Efficacy Evaluable Population: Subjects in the Expansion portion who receive any study medication as 
randomized and have an evaluable baseline and post-baseline tumor assessment, unless discontinued from 
treatment because of disease progression or death. Efficacy Evaluable Population will be used as the 
primary analysis population for efficacy. 
PK Analysis Population: All subjects who receive any study medication and have measurable study drug 
concentrations in at least 1 sample collected for PK analysis. PK Analysis Population will be used for PK 
analysis. 
Analyses 
Analysis of Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized using the Enrolled Population. The 
following demographic and baseline characteristics will be summarized: age, sex, race, height, weight, 
medical history, disease characteristics, and treatment history. 
Efficacy Analyses 
All efficacy analyses will be conducted using the Efficacy Evaluable population and treated population. 
The Efficacy Evaluable population will be the primary analysis population for efficacy. All statistical tests 
will be conducted at the 1-sided alpha level of 0.1. No adjustment of alpha level will be made for multiple 
tests. 
ORR will be calculated as the number of subjects with a CR or PR divided by the number of subjects in 
the analysis population. For the approximately 50 subjects enrolled in the Expansion portion through 
Protocol Amendment 2, the treatment difference between each of the investigational arms and the control 
arm will be tested using the 1-sided Fisher’s Exact test. Median DOR will be estimated by treatment arm 
using the Kaplan-Meier method. The DCR will be analyzed similarly to the ORR. For the additional 
cohort of approximately 15 subjects enrolled in the Expansion portion under Protocol Amendment 3 
receiving PEGCISGEMATEZO, the ORR will be presented and its 80% confidence interval will be 
calculated using the exact method. Median DOR, DCR, and PFS in these subjects will be analyzed in a 
similar manner as for subjects enrolled through Protocol Amendment 2. No statistical comparison of 
ORR, DOR, DCR, and PFS will be made between subjects in this additional cohort and subjects enrolled 
prior to Protocol Amendment 3. 
PFS is defined as time from randomization to radiological disease progression or death. Kaplan-Meier 
method will be used to estimate the median PFS and its 80% confidence interval (CI), first and third 
quartiles, and PFS rates at Months 6, 9, and 12 by treatment arm. The PFS comparison between the 
PEGCISGEM and PEGCISGEMATEZO treatment arm versus CISGEM treatment arm will be based on a 
1-sided log-rank test. The hazard ratio and 80% CI for the treatment effect will be estimated using the Cox 
proportional hazards regression model. Estimated survival curves of PFS of the three treatment arms will 
be displayed graphically. 
OS is defined as time from randomization to death at any time. OS will be analyzed similarly as PFS. 
Safety Analyses 
All safety parameters will be summarized by treatment using the Treated Population. 
All AEs will be presented in incidence tables coded by the Medical Dictionary for Regulatory Activities 
(MedDRA) v18.0 Preferred Term and System Organ Class. Additionally, separate AE incidence tables, 
coded by MedDRA, will be presented by: 1) toxicity grade (severity) graded by the CTCAE and 2) 
relationship to study medication (PEGPH20, CIS, GEM, and atezolizumab). 
All AEs, serious adverse events, AEs leading to treatment discontinuation, and deaths occurring during 
the study will be summarized. 
Laboratory parameters and vital signs and the corresponding change from baseline over time will be 
summarized. 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Pharmacokinetic Analyses 
Noncompartmental analysis will be performed where possible/appropriate on PEGPH20, GEM, CIS 
(bound and free), and atezolizumab. The PK parameters AUC, Cmax, Cmin, CL, Vd, kel, and t1/2 will be 
summarized from noncompartmental analysis along with descriptive statistics, when applicable. Other PK 
analyses will be performed when appropriate. 
Exploratory Analyses 
Descriptive summaries will be provided for all exploratory endpoints 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES 
TABLE OF CONTENTS 
1. 
SYNOPSIS ...................................................................................................................3 
2. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............23 
3. 
STUDY SCHEDULES OF EVENTS ........................................................................34 
4. 
BACKGROUND AND RATIONALE .......................................................................49 
4.1. 
Biliary Tract Cancers ..................................................................................................49 
4.2. 
Hyaluronan and Malignancy .......................................................................................50 
4.3. 
PEGylated Recombinant Human Hyaluronidase........................................................51 
4.3.1. 
PEGPH20 and Chemotherapy ....................................................................................51 
4.4. 
Clinical Experience With PEGPH20 and Clinical Development Plan .......................52 
4.4.1. 
Phase 1 Study HALO-109-101 ...................................................................................52 
4.4.2. 
Phase 1 Study HALO-109-102 ...................................................................................52 
4.4.3. 
Phase 1b Study HALO-109-201 .................................................................................53 
4.4.4. 
Phase 2 Study HALO-109-202 ...................................................................................53 
4.4.5. 
Phase 1b/2 Study HALO-107-201 ..............................................................................53 
4.4.6. 
Phase 3 Study HALO-109-301 ...................................................................................54 
4.4.7. 
Safety ..........................................................................................................................54 
4.4.7.1. 
Musculoskeletal Events ..............................................................................................54 
4.4.7.2. 
Thromboembolic Events .............................................................................................55 
4.4.8. 
Efficacy .......................................................................................................................56 
4.4.9. 
Clinical Pharmacokinetics ..........................................................................................57 
4.5. 
Study Rationale ...........................................................................................................57 
4.5.1. 
Rationale for Dose and Schedule Selection ................................................................58 
5. 
STUDY OBJECTIVES AND ENDPOINTS ..............................................................60 
5.1. 
Study Objectives .........................................................................................................60 
5.2. 
Study Endpoints ..........................................................................................................62 
6. 
INVESTIGATIONAL PLAN .....................................................................................63 
6.1. 
Overall Study Design and Plan: Description ..............................................................63 
6.1.1. 
Phase 1b Run-in ..........................................................................................................70 
6.1.2. 
Phase 1b Dose Expansion ...........................................................................................72 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
6.1.3. 
Study Duration ............................................................................................................74 
6.1.4. 
Disease Progression ....................................................................................................75 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS AND STUDY 
TERMINATION .........................................................................................................75 
7.1. 
Inclusion Criteria ........................................................................................................75 
7.2. 
Exclusion Criteria .......................................................................................................76 
7.3. 
Subject Withdrawal Criteria .......................................................................................80 
7.3.1. 
Discontinuation of Treatment .....................................................................................80 
7.3.2. 
Discontinuation from Study ........................................................................................81 
7.4. 
Sponsor Study Stopping Rules ...................................................................................81 
8. 
STUDY PROCEDURES AND ASSESSMENTS......................................................82 
8.1. 
Study Procedures by Visit ..........................................................................................82 
8.1.1. 
Screening ....................................................................................................................82 
8.1.1.1. 
Within 28 Days Prior to Day 1 (Unless Otherwise Indicated) ...................................82 
8.1.2. 
Treatment Period ........................................................................................................83 
8.1.2.1. 
Subjects Receiving PEGCISGEM Treatment (Run-in and Expansion) .....................84 
8.1.2.2. 
Subjects Receiving PEGCISGEMATEZO Treatment (Run-in and 
Expansion) ..................................................................................................................87 
8.1.2.3. 
Subjects Receiving CISGEM (Expansion only) .........................................................94 
8.1.2.4. 
End of Treatment Visit ...............................................................................................95 
8.1.2.5. 
Long-Term Follow-Up ...............................................................................................96 
8.1.3. 
Procedures for Study Treatment Discontinuation .......................................................96 
8.2. 
Study Assessments......................................................................................................96 
8.2.1. 
Informed Consent .......................................................................................................96 
8.2.2. 
Inclusion/Exclusion Criteria .......................................................................................97 
8.2.3. 
Medical History (including bile duct adenocarcinoma history) .................................97 
8.2.4. 
Concomitant Medications ...........................................................................................97 
8.2.5. 
Adverse Events ...........................................................................................................97 
8.2.6. 
Physical Examination .................................................................................................97 
8.2.7. 
Height and Weight ......................................................................................................97 
8.2.8. 
ECOG Performance Status .........................................................................................97 
8.2.9. 
Vital Signs ..................................................................................................................97 
8.2.10. 
12-lead ECG ...............................................................................................................97 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
8.2.11. 
Central Laboratory Tests ............................................................................................97 
8.2.12. 
Pregnancy Test ............................................................................................................98 
8.2.13. 
Contraception ..............................................................................................................99 
8.2.14. 
Immunogenicity ..........................................................................................................99 
8.2.15. 
Imaging/Radiologic Evaluation ..................................................................................99 
8.2.15.1. 
Chest Computed Tomography to Exclude Pulmonary Embolism ............................100 
8.2.16. 
Doppler Ultrasound Scanning for Assessment of Deep Vein Thrombosis ..............101 
8.2.17. 
Pharmacokinetic Assessments ..................................................................................101 
8.2.18. 
CA19-9 .....................................................................................................................101 
8.2.19. 
CEA ..........................................................................................................................101 
8.2.20. 
Pharmacodynamic and Biomarker Assessments ......................................................101 
8.2.20.1. 
Tumor Biopsies .........................................................................................................102 
8.2.20.2. 
Blood Samples ..........................................................................................................102 
8.3. 
Study Drug Administration.......................................................................................102 
8.3.1. 
PEGPH20 ..................................................................................................................104 
8.3.1.1. 
PEGPH20 Administration ........................................................................................104 
8.3.1.2. 
Hypersensitivity Reactions .......................................................................................104 
8.3.1.3. 
PEGPH20 Dose Modification Guidelines ................................................................105 
8.3.2. 
Atezolizumab ............................................................................................................108 
8.3.2.1. 
Atezolizumab Administration ...................................................................................108 
8.3.2.2. 
Identified Risks of Atezolizumab Treatment ............................................................108 
8.3.2.3. 
Atezolizumab Dose Adjustment and Toxicity Management ....................................108 
8.3.3. 
Cisplatin and Gemcitabine ........................................................................................108 
8.3.3.1. 
Cisplatin Administration ...........................................................................................108 
8.3.3.2. 
Gemcitabine Administration .....................................................................................109 
8.3.3.3. 
Identified Risks of CIS and GEM Treatment ...........................................................109 
8.3.3.4. 
Cisplatin and Gemcitabine Dose Adjustment and Toxicity Management ................109 
8.4. 
Excluded Concomitant Medications and Study Restrictions ....................................112 
8.5. 
Treatment Compliance ..............................................................................................112 
9. 
STUDY DRUG AND MATERIALS .......................................................................112 
9.1. 
Study Drug Description ............................................................................................112 
9.1.1. 
PEGPH20 ..................................................................................................................112 
9.1.2. 
Atezolizumab ............................................................................................................113 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
9.1.3. 
Cisplatin ....................................................................................................................114 
9.1.4. 
Gemcitabine ..............................................................................................................114 
9.2. 
Study Drug Packaging and Labeling ........................................................................115 
9.2.1. 
PEGPH20 ..................................................................................................................115 
9.2.2. 
Atezolizumab ............................................................................................................115 
9.2.3. 
Cisplatin ....................................................................................................................115 
9.2.4. 
Gemcitabine ..............................................................................................................115 
9.3. 
Study Drug Storage ...................................................................................................116 
9.3.1. 
PEGPH20 ..................................................................................................................116 
9.3.2. 
Atezolizumab ............................................................................................................116 
9.3.3. 
Cisplatin ....................................................................................................................116 
9.3.4. 
Gemcitabine ..............................................................................................................117 
9.4. 
Study Drug Preparation ............................................................................................117 
9.4.1. 
PEGPH20 ..................................................................................................................117 
9.4.2. 
Atezolizumab ............................................................................................................117 
9.4.3. 
Cisplatin ....................................................................................................................117 
9.4.4. 
Gemcitabine ..............................................................................................................117 
9.5. 
Study Drug Accountability .......................................................................................117 
10. 
SAFETY ASSESSMENTS ......................................................................................118 
10.1. 
Management of Thromboembolic Events ................................................................118 
10.1.1. 
Enoxaparin Management ..........................................................................................119 
10.2. 
Adverse Event Definitions ........................................................................................120 
10.3. 
Reporting Serious Adverse Events ...........................................................................121 
10.4. 
Reporting Adverse Events of Special Interest ..........................................................121 
10.4.1. 
Thromboembolic Events ...........................................................................................121 
10.4.2. 
Adverse Events of Special Interest for Atezolizumab (Immediately 
Reportable to the Sponsor) .......................................................................................123 
10.4.3. 
Disease-Related Events That Are Endpoints ............................................................124 
10.5. 
Adverse Events .........................................................................................................125 
10.5.1. 
Classification of Adverse Events by Severity ..........................................................126 
10.5.2. 
Classification of Adverse Events by Relationship to Study Drug ............................126 
10.6. 
Abnormal Laboratory Results ...................................................................................127 
10.7. 
Pregnancy .................................................................................................................127 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
10.8. 
Overdose ...................................................................................................................128 
10.9. 
Data Monitoring Committee .....................................................................................128 
10.10. 
Unblinding ................................................................................................................128 
10.11. 
Reporting Safety Information to the Regulatory Authorities and to the 
Institutional Review Board .......................................................................................128 
10.12. 
Concomitant Medications .........................................................................................129 
10.12.1. 
Piroxicam and Toradol .............................................................................................129 
10.12.2. 
Enoxaparin ................................................................................................................130 
10.12.3. 
Steroids .....................................................................................................................130 
10.12.4. 
Hydration and Electrolyte Supplementation .............................................................130 
10.12.5. 
Antiemetics ...............................................................................................................131 
11. 
STATISTICS ............................................................................................................131 
11.1. 
Statistical Methods ....................................................................................................131 
11.1.1. 
Randomization and Blinding ....................................................................................131 
11.1.2. 
Sample Size ..............................................................................................................131 
11.1.3. 
Analysis Populations ................................................................................................132 
11.1.3.1. 
Enrolled Population ..................................................................................................132 
11.1.3.2. 
Treated Population ....................................................................................................132 
11.1.3.3. 
Efficacy Evaluable Population .................................................................................132 
11.1.3.4. 
PK Analysis Population ............................................................................................132 
11.1.4. 
Subject Disposition ...................................................................................................132 
11.1.5. 
Analysis of Demographics and Baseline Characteristics .........................................132 
11.1.6. 
Efficacy Analyses .....................................................................................................133 
11.1.7. 
Analysis of Treatment Exposure ..............................................................................133 
11.1.7.1. 
Pharmacokinetic Analyses ........................................................................................133 
11.1.7.2. 
Plasma Hyaluronan ...................................................................................................133 
11.1.7.3. 
Exploratory Analyses ................................................................................................134 
11.1.8. 
Safety Analyses ........................................................................................................134 
11.1.9. 
Interim Analysis ........................................................................................................134 
12. 
SPONSOR AND INVESTIGATOR RESPONSIBILITIES ....................................134 
12.1. 
Protocol Compliance ................................................................................................134 
12.1.1. 
Protocol Waivers ......................................................................................................134 
12.1.2. 
Protocol Deviations ..................................................................................................134 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
12.2. 
Study Monitoring ......................................................................................................135 
12.3. 
Data Collection and Electronic Case Report Forms .................................................135 
12.4. 
Financial Disclosure .................................................................................................135 
12.5. 
Investigator’s Final Report .......................................................................................135 
12.6. 
Data Disclosure and Publication ...............................................................................136 
13. 
QUALITY CONTROL AND QUALITY ASSURANCE .......................................136 
14. 
ETHICS ....................................................................................................................136 
14.1. 
Institutional Review Board and Approval ................................................................137 
14.2. 
Written Informed Consent ........................................................................................137 
15. 
DATA HANDLING AND RECORD KEEPING ....................................................137 
15.1. 
Record Inspection .....................................................................................................137 
15.2. 
Study Documentation and Record Retention ...........................................................138 
16. 
REFERENCES .........................................................................................................139 
17. 
APPENDICES ..........................................................................................................144 
APPENDIX A. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCES STATUS ..................................................................................144 
APPENDIX B. RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
VERSION 1.1 (RECIST V1.1) .................................................................................145 
APPENDIX C. NEW YORK HEART ASSOCIATION CLASSIFICATIONS ......................152 
APPENDIX D. IMMUNE-MODIFIED RESPONSE EVALUATION CRITERIA IN 
SOLID TUMORS (IMMUNE-MODIFIED RECIST) .............................................153 
APPENDIX E. ANAPHYLAXIS PRECAUTIONS .................................................................155 
APPENDIX F. MANAGEMENT OF ATEZOLIZUMAB-SPECIFIC ADVERSE 
EVENTS ...................................................................................................................156 
 
LIST OF TABLES 
Table 1: 
Study Schedule of Events: Screening (Run-in and Expansion)..................................34 
Table 2: 
Study Schedule of Events: PEGCISGEM and PEGCISGEMATEZO 
Treatments (Run-in and Expansion) ...........................................................................36 
Table 3: 
Study Schedule of Events: CISGEM (Control) Treatment (Expansion only) ............41 
Table 4: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and 
Translational Medicine Sample Collection - PEGCISGEM and 
PEGCISGEMATEZO Treatments (Run-in and Expansion) ......................................44 
Table 5: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and 
Translational Medicine Sample Collection - CISGEM Arm (Expansion only) .........47 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Table 6: 
Dose Allocation and Cohort Schedule - Run-in Portion (PEGCISGEM and 
PEGCISGEMATEZO treatments)..............................................................................71 
Table 7: 
Study Medication Dosing and Treatment Schedule ...................................................73 
Table 8: 
Guidelines for Management of PEGPH20 or atezolizumab infusion-related 
reactions ....................................................................................................................105 
Table 9: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines .......................106 
Table 10: PEGPH20 Dose Reduction Guidelines .....................................................................108 
Table 11: Enoxaparin 1 mg/kg/day Dosage ..............................................................................119 
Table 12: CTCAE Version 4.03 Grading for Thromboembolic Events ...................................122 
Table 13: Criteria for Overall Response at a Single Timepoint: Patients with Target 
Lesions (With or Without Non-Target Lesions) .......................................................150 
Table 14: Comparison of RECIST v1.1 and Immune-Modified RECIST................................154 
 
LIST OF FIGURES 
Figure 1: 
Study Design - Phase 1b Run-in and Expansion (HALO-110-101) ...........................68 
Figure 2: 
Structure of PEGPH20 ..............................................................................................113 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
LIST OF ABBREVIATIONS 
The following abbreviations are used in this protocol.  
Abbreviation 
Definition 
18F-FDG PET/CT 
2-deoxy-2-[fluorine-18] fluoro- D-glucose integrated with positron 
emission tomography-computed tomography 
ADA 
anti-drug antibodies 
AE 
adverse event 
AG 
nab-paclitaxel plus gemcitabine 
ALK 
anaplastic lymphoma kinase  
ALT 
alanine aminotransferase  
ANC 
absolute neutrophil count 
anti-TNF-α 
anti-tumor necrosis factor alpha 
AST 
aspartate aminotransferase  
AUC 
area-under-the-concentration time curve 
BSA 
body surface area 
BUN 
blood urea nitrogen 
CA19-9 
cancer antigen 19-9 
CBC 
complete blood count 
CCA 
cholangiocarcinoma 
CEA 
carcinoembryonic antigen 
CFR 
Code of Federal Regulations 
CI 
Confidence Interval 
CIS 
cisplatin 
CISGEM 
cisplatin in combination with gemcitabine 
CIV 
Central Imaging Vendor 
CL 
clearance 
Cmax 
maximum observed concentration 
Cmin 
minimum observed concentration 
CR 
complete response 
CT 
computed tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
CTLA-4 
cytotoxic T-lymphocyte-associated protein 4 
DCR 
disease control rate 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Abbreviation 
Definition 
DLT 
dose limiting toxicity 
DMC 
Data Monitoring Committee 
DNA 
deoxyribonucleic acid  
Doc 
docetaxel alone  
DOR 
duration of response 
DVT 
deep vein thrombosis 
EC 
Ethics Committee 
ECC 
extrahepatic cholangiocarcinoma 
ECG 
electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
electronic case report form 
EDC 
electronic data capture 
EGFR 
epidermal growth factor receptor 
EMT 
epithelial-mesenchymal transition 
EOT 
End of Treatment 
FDA 
Food and Drug Administration 
FU 
5-fluorouracil 
GCP 
Good Clinical Practice 
GEM 
gemcitabine 
GFR 
glomerular filtration rate 
HA 
hyaluronan 
HA-high 
high expression of HA 
HBcAB 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
HR 
hazard ratio 
IB 
Investigator’s Brochure 
ICC 
intrahepatic cholangiocarcinoma 
ICF 
Informed Consent Form  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Abbreviation 
Definition 
ICH 
International Conference on Harmonisation  
INR 
international normalized ratio 
IRB 
Institutional Review Board  
IRR 
infusion-related reaction 
IUD 
intrauterine device  
IUS 
intrauterine hormone releasing system  
IV 
intravenous 
IWRS 
Interactive Web Response System 
kel 
elimination rate constant 
KPC 
KrasLSL-G12D/þ; Trp53LSL-R172H/þ; Cre 
mAb 
monoclonal antibody 
MedDRA 
Medical Dictionary of Regulatory Activities 
MRI 
magnetic resonance imaging 
MSE 
musculoskeletal event 
MTD 
maximum tolerated dose 
NAB 
nab-paclitaxel 
NCCN 
National Comprehensive Cancer Network 
NCI  
National Cancer Institute  
NSAID 
nonsteroidal anti-inflammatory drugs 
NSCLC 
non-small cell lung cancer 
ORR 
objective response rate 
OS 
overall survival 
OTC 
over-the-counter  
PAG 
PEGPH20 combined with nab-paclitaxel plus gemcitabine 
PD 
progressive disease 
PD-1 
programmed cell death-1 
PDA 
pancreatic ductal adenocarcinoma 
PD-L1 
PD-1 ligand 1 
PDoc 
PEGPH20 plus docetaxel 
PDx 
patient-derived xenografts 
PE 
pulmonary embolism 
PEG 
polyethylene glycol 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
Abbreviation 
Definition 
PEGCISGEM 
PEGPH20 in combination with cisplatin and gemcitabine  
PEGCISGEMATEZO 
PEGPH20 in combination with cisplatin, gemcitabine, and atezolizumab  
PEGPH20 
PEGylated recombinant human hyaluronidase 
PFS 
progression-free survival 
PGx 
Pharmacogenetics 
PH20 
recombinant human hyaluronidase 
PI 
Principal Investigator 
PK 
pharmacokinetic(s) 
PR 
partial response 
PT 
prothrombin time 
PTT 
partial thromboplastin time 
PUVA 
psoralen plus ultraviolet A radiation 
Q3W 
every 3 weeks 
RECIST 
Response Evaluation Criteria in Solid Tumors 
rHuPH20 
recombinant human hyaluronidase 
RNA 
ribonucleic acid 
RP2D 
recommended Phase 2 dose 
SAE  
serious adverse event  
SD 
stable disease 
SMQ 
Standardized MedDRA Queries  
SUSAR 
suspected unexpected serious adverse reactions  
t1/2 
terminal half-life 
T3 
triiodothyronine 
T4 
total thyroxine 
TE 
thromboembolic 
TME 
tumor microenvironment 
TSH 
thyroid stimulating hormone 
ULN 
upper limit of normal 
US 
United States 
Vd 
volume of distribution 
WBC 
white blood cell 
WOCBP 
women of childbearing potential 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
3. 
STUDY SCHEDULES OF EVENTS 
Table 1: 
Study Schedule of Events: Screening (Run-in and Expansion) 
Tests and Assessmentsa  
≤28 Days Before Day 1 
Sign and date Informed Consent  
X 
Study procedure-associated SAE recording 
X 
Inclusion/exclusion criteria 
X 
Medical history  
X 
Bile duct adenocarcinoma history (intrahepatic, extrahepatic, and gallbladder adenocarcinoma) 
X 
Prior medication history 
X 
Confirm availability of and retrieve tumor tissueb 
X 
Disease assessment (CT scan/MRI scan of chest, abdomen, pelvis, and other areas of known or newly suspected disease)c, d 
X 
Doppler ultrasound of lower extremities 
X 
12-Lead ECG  
X 
Physical examinationc 
X 
Vital signsc 
X 
ECOG Performance Status 
X 
Height and weight/BSAc 
X 
Local Laboratory Tests 
 
Urine/serum pregnancy tests (WOCBP)e 
X 
Central Laboratory Testsf 
 
Hematology  
X 
 
Blood chemistry  
X 
 
Urinalysis 
X 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 1: 
Study Schedule of Events: Screening (Run-in and Expansion) (Continued) 
Tests and Assessmentsa 
≤28 Days Before Day 1 
 
Coagulationg  
X 
 
Plasma HA 
X 
 
CA19-9 
X 
 
CEA 
X 
 
Plasma biomarker 
X 
 
Thyroid function testsh 
X 
 
Viral serologyi 
X 
Subject registration following signing of ICF  
X 
Subject enrollment (in both portions) and randomization (in Expansion only)  
X 
Abbreviations: BSA = body surface area; CA19-9 = cancer antigen 19-9; CEA = carcinoembryonic antigen; CT = computed tomography; ECOG = Eastern 
Cooperative Oncology Group; ECG = electrocardiogram; ICF = Informed Consent Form; HA = hyaluronan; INR = International normalized ratio; PT = 
prothrombin time; MRI = magnetic resonance imaging; PTT = partial thromboplastin time WOCBP = women of childbearing potential. 
a See Section 8.2 for details on individual assessments. 
b  Archived tissue from the primary or a metastatic lesion is required. Refer to the Laboratory Manual for tumor tissue requirements. Subjects’ tumor samples will 
be tested retrospectively for HA and PD-L1 expression levels. 
c If these procedures are performed as part of standard-of-care prior to the subject’s signing of the ICF, the results may be used for screening purposes provided 
the procedures were performed within the screening window. 
d Chest CT scans should be read locally to evaluate for the presence of pulmonary embolism (PE). If a subject shows signs or symptoms of PE after the initial 
scan was completed, the chest scan should be repeated prior to enrollment (in Run-in)/randomization (in Expansion) to assess for the presence of PE. If a PE is 
present, the subject will be excluded from the study. 
e To be performed within 7 days prior to Day 1 (first dose of study medication). 
f If central laboratory results are delayed, local laboratory results may be used to determine subject eligibility (all central laboratory testing is still required). 
Refer to Section 8.2.11 for further details. 
g After the screening (baseline) assessment, coagulation tests (PT, PTT, INR) will be performed upon determination of disease progression. 
h Blood samples will be collected for baseline testing of thyroid hormones (free triiodothyronine [T3 or total T3 for sites where free T3 is not performed], free 
total thyroxine [T4] and thyroid stimulating hormone [TSH]). 
i Subjects will be tested for HIV (unless not permitted per local regulations) and HBsAg, HBsAb, total HBcAb, and HCV antibody. An HBV DNA test should 
be performed if a subject has a negative HBsAg result and a positive total HBcAb result at Screening. If a subject has a positive HCV antibody result at 
Screening, an HCV RNA test must also be performed to determine if the subject has an active HCV infection. 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 2: 
Study Schedule of Events: PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 weeks) 
Treatment Cycles 2+ 
(Repeats every 3 weeks) 
Confirmatory 
CT/MRI Scan 
End of 
Cycle #3 
and Every 
3rd Cycle 
Thereafter 
End of 
Treatmentb 
Long-
Term 
Follow
-Upc 
Wk 1 
Wk 2 
Wk 3 
Wk 1 
Wk 2 
Wk 3 
 
 
 
 
 
D1 
D2 
D4d 
D8 
D9 
D11d 
D15 
D18d 
D1 
D2 
D8 
D9 
D15 
 
 
 
 
Confirm Eligibility 
Based on 
Inclusion/Exclusion 
Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examinatione  
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Vital signse 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
ECOG Performance 
Statuse 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Weight/BSAe 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
12-lead ECGf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Disease assessment 
(CT/MRI scan)g 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Xh 
 
Confirmatory scan for 
response and/or disease 
progressioni 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
Pregnancy testj 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 2: 
Study Schedule of Events: PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) 
(Continued) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 weeks) 
Treatment Cycles 2+ 
 (Repeats every 3 weeks) 
Confirmatory 
CT/MRI 
Scan  
End of 
Cycle #3 
and Every 
3rd Cycle 
Thereafter 
End of 
Treatmentb 
Long-
Term 
Follow
-Upc 
Wk 1 
Wk 2 
Wk 3 
Wk 1 
Wk 2 
Wk 3 
 
D1 
D2 
D4d 
D8 
D9 
D11d 
D15 
D18d 
D1 
D2 
D8 
D9 
D15 
 
 
 
 
Central Laboratory Tests 
Hematologye 
X 
 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
 
X 
 
Blood chemistry 
(PEGCISGEM onlye) 
X 
 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
X 
 
Blood chemistry 
(PEGCISGEMATEZO 
onlyk) 
X 
 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
 
X 
 
Thyroid function  testsl 
(PEGCISGEMATEZO 
only) 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
CA19-9e  
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
CEAe  
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Urinalysise 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
Coagulation testsm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PK, ADA, plasma HA, 
exp. biomarkers, PGx, 
tumor biopsy 
Collection schedule and details for PK, immunogenicity (ADA), plasma HA, exploratory biomarkers, PGx, and tumor biopsy samples provided in 
Table 4 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 2: 
Study Schedule of Events: PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) 
(Continued) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 weeks) 
Treatment Cycles 2+ 
 (Repeats every 3 weeks) 
Confirmatory 
CT/MRI 
Scan  
End of 
Cycle #3 
and Every 
3rd Cycle 
Thereafter 
End of 
Treatmentb 
Long-
Term 
Follow
-Upc 
Wk 1 
Wk 2 
Wk 3 
Wk 1 
Wk 2 
Wk 3 
 
D1 
D2 
D4d 
D8 
D9 
D11d 
D15 
D18d 
D1 
D2 
D8 
D9 
D15 
 
 
 
 
Piroxicamn 
X 
 
X 
X 
 
X 
X 
X 
X 
 
X 
 
X 
 
 
 
 
Proton pump inhibitoro 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
Enoxaparin 
administrationp 
X 
 
 
 
 
PEGPH20 
administration  
X 
 
X 
X 
 
X 
X 
X 
X 
 
X 
 
X 
 
 
 
 
Atezolizumab 
administrationq 
(PEGCISGEMATEZO 
only) 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
Cisplatin (CIS) 
administrationr 
 
X 
 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
 
Gemcitabine (GEM) 
administrationr 
 
X 
 
 
X 
 
 
 
 
X 
 
X 
 
 
 
 
 
EOT tumor biopsys 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Concomitant 
medication and 
procedure recording 
X 
 
 
X 
 
Adverse event 
recording 
X 
 
 
X 
 
Long-term follow-up 
 
 
 
 
X 
Abbreviations: ADA = anti-drug antibodies; BSA = body surface area; CA19-9 = cancer antigen 19-9; CEA = carcinoembryonic antigen; CT = computed 
tomography; D = Day; DMC = Data monitoring committee; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EOT = End of 
Treatment; exp. = exploratory; HA = hyaluronan; MRI = magnetic resonance imaging; PK = pharmacokinetics; INR = International normalized ratio; 
PGx = pharmacogenetics; PT = prothrombin time; PTT = partial thromboplastin time. 
Note: Scheduled visits should occur within ±2 days of the specified dates as long as doses are separated by the appropriate amount of time. 
a 
See Section 8.2 for details on individual assessments. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
b 
End of Treatment Visit will occur within approximately 7 days after disease progression determination or treatment discontinuation.  
c 
Subjects will enter Long-Term Follow-Up after the End of Treatment Visit. The site will obtain information about the subject’s survival and subsequent 
anticancer therapy every 12 weeks until the subject dies, is lost to follow-up, or withdraws consent. Subjects may be contacted more frequently to collect 
information on survival and subsequent anticancer therapy, as required, prior to important study timepoints, including DMC meetings and database locks. 
d 
This visit is applicable to the cohort of ~15 subjects enrolled under Protocol Amendment 3 only. 
e 
Perform the following pre-dose during all Treatment Cycles and at the End of Treatment Visit: physical examination, vital sign measurements, ECOG, 
weight/BSA, hematology, blood chemistry, CA19-9, CEA, and urinalysis 
f 
12-lead electrocardiogram will be done at End of Treatment and otherwise when clinically indicated. 
g 
Tumor assessment scans (computed tomography [CT]/ magnetic resonance imaging [MRI] of chest, abdomen, pelvis, and other areas of known or newly 
suspected disease) will be obtained and read by a local reviewer at the end of Cycle 3 and at the end of every third treatment cycle thereafter (i.e., end of 
Week 3 of Cycles 6, 9, etc.) for response evaluation based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in subjects receiving 
PEGCISGEM and PEGCISGEMATEZO and Immune-Modified Response Evaluation Criteria in Solid Tumors (Immune-Modified RECIST) in subjects 
receiving PEGCISGEMATEZO only. Scans may be obtained any time on or after Day 15 to allow enough time for the scan to be reviewed locally prior to 
the subject’s next scheduled dosing visit. All scans for tumor assessments performed during the study should be archived in accordance with the standard 
local practice. The scans will be submitted to a central imaging vendor selected by the Sponsor for potential central review at a later timepoint. For subjects 
who are withdrawn from the study due to clinical disease progression, a CT scan should be requested as soon as possible after clinical progression is 
determined. 
h 
CT should only be done if radiologic progressive disease was not documented in the previous CT scan, unless the latter was performed within the last 
14 days. 
i 
A confirmatory scan is required in both portions of the study for subjects with CR or PR for confirmation of response, to be performed at the earliest 28 days 
after the date of the first documented response (per RECIST v1.1) (preferred) or at the next scheduled imaging timepoint, whichever is clinically indicated. A 
confirmatory scan is required for subjects receiving PEGCISGEMATEZO treatment to confirm radiological disease progression (per Immune-Modified 
RECIST), to be performed no sooner than 28 days after the initial scan that showed progression (this can be the next scheduled tumor assessment scan). 
(Details in Section 8.2.15.)  
j 
Pregnancy test will be performed at local laboratory pre-dose for women of childbearing potential (WOCBP). 
k 
In subjects receiving PEGCISGEMATEZO, measurements of total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) (as part 
of blood chemistry) must be obtained prior to dosing (within 48 hours is acceptable) on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycle 2. Local laboratories 
may be used for these measurements. Dosing can only take place if AST, and ALT values are within the ranges specified in the Inclusion Criterion. For total 
bilirubin, dosing can take place only if the total bilirubin is ≤3.0 × ULN in Cycle 1 (Day 1, Day 8, and Day 15) and Cycle 2 Day 1. If a subject has any of the 
values outside the specified ranges for ALT, AST, and total bilirubin on Day 1 of Cycle 2, the Investigator should discuss further dosing plans for the subject 
with the Sponsor. 
l 
Thyroid hormone tests (free triiodothyronine [T3], or total T3 for sites where free T3 is not performed], free total thyroxine [T4], and thyroid stimulating 
hormone) will be performed on Day 1 of Cycle 1 and every third cycle thereafter (i.e., Day 1 of Cycles 3, 6, 9 etc.). 
m Coagulation tests (PT, PTT, INR) will be performed upon determination of disease progression. 
n 
Piroxicam (20 mg) will be administered at least 1 hour prior to PEGPH20 administration on the day of dosing (timing will be at the Investigator’s discretion 
based on the piroxicam manufacturer’s Prescribing Information, institutional practices, and subject’s convenience) to minimize the severity of MSEs. A non-
steroidal analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered instead of piroxicam to reduce potential MSEs, at the discretion of 
the Investigator. 
o 
Prophylactic use of a proton pump inhibitor is mandated for all subjects while receiving PEGPH20 (e.g., 20 mg omeprazole daily or over-the-counter 
equivalent).  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
p 
During the Treatment Period, enoxaparin will be given subcutaneously at 1 mg/kg/day to subjects in the PEGCISGEM and PEGCISGEMATEZO arms 
enrolled through Protocol Amendment 2 and to the additional cohort of subjects enrolled under Protocol Amendment 3 receiving PEGCISGEMATEZO (see 
Section 10.1.1 for additional details). On PEGPH20 dosing days, enoxaparin will be administered prior to the infusion of the study medication. 
q 
Atezolizumab will be given 1 to 3 hours after PEGPH20, on Day 1 of all cycles. 
r 
Cisplatin (CIS) and gemcitabine (GEM) will be given 24 ± 4 hours after a dose of PEGPH20 in the PEGCISGEM and PEGCISGEMATEZO arms, on Day 2 
and Day 9 in all cycles. Note: Hydration and electrolyte supplementation with potassium and magnesium must be given prior to CIS infusion per individual 
institutional standards. Antiemetics will be administered as standard-of-care prior to CIS and GEM infusions. Steroids can only be administered if emesis is 
not controlled with other antiemetics. 
s 
If deemed clinically feasible by the Investigator, an End of Treatment tumor biopsy will be collected at the time of disease progression per RECIST v1.1, loss 
of clinical benefit as determined by the Investigator, or unacceptable toxicity. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 3: 
Study Schedule of Events: CISGEM (Control) Treatment (Expansion only) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 weeks) 
Treatment Cycles 2+ 
 (Repeats every 3 weeks) 
Confirmatory 
CT/MRI 
Scan 
End of 
Cycle #3 
and Every 
3rd Cycle 
Thereafter 
End of 
Treatmentb 
Long-
Term 
Follow-
Upc 
 
Week 1 
Week 2 
Week 1 
Week 2 
 
 
 
 
 
D1 
D8 
D1 
D8 
 
 
 
 
Confirm Eligibility 
Based on 
Inclusion/Exclusion 
Criteria 
X 
 
 
 
 
 
 
 
Physical examinationd 
X 
 
X 
 
 
 
X 
 
Vital signse 
X 
X 
 
X 
X 
 
 
 
X 
 
ECOGd 
X 
 
X 
 
 
 
X 
 
Weight/BSAd 
X 
 
X 
 
 
 
X 
 
12-Lead ECGf 
 
 
 
 
 
 
Xf 
 
Disease assessment 
(CT/MRI scan)g 
 
 
 
 
 
X 
Xh 
 
Response 
confirmation scani 
 
 
 
 
X 
 
 
 
Pregnancy test 
(WOCBP), local 
laboratory; before 
dosing 
 
 
X 
 
 
 
 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 3: 
Study Schedule of Events: CISGEM (Control) Treatment (Expansion only) (Continued) 
Tests and 
Assessmentsa 
Treatment Cycle 1 (3 weeks) 
Treatment Cycles 2+ 
 (Repeats every 3 weeks) 
Confirmatory 
CT/MRI 
Scan 
End of 
Cycle #3 
and Every 
3rd Cycle 
Thereafter 
End of 
Treatmentb 
Long-
Term 
Follow-
Upc 
 
Week 1 
Week 2 
Week 1 
Week 2 
 
 
 
 
 
D1 
D8 
D1 
D8 
 
 
 
 
Central Laboratory Tests 
 
Hematologyd 
X 
X 
X 
X 
 
 
X 
 
 
Blood chemistryd 
X 
X 
X 
X 
 
 
X 
 
 
CA19-9 (serum) 
X 
 
X 
 
 
 
X 
 
 
CEA (serum)d 
X 
 
X 
 
 
 
X 
 
 
Coagulation 
panel  
 
(PT, PTT, INR)j 
 
 
 
 
 
 
X 
 
 
Urinalysisd 
X 
 
X 
 
 
 
X 
 
PK, plasma HA, exp. 
biomarkers, PGx, 
tumor biopsy 
 
Collection schedule and details for PK, plasma HA, exploratory biomarkers, PGx and tumor biopsy samples provided in 
Table 5 
CIS administrationk 
X 
X 
X 
X 
 
 
 
 
GEM administrationk 
X 
X 
X 
X 
 
 
 
 
EOT tumor biopsyl 
 
 
 
 
 
 
X 
 
Concomitant 
medication and 
procedure recording 
X 
 
 
X 
 
Adverse event 
recording 
X 
 
 
X 
 
Long-term follow-upc 
 
 
 
 
X 
Abbreviations: D = Day; BSA = body surface area; CA19-9 = cancer antigen 19-9; CEA = Carcinoembryonic antigen; CT = computed tomography; D = day; 
ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group [Performance Status]; EOT = End of Treatment; exp. = exploratory; 
HA = hyaluronan; MRI = magnetic resonance imaging; PK = pharmacokinetics; INR = international normalized ratio; PGx = pharmacogenetics; 
PT = prothrombin time; PTT = partial thromboplastin time;  
 WOCBP = women of childbearing potential 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Note: Scheduled visits should occur within ±2 days of the specified dates as long as doses are separated by the appropriate amount of time. 
a 
See Section 8.2 for details on individual assessments. 
b 
Subjects should return to the study site for an End of Treatment Visit within approximately 7 days after determination of progressive disease or within 7 days 
after treatment discontinuation for other reasons. 
c 
After the End of Treatment Visit, subjects will enter Long-Term Follow-up during which information on the subject’s survival and subsequent anticancer 
therapy will be obtained by the site every 12 weeks until the subject dies, is lost to follow-up, or withdraws consent. Subjects may be contacted more 
frequently to collect information on survival and subsequent anticancer therapy, as required, prior to important study timepoints, including DMC meetings 
and database locks. 
d 
The following tests and assessments will be performed pre-dose in all cycles: physical examination, ECOG, weight/BSA, hematology, blood chemistry, 
CA 19-9, CEA, and urinalysis 
e 
Vital signs will be taken pre-dose in all cycles and at End-of-Treatment Visit.  
f 
12-lead electrocardiogram will be done at End of Treatment and otherwise when clinically indicated. 
g 
Tumor assessment scans (computed tomography (CT)/ magnetic resonance imaging (MRI) of chest, abdomen, pelvis, and other areas of known or newly 
suspected disease) will be obtained and read by a local reviewer at the end of Cycle 3 and at the end of every third treatment cycle thereafter (i.e., end of 
Week 3 of Cycles 6, 9, etc.) for response evaluation based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Scans may be obtained any time 
on or after Day 15 to allow enough time for the scan to be reviewed locally prior to the subject’s next scheduled dosing visit. All scans for tumor assessments 
performed during the study should be archived in accordance with the standard local practice. The scans will be submitted to a central imaging vendor 
selected by the Sponsor for potential central review at a later timepoint. For subjects who are withdrawn from the study due to clinical disease progression, a 
CT scan should be requested as soon as possible after clinical progression is determined. 
h 
 
i 
CT should only be done if radiologic progressive disease was not documented in the previous CT scan, unless the latter was performed within the last 
14 days. 
A confirmatory scan is required for subjects with CR or PR for confirmation of response, to be performed at the earliest 28 days after the date of the first 
documented response (per RECIST v1.1) (preferred) or at the next scheduled imaging timepoint, whichever is clinically indicated (details in Section 8.2.15). 
j 
After the screening (baseline) assessment, coagulation tests (PT, PTT, INR) will be performed upon determination of disease progression. 
k 
Hydration and electrolyte supplementation with potassium and magnesium must be given prior to CIS infusion per individual institutional standards. 
Antiemetics will be administered as standard-of-care prior to CIS and GEM infusions. Steroids can only be administered if emesis is not controlled with other 
antiemetics. 
l 
If deemed clinically feasible by the Investigator, an End of Treatment tumor biopsy will be collected at the time of disease progression per RECIST v1.1 or 
unacceptable toxicity. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 4: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and Translational Medicine Sample 
Collection - PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) 
Visit / Cycle 
Cycle Week 
Cycle Day 
Timepoint 
Collection Window/Details 
Plasma HA 
Plasma Biomarkers 
PEGPH20 PK (plasma) 
ATEZO PK (serum) b 
CIS PK (plasma) 
GEM PK (plasma) 
PEGPH20 ADA (plasma) 
ATEZO ADA (serum) b 
PGx (whole blood) 
Tumor Biopsy 
SCR 
Screening Visit 
Within -28 days prior to C1D1 
X 
X 
 
 
 
 
 
 
 
X a 
Treatment Cycle 1 
Week 1 
Day 1 
Pre-PEGPH20 dose 
Anytime prior to PEGPH20 SOI 
 
 
 
 
 
 
 
 
X 
 
Pre-PEGPH20 dose 
Within -2 h prior to PEGPH20 SOI 
X 
X 
X 
X 
 
 
X 
X 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
 
 
X 
 
 
 
 
 
 
 
ATEZO EOI b 
Within +2 min after ATEZO EOI 
 
 
 
X 
 
 
 
 
 
 
1 to 2 h post-ATEZO b 
i.e., 90 min (±30 min) post-ATEZO SOI 
X 
 
X 
 
 
 
 
 
 
 
5 to 7 h post-ATEZO b 
i.e., 6 h (±1 h) post-ATEZO SOI 
X 
 
X 
X 
 
 
 
 
 
 
Day 2 
24 h post-PEGPH20 dose/ 
(pre-CIS dose) 
Within -15 min prior to CIS SOI 
X 
X 
X 
X 
X 
 
 
 
 
 
CIS mid-infusion  
30 min post-CIS SOI (±5 min) 
 
 
 
 
X 
 
 
 
 
 
CIS EOI 
Within +2 min after CIS EOI 
 
 
 
 
X 
 
 
 
 
 
Pre-GEM dose 
Within -15 min prior to GEM SOI 
 
 
 
 
 
X 
 
 
 
 
GEM mid-infusion 
15 min post-GEM SOI (±5 min) 
 
 
 
 
 
X 
 
 
 
 
GEM EOI 
Within +2 min after GEM EOI 
 
 
 
 
 
X 
 
 
 
 
2 to 4 h post-GEM  
i.e., 3 h (±1 h) after GEM EOI 
X 
 
X 
X 
X 
X 
 
 
 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 4: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and Translational Medicine Sample 
Collection - PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) (Continued) 
Visit / Cycle 
Cycle Week 
Cycle Day 
Timepoint 
Collection Window/Details 
Plasma HA 
Plasma Biomarkers 
PEGPH20 PK (plasma) 
ATEZO PK (serum) b 
CIS PK (plasma) 
GEM PK (plasma) 
PEGPH20 ADA (plasma) 
ATEZO ADA (serum) b  
PGx (whole blood) 
Tumor Biopsy 
 
 
Day 4 d 
Pre-PEGPH20 dose 
Within -2 h prior to PEGPH20 SOI 
X 
X 
X 
 
 
 
 
 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
 
 
X 
 
 
 
 
 
 
 
Treatment Cycle 1 
Week 2 
Day 8 
Pre-PEGPH20 dose  
Within -15 min prior to PEGPH20 SOI 
X 
X 
X 
X 
 
 
 
 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
 
 
X 
 
 
 
 
 
 
 
Day 9 
Pre-CIS dose 
Within -15 min prior to CIS SOI 
 
X 
 
 
X 
 
 
 
 
 
CIS mid-infusion  
30 min post-CIS SOI (±5 min) 
 
 
 
 
X 
 
 
 
 
 
CIS EOI 
Within +2 min after CIS EOI 
 
 
 
 
X 
 
 
 
 
 
Pre-GEM dose 
Within -15 min prior to GEM SOI 
 
 
 
 
 
X 
 
 
 
 
GEM mid-infusion 
15 min post-GEM SOI (±5 min) 
 
 
 
 
 
X 
 
 
 
 
GEM EOI 
Within +2 min after GEM EOI 
 
 
 
 
 
X 
 
 
 
 
2 to 4 h post-GEM  
i.e., 3 h (±1 h) after GEM EOI 
X 
 
X 
X 
X 
X 
 
 
 
 
Day 11 d 
Pre-PEGPH20 dose  
Within -15 min prior to PEGPH20 SOI 
X 
X 
X 
 
 
 
 
 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
 
 
X 
 
 
 
 
 
 
 
W3 
D15 
Pre-PEGPH20 dose 
Within -15 min prior to PEGPH20 SOI 
 
X 
X 
 
 
 
 
 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
X 
 
X 
X 
 
 
 
 
 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 4: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and Translational Medicine Sample 
Collection - PEGCISGEM and PEGCISGEMATEZO Treatments (Run-in and Expansion) (Continued) 
Visit / Cycle 
Cycle Week 
Cycle Day 
Timepoint 
Collection Window/Details 
Plasma HA 
Plasma Biomarkers 
PEGPH20 PK (plasma) 
ATEZO PK (serum) b 
CIS PK (plasma) 
GEM PK (plasma) 
PEGPH20 ADA (plasma) 
ATEZO ADA (serum) b  
PGx (whole blood) 
Tumor Biopsy 
 
 
Day 
18 d 
Pre-PEGPH20 dose 
Within -15 min prior to PEGPH20 SOI 
X 
X 
X 
 
 
 
 
 
 
 
 
 
PEGPH20 EOI 
Within +2 min after PEGPH20 EOI 
X 
 
X 
 
 
 
 
 
 
 
C2+  
W1 
D1 
Pre-PEGPH20 dose 
Within -2 h prior to PEGPH20 SOI 
 
 
 
X 
 
 
X 
X 
 
 
Pre-PEGPH20 dose 
Within -15 min prior to PEGPH20 SOI 
 
X 
 
 
 
 
 
 
 
 
EOT 
End of Treatment Visit 
 
 
X 
 
X 
 
 
X 
X 
 
Xc 
Abbreviations: ADA = anti-drug antibodies (i.e., immunogenicity); ATEZO = atezolizumab; C = Cycle; C2+ = Cycle 2 and beyond (repeats every 3 weeks); 
CIS = cisplatin; D = Day; EOI = End of Infusion; EOT = End of Treatment; GEM = gemcitabine; h = hour; HA = hyaluronan; min = minute; i.e. = id est (in 
other words);  RECIST = Response Evaluation Criteria in Solid Tumors; PGx = pharmacogenetic(s); PK = pharmacokinetic(s); SCR = Screening; SOI = Start of 
Infusion; W = week. 
 a Tumor biopsy tissue to be obtained and assessed as per Section 8.2.20.1 at SCR (mandatory for eligibility determination). 
b This sampling timepoint is for subjects receiving PEGCISGEMATEZO only. 
c If deemed clinically feasible by the Investigator, an EOT tumor biopsy will be obtained at the time of disease progression (as defined per RECIST v1.1), loss of 
clinical benefit as determined by the Investigator, or unacceptable toxicity. 
d This visit is applicable to the cohort of ~15 subjects enrolled under Protocol Amendment 3 only. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 5: 
Study Schedule of Events: Pharmacokinetic, Pharmacodynamic, and Translational Medicine Sample 
Collection - CISGEM Arm (Expansion only) 
(Table Abbreviations and Notes on next page) 
Visit / Cycle 
Cycle Week 
Cycle Day 
Timepoint 
Collection Window/Details 
Plasma HA 
Plasma Biomarkers 
CIS PK (plasma) 
GEM PK (plasma) 
PGx (whole blood) 
Tumor Biopsy 
SCR 
Screening Visit 
Within -28 days prior to C1D1 
X 
X 
 
 
 
Xa 
Treatment Cycle 1 
Week 1 
Day 1 
Pre-CIS dose 
Within -15 min prior to CIS SOI 
X 
X 
X 
 
X 
 
CIS mid-infusion  
30 min post-CIS SOI (±5 min) 
 
 
X 
 
 
 
CIS EOI 
Within +2 min after CIS EOI 
 
 
X 
 
 
 
Pre-GEM dose 
Within -15 min prior to GEM SOI 
 
 
 
X 
 
 
GEM mid-infusion 
15 min post-GEM SOI (±5 min) 
 
 
 
X 
 
 
GEM EOI 
Within +2 min after GEM EOI 
 
 
 
X 
 
 
2 to 4 h post-GEM  
i.e., 3 h (±1 h) after GEM EOI 
 
 
X 
X 
 
 
Week 2 
Day 8 
Pre-CIS dose 
Within -15 min prior to CIS SOI 
 
X 
X 
 
 
 
CIS mid-infusion  
30 min post-CIS SOI (±5 min) 
 
 
X 
 
 
 
 
CIS EOI 
Within +2 min after CIS EOI 
 
 
X 
 
 
 
Pre-GEM dose 
Within -15 min prior to GEM SOI 
 
 
 
X 
 
 
GEM mid-infusion 
15 min post-GEM SOI (±5 min) 
 
 
 
X 
 
 
GEM EOI 
Within +2 min after GEM EOI 
 
 
 
X 
 
 
C2+ 
W1 
D1 
Pre-CIS dose 
Within -15 min prior to CIS SOI 
Xb 
Xc 
 
 
 
 
EOT 
End of Treatment Visit 
 
 
X 
 
 
 
Xd 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Abbreviations: C = [Treatment] Cycle; C2+ = Cycle 2 and beyond (repeats every 3 weeks); CIS = cisplatin; D = Day; EOI = End of Infusion; EOT = End of 
Treatment; GEM = gemcitabine; h = hour; HA = hyaluronan; min = minute; i.e. = id est (in other words); RECIST = Response Evaluation Criteria in Solid 
Tumors; PGx = pharmacogenetic(s); PK = pharmacokinetic(s); SCR = Screening; SOI = Start of Infusion; W = week. 
a Tumor biopsy tissue to be obtained and assessed as per Section 8.2.20.1 at SCR (mandatory for eligibility determination). 
b Sample for plasma HA to be obtained only on Cycle 2, Day 1 (does not repeat every 3 weeks). 
c Collect sample for plasma biomarker on Day 1 of Treatment Cycles 2+ (repeats every 3 weeks).  
d If deemed clinically feasible by the Investigator, an EOT tumor biopsy will be obtained at the time of disease progression (as defined per RECIST v1.1), loss of 
clinical benefit as determined by the Investigator, or unacceptable toxicity. 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
4. 
BACKGROUND AND RATIONALE 
4.1. 
Biliary Tract Cancers 
Biliary tract cancer refers to a group of cancers of the biliary tract, including gallbladder cancer 
and cholangiocarcinoma (CCA) of intrahepatic and extrahepatic bile ducts and cancers of the 
ampulla and papilla of Vater (Park 2015). 
Cholangiocarcinoma 
CCA is an aggressive epithelial malignancy of the bile ducts that often presents with locally 
advanced or metastatic disease and carries an extremely poor prognosis (Saha 2016). It is the 
second most common primary liver tumor after hepatocellular carcinoma and accounts for about 
3% of all gastrointestinal tumors (Bergquist 2015). 
Named after its presumed cell of origin, CCA tumors can arise from anywhere in the biliary tract 
and may be difficult to identify on the basis of histopathologic analysis alone. The disease is 
subclassified anatomically, with intrahepatic cholangiocarcinoma (ICC) arising from within the 
liver and extrahepatic cholangiocarcinoma (ECC) arising from the extra hepatic bile ducts 
(Saha 2016). 
The epidemiology of CCA is heterogeneous, and the incidence seems to be increasing 
(Bergquist 2015). In the United States (US), CCA accounts for approximately 5000 deaths per 
year (Esnaola 2016). In Asia, high incidence rates (85/100,000) has been reported in northeast 
Thailand (where CCA represents approximately 85% of total primitive liver cancers) and other 
Asian countries, such as China and Korea (Bragazzi 2012). 
Patients with CCA usually present at late stages of the disease, and symptoms might be 
nonspecific, such as painless jaundice, weight loss, or cholangitis. Therefore, these cancers 
remain difficult to diagnose and treat and their prognosis is generally poor. Approximately half 
of the untreated patients die within 3 to 4 months of presentation from the indirect effects of 
local tumor progression, bile duct obstruction, liver failure or sepsis from cholangitis and 
abscesses (Patel 2011). 
Although 1-year mortality has improved over time, the 5-year survival is still as low as 10%. 
Only about one third of the patients with CCA are available for curative treatment at diagnosis 
(Bergquist 2015). 
Surgery is the only curative treatment for CCA but few patients are candidates for potentially 
curative surgical resection at the time of presentation (Park 2015; Patel 2011). Moreover, the 
outcomes after resection with curative intent are poor. Many patients are not well enough to 
undergo aggressive chemotherapy or radiation therapy. Furthermore, CCAs respond poorly to 
these therapies. In a study published in 2010, a median survival of 11.7 months was noted when 
systemic therapy with cisplatin (CIS) and gemcitabine (GEM; Gemzar®) was used to treat 
patients with unresectable biliary tract cancers. Although treatment with this combination has 
being touted as the standard-of-care for all biliary tract cancers novel approaches are in need to 
improve the poor outcome of this rare and deadly disease (Patel 2011). 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Gallbladder Cancer 
Gallbladder cancer is the most common malignancy of the biliary tract, accounting for 80% to 
95% of biliary tract cancers (Hundal 2014). Over 80% of the gallbladder cancer cases are 
adenocarcinomas and originate from the fundus (60%), body (30%), or neck (10%) of the 
gallbladder (Shaffer 2008). 
The American Cancer Society’s estimates for cancer of the gallbladder and nearby large bile 
ducts in the US for 2016 are as follows (American Cancer Society 2016): 
• About 11,420 new cases diagnosed: 5270 in men and 6150 in women 
• About 3710 deaths from these cancers: 1630 in men and 2080 in women 
The incidence rates of gallbladder cancer are extraordinarily high in Latin America and Asia. 
Asia is a high risk continent, where an increased frequency of gallbladder cancer occurs in 
northern Indian females, Pakistani females, and Korean males. Ethnic rates can prevail even in 
different geographic locations. The Korean people have the highest incidence rate (per 100,000) 
of gallbladder cancer in Asia: 8.1 for males and 5.6 for females. Korean males living in Los 
Angeles County, California also carry the highest US ethnic incidence rate at 5.9 (Hundal 2014) 
The overall mean survival rate for patients with gallbladder cancer is 6 months, with a 5-year 
survival rate of 5% (Hundal 2014). 
Complete surgical resection is the only effective treatment for gallbladder carcinoma. As early 
symptoms are vague and anatomically the gallbladder lacks a serosa to limit the spreading of 
cancer, the diagnosis of gallbladder cancer frequently occurs at an advanced stage, typically with 
an abysmal prognosis (Shaffer 2008). Only 10% of patients with gallbladder carcinoma present 
with early-stage disease and are considered surgical candidates. Among those patients who do 
undergo “curative” resection, recurrence rates are high. Patients with unresectable or metastatic 
gallbladder cancer have a poor prognosis. The role of adjuvant therapies, including systemic 
chemotherapy and radiotherapy, furthermore have been reported to have only a modest 
therapeutic effect (Zhu 2010). 
In a Phase 3 study conducted in 410 patients, including 149 patients with gallbladder cancer, the 
addition of CIS to GEM (CISGEM) afforded significant progression-free survival (PFS; median, 
8.4 months versus 6.5 months; hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.57-0.90; 
p = 0.003) and overall survival (OS; median, 11.7 months versus 8.3 months; HR, 0.70; 95% CI, 
0.54-0.89; p = 0.002) benefits (Zhu 2010). Although treatment with this combination may be 
considered as the standard-of-care for gallbladder cancer, novel approaches are in need to 
improve the poor outcome of this rare and deadly disease. 
4.2. 
Hyaluronan and Malignancy 
Hyaluronan (HA) is a high-molecular-mass polysaccharide found in the extracellular matrix of 
tumors. Accumulation of HA in several malignant diseases is associated with aggressive tumor 
type, cancer progression/metastasis, and poor prognosis (Toole 2008; Setälä 1999; 
Shepard 2015; Sironen 2011). Interaction of pericellular HA and CD44 has been shown to 
influence drug resistance (Toole 2008). Local aberrations of HA metabolism have been reported 
in many solid tumor malignancies, where elevated levels of HA frequently correlate with poor 
prognosis in tumors, such as pancreatic (Kultti 2012; Whatcott 2011), breast (Auvinen 2000), 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
gastric (Setälä 1999), colorectal (Ropponen 1998), ovarian (Anttila 2000), prostate 
(Bharadwaj 2009), lung carcinoma (Chow 2010), and CCA (Padrnos 2016). 
4.3. 
PEGylated Recombinant Human Hyaluronidase 
Halozyme, Inc. (Halozyme) has developed an investigational new molecular entity, PEGylated 
recombinant human hyaluronidase (PEGPH20), which uses a novel mechanism of action to 
systemically target tumors that accumulate HA. In preclinical models, both tumor xenografts in 
immunocompromised mice and autochthonous tumors from genetically engineered 
KrasLSL-G12D/þ; Trp53LSL-R172H/þ; Cre (KPC) mice, depletion of HA from the tumor 
microenvironment (TME) has been shown to inhibit the growth of tumors characterized by 
accumulation of HA (Thompson 2010; Jiang 2012; Provenzano 2012; Jacobetz 2013). 
The recombinant human hyaluronidase (PH20) enzyme is a soluble domain of the endogenous 
human PH20 glycoprotein, devoid of its carboxy-terminal, lipid anchor attachment site. To 
increase the plasma half-life (t1/2) and enable systemic therapeutic exposure not possible with 
existing recombinant human PH20 (rHuPH20), Halozyme developed a PEGylated version of 
rHuPH20. Like rHuPH20, PEGPH20 removes HA from the extra cellular matrix by 
depolymerizing the substrate (Thompson 2010). In many different tumor types tested in murine 
xenograft models, response to PEGPH20 has been shown to be more robust for tumors 
characterized by higher HA accumulation (Jiang 2012). PEGPH20 has a terminal t1/2 of 
approximately 3.2 hours in rodents and 50 hours in monkeys. A population PK model of 
PEGPH20 combining data from 218 subjects across 4 studies (HALO-109-101, HALO-109-102, 
HALO-109-201, and HALO-109-202) demonstrated a t1/2 of 14.5 hours for the initial phase and 
79.2 hours for the terminal phase (Halozyme Report 18218) (as compared with <10 minutes for 
rHuPH20 intravenous [IV] hyaluronidase [Halozyme Clinical Study Report HALO-104-104]). 
The increased t1/2 of PEGPH20 makes sustained degradation of tumor-associated HA feasible. 
4.3.1. 
PEGPH20 and Chemotherapy 
Enzymatic depletion of HA from the TME, with PEGPH20 either alone or in combination with 
chemotherapy, represents an innovative potential treatment that could provide improved 
therapeutic outcomes for patients (Pillwein 1998; Baumgartner 1998; Klocker 1998), based on a 
reduction in interstitial fluid pressure, and the subsequent vascular decompression, increased 
blood volume, and concomitantly enhanced drug penetration into HA-rich tumors (Spruss 1995; 
Brekken 1998; Eikenes 2005; Thompson 2010), and on the reduction of tumor HA levels, which 
was reported to reduce in vitro tumor cell proliferation, motility, and invasion, and to reduce the 
growth of implanted tumors (Shuster 2002; Simpson 2002; Kim 2004; Nishida 2005; 
Udabage 2005; Li 2007; Thompson 2010; Provenzano 2012; Jacobetz 2013). 
In the autochthonous KPC pancreatic model, PEGPH20 treatment induced fenestrations and 
interendothelial junctional gaps in pancreatic endothelia (Jacobetz 2013). Independent studies in 
the same model reported that the increased vascular perfusion observed when PEGPH20 is given 
in combination with GEM persisted for weeks after therapy ceased, suggesting that the TME was 
permanently remodeled following PEGPH20 treatment (Provenzano 2012; Provenzano 2013). In 
mouse pancreatic xenografts, PEGPH20 treatment induced translocation of E-cadherin and 
β-catenin to the plasma membrane of cancer cells, suggesting at least a partial reversal of the 
classic epithelial-mesenchymal transition (EMT) observed during the progression of malignancy 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
(Kultti 2014). Finally, in non-small cell lung cancer (NSCLC) patient-derived xenografts (PDx) 
the antitumor effect of PEGPH20 in combination with docetaxel (Doc; Taxotere®) was evaluated 
(Halozyme Report 13036). In HA-high PDx tumors, PEGPH20 enhanced the effect of Doc, 
increasing tumor growth inhibition from 52.5% for Doc alone to 115.5% for PEGPH20 plus Doc 
(PDoc), while concomitantly increasing survival by 50% (35 days for Doc alone vs 70 days for 
PDoc). 
4.4. 
Clinical Experience With PEGPH20 and Clinical Development Plan 
PEGPH20 is being developed as an investigational, novel therapeutic agent for use in 
combination with chemotherapy or other agents for the treatment of patients with cancers that 
accumulate HA.  
In the PEGPH20 clinical development program, up to 12 February 2018, a total of 290 subjects 
had received PEGPH20 in clinical studies conducted by the Sponsor: in 2 completed Phase 1 
studies of PEGPH20 monotherapy (HALO-109-101 and HALO-109-102), in 1 completed Phase 
1b study in pancreatic cancer in combination with chemotherapy (GEM; HALO-109-201), in a 
completed Phase 2 study in pancreatic cancer in combination with chemotherapy (GEM plus 
nab-paclitaxel [NAB; Abraxane®]; HALO-109-202), in a discontinued Phase 1b study in lung 
cancer in combination with chemotherapy (docetaxel; HALO-107-201), in the current Phase 1b 
study (HALO-110-101) in subjects with cholangiocarcinoma and gallbladder adenocarcinoma, 
and in an ongoing Phase 1b study in lung cancer in combination with the immunotherapeutic 
drug pembrolizumab (HALO-107-101). Additionally randomized study medication (PEGPH20 
or placebo) is being administered in combination with GEM plus NAB to HA-high subjects with 
Stage IV pancreatic cancer in an ongoing, double-blind Phase 3 study (HALO-109-301; number 
of subjects dosed with PEGPH20 unknown to the Sponsor). 
4.4.1. 
Phase 1 Study HALO-109-101 
This study enrolled 14 subjects with advanced malignancies who experienced disease 
progression after previous therapy. This study was amended due to the observation of severe 
musculoskeletal events (MSEs) and was closed due to these events. 
4.4.2. 
Phase 1 Study HALO-109-102 
This study was initiated to evaluate the safety profile of PEGPH20 using the regimen of once or 
twice weekly PEGPH20 administration in subjects with advanced solid tumors, including 
3 subjects with intrahepatic cholangiocarcinoma. Dexamethasone (pre- and post-PEGPH20 
doses) was added to the regimen to alleviate musculoskeletal toxicities. PEGPH20 doses 
administered ranged from 0.5 to 5.0 μg/kg either once or twice weekly (Day 1 and Day 4) 
schedule for the first cycle (4 weeks) and once per week for subsequent cycles. In addition, 
subjects received 4 or 8 mg dexamethasone 1 hour prior to and 8 to 12 hours after PEGPH20 
administration. Of a total of 26 subjects enrolled in this study, 6 were treated at 3.0 µg/kg once 
weekly and 14 received 3.0 µg/kg twice weekly schedule. The maximum tolerated dose (MTD) 
was determined to be 3.0 µg/kg administered once or twice weekly. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
4.4.3. 
Phase 1b Study HALO-109-201 
This study was initiated to identify the recommended Phase 2 dose (RP2D) of PEGPH20 in 
combination with GEM in subjects with metastatic pancreatic cancer. A total of 28 subjects were 
treated with PEGPH20 administered by IV infusion twice per week for the first 4 weeks, then 
weekly for 3 weeks, followed by 1 week rest. GEM was administered at 1000 mg/m2 via IV over 
30 minutes once per week for 7 weeks followed by 1 week rest. Dexamethasone was used 1 hour 
pre- and 8 hours post-PEGPH20 dosing. From Cycle 2 onward, PEGPH20 and GEM were 
administered once weekly for 3 weeks in a 4-week cycle. 
4.4.4. 
Phase 2 Study HALO-109-202 
This was a Phase 2 multicenter, open-label, randomized study that enrolled/randomized a total of 
279 subjects with Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA) who 
received either PEGPH20 combined with NAB plus GEM (PAG treatment) or NAB plus GEM 
(AG treatment). The study was blinded to the Sponsor.  
In April 2014, the HALO-109-202 Data Monitoring committee (DMC) reported an imbalance in 
thromboembolic (TE) events with a higher incidence in subjects treated with PAG than AG 
therapy alone (28.4% vs. 14.8%, respectively). Based on these findings, the study was placed on 
a temporary clinical hold. All 29 ongoing subjects in the PAG group stopped PEGPH20 therapy 
and remained on AG therapy alone. In June 2014, the temporary clinical hold was lifted and the 
study protocol was amended to: (1) include concomitant use of prophylactic enoxaparin for all 
subjects, (2) requirement to discontinue PEGPH20 permanently after a TE event occurred, and 
(3) exclude subjects with evidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) 
as well as those subjects determined to be at high risk of TE events. Stage 1 of this study 
included subjects who were enrolled prior to the clinical hold (N = 146 randomized). Stage 2 
included subjects enrolled after the clinical hold and subsequent protocol amendment (N = 133 
randomized).  
The final analysis was performed with a database lock date of 01 May 2018 (Halozyme Clinical 
Study Report HALO-109-202). Safety and efficacy data from this study are presented in 
Section 4.4.7 Safety and Section 4.4.8 Efficacy. 
4.4.5. 
Phase 1b/2 Study HALO-107-201 
This was a Phase 1b/2, randomized, multicenter study of PEGPH20 in subjects with recurrent 
previously treated locally advanced or metastatic NSCLC receiving either PDoc or Doc alone. 
The study was designed to have a Phase 1b Dose Escalation portion and a Safety Evaluation 
portion, in all-comers (i.e., subjects not selected based on HA status), and a Cohort Expansion 
portion in prospectively selected HA-high subjects followed by a Phase 2 portion. 
In the Phase 1b Dose Escalation portion, approximately 3 to 6 subjects/cohort were to receive 
PEGPH20 at each increasing dose level (1.6, 2.2, 2.8, and 3.0 µg/kg) once/cycle in combination 
with standard dosing of Doc (75 mg/m2 every 21 days). Additional Safety Evaluation (in up to 
20 subjects) and Cohort Expansion portions (in up to 50 subjects) were to further evaluate the 
safety and tolerability of PDoc treatment before initiating Phase 2. Safety and preliminary 
pharmacokinetic (PK) results from all subjects dosed in Phase 1b were to be used to determine 
the RP2D for the Phase 2 portion. In Phase 2, approximately 188 subjects prospectively selected 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
for high HA levels were planned to be randomized in a 1:1 ratio to receive PDoc at the 
PEGPH20 dose selected in Phase 1b or Doc alone (75 mg/m2 once in each 21-day cycle). 
This study was discontinued during the Dose Escalation portion due to evolving standard-of-care 
in the NSCLC treatment landscape. At the time of termination, 16 subjects had been enrolled in 
the Dose Escalation portion, of which 15 were dosed at 3 different dose levels of PEGPH20 
(1.6, 3.0, and 2.2 µg/kg). TE event data from this study are provided in Section 4.4.7.2. 
Additional safety data are provided in the PEGPH20 Investigator’s Brochure. 
4.4.6. 
Phase 3 Study HALO-109-301 
This is an ongoing randomized, double-blind, placebo-controlled, multicenter study of PEGPH20 
(3.0 μg/kg) in combination with NAB (125 mg/m2) plus GEM (1000 mg/m2) (PAG treatment) 
compared with placebo plus NAB and GEM (AG treatment) in 420 and up to 570 subjects with 
HA-high Stage IV previously untreated PDA. 
Eligible subjects are randomized in a double-blind fashion to 1 of 2 treatment arms in a 2:1 ratio 
for PAG:AG. Randomization is stratified by geographic region (North America, Europe, and 
Others). 
The Treatment Period consists of 4-week treatment cycles (28 days), with Week 4 of every cycle 
being a rest week (i.e., no treatment is given). PEGPH20 or placebo is administered as an IV 
infusion twice weekly for Weeks 1 to 3 of Cycle 1, then once weekly for Weeks 1 to 3 of Cycle 2 
and beyond; NAB and GEM are administered as IV infusions once weekly for Weeks 1 to 3 of 
all treatment cycles.  
4.4.7. 
Safety 
The majority of safety data from Halozyme-sponsored clinical studies are from the largest 
dataset comprising the subject population of Phase 2 Study HALO-109-202 of PEGPH20 in 
combination with GEM and NAB compared to GEM and NAB in Stage IV PDA (N = 260 total 
subjects treated). Additional updated safety data are from 2 Phase 1b studies, HALO-107-201 
(PEGPH20 in combination with docetaxel) in NSCLC subjects, and HALO-107-101 (PEGPH20 
in combination with pembrolizumab) in NSCLC and gastric adenocarcinoma subjects.  
Based on a review of the available safety data across studies up to 12 February2018, important 
identified risks of PEGPH20 include MSEs and TE events. Refer to the PEGPH20 Investigator’s 
Brochure for additional safety information. 
4.4.7.1. 
Musculoskeletal Events 
Musculoskeletal adverse events (AEs) have been well documented during PEGPH20 treatment 
and were first observed during the monotherapy dose escalation studies. Prior to the initiation of 
study HALO-109-102, MSEs had been as severe as Grade 3/4; however, since the use of pre- 
and post-dose prophylaxis with dexamethasone in studies of PEGPH20 in combination with 
chemotherapy, the majority are Grade 1/2 in severity and, in general, have not led to treatment 
discontinuations. Since this study uses an immunotherapeutic agent (atezolizumab) and 
dexamethasone and other steroids may suppress an immune response, steroids should only be 
used when prescribed by the Investigator for management of ≥ Grade 3 MSEs that are refractory 
to non-steroid management (additional details in Table 9).  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Piroxicam and Toradol have been investigated in an animal model of MSEs and may be helpful 
in decreasing the severity of MSEs in subjects (internal unpublished Halozyme report). In this 
study, piroxicam will therefore be administered to decrease the severity of MSE’s; Toradol may 
be given for severe pain as recommended in the Prescribing Information (see Section 10.12 for 
additional details). 
4.4.7.2. 
Thromboembolic Events 
Thromboembolic events and their sequelae have been observed in clinical studies evaluating 
PEGPH20 monotherapy and combination therapies. 
In the 2 completed Phase 1 studies of PEGPH20 monotherapy in subjects with advanced solid 
tumors (HALO-109-101 and HALO-109-102; N = 40), TE events were observed in 1 subject 
(2.5%) who experienced embolism. 
In the Phase 1b Study HALO-107-201 in NSCLC, which was discontinued early by the Sponsor 
in August 2016 due to the changing treatment landscape for NSCLC, up to the date of study 
discontinuation, 4 of 15 (27%) treated subjects experienced a TE event, including DVT and 
superficial thrombophlebitis. 
In completed Study HALO-109-201 of PEGPH20 in combination with GEM in pancreatic 
cancer, the incidence of TE events was approximately 28%, the majority being of venous origin. 
Regarding the Phase 2 Study HALO-109-202 in pancreatic cancer, as discussed in Section 4.4.4, 
an imbalance was observed in the rate of TE events between the PAG and AG (PAG) treatment 
arms (28.4% vs. 14.8%) in Stage 1 of the study that led to the implementation of risk mitigation 
measures, including the exclusion of high-TE event risk subjects and the administration of 
enoxaparin prophylaxis in all subjects. The majority of the TE events were of venous origin 
(DVT and PE); however, arterial events were also reported. It is widely accepted that pancreatic 
cancer is a tumor type with a high TE event background rate. Published studies have reported a 
TE event incidence in these patients ranging from 17% to 57.7% (Khorana 2004, Bapat 2016).  
Since the implementation of the aforementioned measures in Stage 2 of HALO-109-202, the 
incidence of TE events decreased considerably compared with that observed in Stage 1. The TE 
event rate in the PAG and AG groups, respectively, decreased from 43% and 25% in Stage 1 (no 
enoxaparin prophylaxis) to 10% and 6% in Stage 2 (with enoxaparin 1 mg/kg/day prophylaxis). 
Additional details are provided in the PEGPH20 Investigator’s Brochure. 
While the rate of TE events in pancreatic cancer is reported to be highest among malignancies 
(Pelzer 2015), rates of TE events in CCA and gallbladder cancers have also been reported to be 
elevated (Jeon 2012; Martin 2012). In a trial evaluating the efficacy of 
chemotherapy  (single-agent GEM and CIS/GEM doublet) in advanced biliary tract cancer 
patients (ABC-02 trial; Valle 2010), Grade 3 or 4 DVT was reported for 2% [4/198], and Grade 
3 or 4 TE events for 3.5% [7/198] of subjects treated with GEM and CIS. Grade 3 or Grade 4 PE 
was not reported for any patients on the study. Based on these data and on the incidence of TE 
events reported to date in the current study (details in Section 10.1.1), the following safety 
measures will be taken to safeguard subjects: 
1. Subjects with clinical evidence of DVT or PE at baseline will be excluded from this trial. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
2. All subjects receiving PEGPH20 will be given prophylactic enoxaparin 1 mg/kg/day for 
thromboprophylaxis. 
3. If enoxaparin is discontinued for any reason, PEGPH20 will also be discontinued. 
Treatment with the other drugs, however, may continue as deemed appropriate by the 
Investigator. 
4. Sites will report any TE event to the Sponsor immediately and no later than 24 hours of 
awareness. 
4.4.8. 
Efficacy 
In the Phase 1b study (HALO-109-201) in subjects with pancreatic cancer, responses were 
assessed by an independent central radiologist. Partial Response (PR) was reported in 10 of the 
24 subjects who received PEGPH20 at either the 1.6 or 3.0 µg/kg dose level. In addition, 
subjects who had HA high in tissue biopsies experienced better responses (5/6 subjects), which 
correlated with prolonged PFS (219 days) and OS (approximately 395 days). PRs were seen in 
4 of the 11 subjects who had lower HA in tissue biopsies (Halozyme Clinical Study Report 
HALO-109-201). The PFS and OS in the low-HA group were 108 days and 174 days, 
respectively (Hingorani 2015). Further details about efficacy in early studies are provided in the 
PEGPH20 Investigator’s Brochure. 
Halozyme is developing, in collaboration with a diagnostic company, Ventana Medical Systems, 
Inc., a novel co-developed investigational diagnostic assay to identify subjects who might benefit 
most, based on HA tumor content, from the administration of PEGPH20 in conjunction with 
other cancer therapeutics. This assay uses an affinity-histochemistry-based staining method to 
evaluate HA levels in tumor biopsies.  
In the completed Phase 2 HALO-109-202 study, the final analysis was performed as of a 
database lock date of 01 May 2018. Tumor samples were collected and analyzed in a 
prospective-retrospective fashion using the investigational diagnostic assay. Statistical 
significance of efficacy endpoints was declared at the 2-sided alpha level of 0.1 per protocol.  
As of 01 May 2018, of the 279 subjects comprising the ITT Population, 99.6% (278/279) of 
subjects in the Stage 1 + Stage 2 combined were off treatment. The median PFS was 9.2 months 
with PAG vs. 5.2 months with AG (HR: 0.57; p-value: 0.092) in the combined Stage 1 + Stage 2 
ITT HA-high Population (n = 84 [49 PAG, 35 AG]), representing a statistically significant, 
4.0-month improvement with PAG for the total HA-high study population. Despite the 
limitations of the Stage 1 data set due to the clinical hold (e.g., subjects discontinuing PEGPH20 
and continuing on AG alone), there was a 3-month improvement in median OS, which was 
11.5 months with PAG vs. 8.5 months with AG (HR: 0.92).  
The clinically meaningful improvements seen with PAG, compared with AG, in both median 
PFS (8.6 months vs. 4.5 months; HR: 0.84; p-value: 0.748) and median OS (11.7 months vs. 
7.8 months HR: 0.64; p-value: 0.281) in the Stage 2 HA-high population support the hypothesis 
of HA being a potential predictive biomarker for subject selection for PEGPH20 treatment. 
Additional details are provided in the PEGPH20 Investigator’s Brochure.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
4.4.9. 
Clinical Pharmacokinetics 
Subjects enrolled in the Phase 1 studies received PEGPH20 at doses ranging from 0.5 to 
50 μg/kg with or without dexamethasone. Blood samples were collected at scheduled timepoints, 
and plasma was analyzed for PEGPH20 concentrations. PK analysis suggests that a linear 
2-compartment PK model adequately described the available PEGPH20 plasma concentration 
versus time profiles. The maximum plasma concentrations were estimated to be between 0.4 and 
1.0 hours after dosing. A population PK model of PEGPH20 combining data from 218 subjects 
across 4 studies (HALO-109-101, HALO-109-102, HALO-109-201, and HALO-109-202) 
demonstrated a t1/2 of 14.5 hours for the initial phase and 79.2 hours for the terminal phase 
(Halozyme Report 18218). The population PK model estimates of 3.99 L for the central volume 
and 2.94 L for the peripheral volume are consistent with expectations for therapeutic 
macromolecules. The prolonged t1/2 of PEGPH20 makes sustained depletion of tumor-associated 
HA feasible. Clinical experience to date (largely involving combination therapy with GEM or 
GEM plus NAB) indicates that the linear PK characteristics of PEGPH20 given alone are 
maintained in combination therapy. Details of the PK characteristics of PEGPH20 are provided 
in the PEGPH20 Investigator’s Brochure. 
4.5. 
Study Rationale 
Cancers of the biliary tract, which include intrahepatic and extrahepatic biliary cancers and 
gallbladder carcinoma, are a heterogeneous group of cancers with a low incidence and high 
mortality. They are diagnosed at an advanced, unresectable stage. Five-year survival rates are 
5% to 10% for gallbladder cancer and 10% to 40% for biliary cancers (Bang 2015). In a study 
published in 2010, a median survival of 11.7 months was noted when systemic therapy with CIS 
and GEM was used to treat patients with unresectable biliary tract cancers (Valle 2010). 
Although treatment with this combination is considered as the standard-of-care first line therapy 
for all biliary tract cancers, novel approaches are in need to improve the poor outcome of this 
deadly disease. 
Accumulation of HA in several malignant diseases is associated with aggressive tumor type, 
cancer progression/metastasis, and poor prognosis (Toole 2008; Setälä 1999; Shepard 2015; 
Sironen 2011). 
Interaction of pericellular HA and CD44 has been shown to influence drug resistance 
(Toole 2008). Changes in HA metabolism have been reported in many solid tumor malignancies, 
where elevated levels of HA frequently correlate with poor prognosis in tumors, such as 
pancreatic (Kultti 2012; Whatcott 2011), breast (Auvinen 2000), gastric (Setälä 1999), colorectal 
(Ropponen 1998), ovarian (Anttila 2000), prostate (Bharadwaj 2009), lung carcinoma 
(Chow 2010), and CCA (Padrnos 2016). 
PEGPH20 is a recombinant human hyaluronidase enzyme (rHuPH20) that has been PEGylated 
to increase its t1/2 in plasma. Nonclinical data demonstrate several actions of PEGPH20 in vitro 
and in vivo, including catabolism of tumor-associated and stromal HA, inhibition of tumor 
growth, reversal of some markers of the EMT, rapid “reperfusion-like” expansion of blood 
vessels, decreased hypoxia, enhancement of delivery of systemic chemotherapy, and increased 
access of monoclonal antibodies and immune cells to the tumor. PEGPH20 is currently in 
Phase 3 clinical development for Stage IV previously untreated pancreatic ductal 
adenocarcinoma, a tumor characterized by high HA accumulation. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
In clinical studies (109-201 and 109-202), PEGPH20 in combination with GEM or with NAB 
plus GEM has led to clinically meaningful improvements in efficacy in terms of PFS, OS, and/or 
objective response rate (ORR), with the greatest improvements reported in subjects whose 
tumors were determined to be HA-high. In a Halozyme internal research study using clinical 
annotated samples, 133 of the 175 ICC primary tumors were shown to be HA-high. In a Phase 1 
clinical study (HALO 109-102), 3 patients with ICC were treated with PEGPH20 at 3 μg/kg; 2 of 
the 3 patients were shown to have a partial metabolic response when assessed by 2-deoxy-2-
[fluorine-18] fluoro- D-glucose integrated with positron emission tomography-computed 
tomography (18F-FDG PET/CT). Of the 2 patients who were shown to have a partial metabolic 
response, 1 had a post biopsy sample showing significant HA removal, indicating that PEGPH20 
was biologically active in this patient with ICC (Padrnos 2016). 
A new form of immunotherapy based on inhibition of programmed death-1 (PD-1) receptors and 
programmed death-ligand 1 (PD-L1) is showing promise in cancer patients and offers patients 
and clinicians new hope. PD-L1 is an immune-checkpoint protein expressed on tumor cells and 
tumor-infiltrating immune cells that downregulates antitumoral T-cell function through binding 
to PD-1 and B7.1 (also known as CD80) receptors (Fehrenbacher 2016). In a study conducted by 
Bang et.al. (Interim results of Keynote-028 study), a response rate of 17.4% (95% CI, 5.0-38.8) 
was observed in previously treated PD-L1 positive advanced biliary tract cancer patients when 
treated with monoclonal antibody (mAb) pembrolizumab (Keytruda®; a humanized antibody that 
targets PD-1 receptor). 
This Phase 1b study will evaluate the safety and early biological activity of PEGPH20 combined 
with another immunotherapeutic mAb, atezolizumab (Tecentriq®) and standard-of-care 
chemotherapy, CIS and GEM in subjects with ICC and ECCs, and gastric adenocarcinoma. 
Atezolizumab an engineered, humanized, immunoglobulin 1 monoclonal anti-PD-L1 antibody 
blocks PD-L1-PD-1, and PD-L1-B7.1 interactions, resulting in restoration of antitumor T-cell 
activity and enhanced T-cell priming (Fehrenbacher 2016). The anticipated mechanism of action 
of PEGPH20 is to degrade HA in tumors and decompress the existing tumor vasculature, thus 
increasing delivery of immuno- and chemotherapeutic agents. 
4.5.1. 
Rationale for Dose and Schedule Selection 
A dose of 3.0 μg/kg was identified as the MTD for PEGPH20 as either a single agent or in 
combination with GEM in 3 separate trials (two Phase 1 and one Phase 1b clinical study). In the 
Phase 1 trial Study HALO-109-101, PEGPH20 was administered once every 21 days. In the 
Phase 1 trial, Study HALO-109-102, PEGPH20 was administered twice per week for the first 
4 weeks followed by once a week for the following 4-week cycles (no washout in week 4). In the 
Phase 1b trial, Study HALO-109-201, PEGPH20 was administered twice weekly for the first 
4 weeks, then once weekly for 3 of every 4 weeks for the duration of subject participation. 
Additionally, in a completed Phase 2 study, HALO-109-202, in which PEGPH20 was 
administered twice weekly for Weeks 1 to 3 of Cycle 1, then once weekly for Weeks 1 to 3 of 
Cycle 2 and beyond, the dose level of 3.0 µg/kg of PEGPH20 plus NAB and GEM was shown to 
be tolerable.  
This Phase 1b/2 study will therefore evaluate PEGPH20 at a dose of 3.0 µg/kg in combination 
with GEM, CIS, and atezolizumab. PEGPH20 will be administered once weekly in all cycles in 
both portions of the study for subjects enrolled through Protocol Amendment 2. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
For the additional cohort of approximately 15 subjects to be enrolled in the Expansion portion 
under Protocol Amendment 3 receiving PEGCISGEMATEZO treatment, PEGPH20 3.0 μg/kg 
will be administered twice weekly in Cycle 1; for subsequent cycles, the PEGPH20 dosing 
frequency is once weekly. This additional cohort will allow the Sponsor to evaluate the efficacy 
and safety of the PEGCISGEMATEZO combination treatment at a higher PEGPH20 dosing 
frequency. The rationale for the increased PEGPH20 dosing frequency in Cycle 1, to potentially 
improve the therapeutic effect of treatment, is based on the following considerations:  
• An exposure-response analysis of efficacy data from the completed Phase 2 study of 
PEGPH20 in combination with NAB and GEM in subjects with metastatic pancreatic 
cancer (HALO-109-202) showed improvements in PFS and OS to be associated with 
increased PEGPH20 exposure (Halozyme Report 18250).  
• The safety profile of PEGPH20 in subjects receiving PEGCISGEMATEZO treatment 
to date in HALO-110-101 is not different from the overall safety profile of PEGPH20 
in combination with chemotherapy or immunotherapy, including Study 
HALO-109-202, which represents the largest dataset to date in the PEGPH20 clinical 
development program (refer to Section 4.4.7 and the PEGPH20 Investigator’s 
Brochure). 
• Data from completed Phase 1 Studies HALO-109-102 and HALO-109-201 and 
Phase 2 Study HALO-109-202, in which PEGPH20 was administered at 3.0 µg/kg 
twice weekly in Cycle 1 (Section 4.4.2, Section 4.4.3, and Section 4.4.4, 
respectively), support the increased dosing frequency (twice weekly) in Cycle 1 for 
the additional cohort of subjects in the current study. 
• Additionally, with the increased PEGPH20 dosing frequency in Cycle 1, the dosing 
schedule for the additional cohort of subjects in this study will be consistent with that 
in both the Phase 2 study (HALO-109-202) and Phase 3 study (HALO-109-301) of 
PEGPH20 in combination with NAB and GEM in pancreatic cancer. 
Atezolizumab will be administered at a fixed dose of 1200 mg every 3 weeks (Q3W) (1200 mg 
on Day 1 of each 21-day cycle), which is the approved dosage for atezolizumab 
(TECENTRIQ® US Prescribing Information 2018). Anti-tumor activity has been observed across 
doses ranging from 1 mg/kg to 20 mg/kg Q3W. In Study PCD4989g, the MTD of atezolizumab 
was not reached and no dose-limiting toxicities (DLTs) were observed at any dose. The fixed 
dose of 1200 mg Q3W (equivalent to an average body weight-based dose of 15 mg/kg Q3W) 
was selected on the basis of both nonclinical studies (Deng 2016) and available clinical 
pharmacokinetic, efficacy, and safety data (refer to the Atezolizumab Investigator's Brochure for 
details). 
The dose and schedule for CIS and GEM in the PEGPH20 in combination with CIS and GEM 
(PEGCISGEM) and PEGPH20 in combination with CIS, GEM, and atezolizumab 
(PEGCISGEMATEZO) treatment arms of the study are per a Phase 3 trial conducted in biliary 
tract cancers, the ABC-02 trial (Valle 2010), with the exception that the first doses of CIS and 
GEM will be given on Day 2 instead of Day 1 and second doses of CIS and GEM will be given 
on Day 9 instead of Day 8. This is based on preclinical data indicating that maximum depletion 
of tumor levels of HA occurs by 24 hours after a dose of PEGPH20, potentially making tumors 
more responsive to the cytotoxic effects of chemotherapy. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
In the Control arm the dose and schedule for CIS and GEM are also per the ABC-02 trial 
(Valle 2010) with CIS and GEM being administered on Day 1 and Day 8 of each 21-day cycle. 
Since PEGPH20 has not been evaluated in clinical studies in combination with atezolizumab, the 
study will have a Run-in portion with PEGCISGEM and PEGCISGEMATEZO treatments to 
evaluate the safety and tolerability of PEGPH20 (at a dose of 3.0 μg/kg) in combination with 
GEM, CIS, and subsequently GEM, CIS, and Atezolizumab, before the randomized Expansion 
portion is initiated. 
5. 
STUDY OBJECTIVES AND ENDPOINTS 
5.1. 
Study Objectives 
Note: The objectives described below will be evaluated in subjects with previously untreated 
unresectable, locally advanced, or metastatic ICC, ECC, and gallbladder adenocarcinoma. 
Run-in Portion 
Primary: 
• To assess the safety and tolerability of (1) PEGCISGEM and (2) 
PEGCISGEMATEZO 
Secondary: 
• To assess the PK of PEGPH20, CIS, GEM, and atezolizumab when given in 
combination 
• To obtain an early assessment of the antitumor activity of PEGCISGEM and 
PEGCISGEMATEZO, as assessed by ORR based on Response Evaluation Criteria in 
Solid Tumors (RECIST) v1.1 
Exploratory: 
• To characterize changes in cancer antigen 19-9 (CA19-9) and carcinoembryonic 
antigen (CEA) from baseline 
• To obtain an early assessment of the antitumor activity of PEGCISGEMATEZO, as 
assessed by ORR based on Immune-Modified Response Evaluation Criteria 
(Immune-Modified RECIST) 
• To obtain an early assessment of the antitumor activity of PEGCISGEM and 
PEGCISGEMATEZO, as assessed by DOR and PFS based on RECIST v1.1, and OS 
• To assess the treatment effect of PEGCISGEM and PEGCISGEMATEZO on plasma 
HA levels and potential biomarkers and correlate those effects with clinical outcome 
• To assess the prognostic and/or predictive value of exploratory biomarkers 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Expansion Portion 
Primary: 
• To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by ORR based on RECIST v1.1 
Secondary: 
• To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by DOR, disease control rate (DCR; complete response [CR] + 
partial response [PR] + stable disease [SD]), and PFS based on RECIST v1.1, and OS 
• To evaluate the efficacy of PEGCISGEMATEZO and PEGCISGEM compared with 
CISGEM, as assessed by ORR, DOR, PFS based on RECIST v1.1 and OS in subjects 
by PD-L1 expression levels 
• To characterize the PK of PEGPH20, CIS, GEM, and atezolizumab when given in 
combination 
• To characterize the PK of PEGPH20, CIS, and GEM when given in combination 
• To evaluate the safety and tolerability profile of PEGCISGEM and 
PEGCISGEMATEZO compared with CISGEM 
Exploratory: 
• To evaluate the efficacy of PEGCISGEMATEZO based on Immune-Modified 
RECIST, as assessed by ORR and DOR 
• To evaluate the efficacy of PEGCISGEMATEZO, as assessed by ORR and DOR 
based on Immune-Modified RECIST in subjects by PD-L1 expression levels 
• To evaluate the DCR of PEGCISGEMATEZO according to Immune-Modified 
RECIST  
• To assess the treatment effect of PEGCISGEM, PEGCISGEMATEZO and CISGEM 
on plasma HA levels and potential biomarkers and correlate those effects with clinical 
outcome 
• To assess the prognostic and/or predictive value of exploratory biomarkers 
• To characterize changes in CA19-9 and CEA from baseline 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
5.2. 
Study Endpoints 
Run-in portion 
Primary: 
• Incidence of AEs, changes in clinical safety laboratory values, changes in 
cardiovascular parameters (electrocardiogram [ECG]), vital signs, and dose 
modifications (e.g., dose interruptions and delays) 
Secondary:  
• PK parameters of PEGPH20: maximum plasma concentration (Cmax), minimum 
plasma concentration (Cmin), elimination rate constant (kel), t1/2, clearance (CL), 
volume of distribution (Vd), and area-under-the-concentration time curve (AUC).  
• PK parameters of atezolizumab: Cmax, Cmin, t1/2, AUC, Vd, and CL when applicable 
• PK parameters for GEM: Cmax, t1/2, AUC, Vd, and CL when applicable 
• PK parameters for CIS (total and unbound): Cmax, t1/2, AUC, Vd, and CL when 
applicable 
• ORR based on RECIST v1.1 
Exploratory: 
• Change in CA19-9 from baseline 
• Change in CEA from baseline 
• ORR based on Immune-Modified RECIST 
• DOR and PFS based on RECIST v1.1 
• OS 
• Changes in plasma HA from baseline 
• Changes in tumor HA from baseline when available 
• Explore co-variates of safety and efficacy parameters with drug exposure, as 
measured by plasma HA levels 
• Explore co-variates of safety and efficacy parameters with exploratory biomarker 
responses 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Expansion portion 
Primary: 
• ORR based on RECIST v1.1 
Secondary: 
• DOR, PFS, and DCR based on RECIST v1.1, and OS 
• ORR, DOR, and PFS based on RECIST v1.1, and OS by PD-L1 expression levels 
• PK parameters of PEGPH20: Cmax, Cmin, kel, t1/2, CL, Vd, and AUC 
• PK parameters of atezolizumab: Cmax, Cmin, t1/2, AUC, Vd, and CL when applicable 
• PK parameters of GEM and CIS (bound and free): Cmax, t1/2, AUC, Vd, and CL when 
applicable 
• Incidence of AEs, changes in clinical safety laboratory values, changes in ECG, vital 
signs, and dose modifications (e.g., dose interruptions and delays) 
Exploratory: 
• ORR and DOR based on Immune-Modified RECIST 
• ORR and DOR based on Immune-Modified RECIST by PD-L1 expression levels 
• DCR, as assessed by the Investigator according to Immune-Modified RECIST 
• Changes in plasma HA from baseline 
• Changes in tumor HA from baseline, when available 
• Explore co-variates of safety and efficacy parameters with drug exposure as measured 
by plasma HA levels 
• Explore co-variates of safety and efficacy parameters with exploratory biomarker 
responses 
• Change in CA19-9 from baseline 
• Change in CEA from baseline 
6. 
INVESTIGATIONAL PLAN 
6.1. 
Overall Study Design and Plan: Description 
This is a Phase 1b, multicenter, randomized, open-label, study of PEGCISGEM and 
PEGCISGEMATEZO treatments compared with CISGEM treatment in previously untreated 
subjects with unresectable, locally advanced or metastatic ICC, ECC, and gallbladder 
adenocarcinoma.  
The study will have a Run-in portion and an Expansion portion. 
The Run-in portion will be used to evaluate the safety profile of the PEGCISGEM and 
PEGCISGEMATEZO treatments prior to evaluating the efficacy and safety of PEGCISGEM and 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
PEGCISGEMATEZO treatments compared with CISGEM treatment in the Expansion portion of 
the study. The study design is depicted in Figure 1. 
Effective with Protocol Amendment 2, all-comers (subjects unselected for tumor HA and PD-L1 
expression levels) will be enrolled in the study and subjects’ tumor samples will be tested 
retrospectively for HA and PD-L1 expression levels. 
In the Run-in portion, approximately 6 subjects will be enrolled in the PEGCISGEM arm and 
undergo at least 1 treatment cycle; thereafter, approximately 6 subjects will be enrolled in the 
PEGCISGEMATEZO arm. An additional 8 subjects may be enrolled in the Run-in portion to 
further assess the tolerability of PEGPH20 in either combination arm in order to establish an 
acceptable safety profile prior to the Expansion portion of the study. 
After the Run-in portion of the study, the Expansion portion will begin. A total of approximately 
65 subjects will be enrolled in the Expansion portion including approximately 50 subjects per 
Protocol Amendment 2 and approximately 15 additional subjects per Protocol Amendment 3. 
The treatment period will consist of 21-day cycles in both the Run-in and Expansion portions of 
the study. 
PEGPH20 will be administered at 3.0 μg/kg once weekly during Weeks 1-3 of all cycles in both 
portions of the study. An additional cohort of approximately 15 subjects will be enrolled in the 
Expansion portion under Protocol Amendment 3 who will receive PEGCISGEMATEZO, with 
PEGPH20 3.0 μg/kg administered twice weekly in Cycle 1 and once weekly in subsequent cycles 
(Table 7), to evaluate the efficacy and safety of the PEGCISGEMATEZO combination treatment 
at a higher PEGPH20 dosing frequency. 
The dosing schedule for atezolizumab administration in the Run-in portion will be the same as 
for subjects in the Expansion portion with 1200 mg atezolizumab administered 1 to 3 hours after 
PEGPH20 on Day 1 of each 21-day cycle in subjects receiving PEGCISGEMATEZO treatment. 
The dosing schedule for CIS and GEM administration in subjects receiving PEGCISGEM and 
PEGCISGEMATEZO treatment in the Run-in portion will be the same as for subjects in the 
Expansion portion with 25 mg/m2 of CIS and 1000 mg/m2 of GEM administered on Day 2 and 
Day 9 of each cycle. 
In the CISGEM control arm, the dosing schedule for CIS and GEM administration will be 
25 mg/m2 of CIS and 1000 mg/m2 of GEM administered on Day 1 and Day 8 of each treatment 
cycle in Expansion portion. 
Treatment in both portions of the study will continue until death, withdrawal of consent from the 
study, disease progression, or unacceptable toxicity (additional details in Section 6.1.3). 
Radiographic disease response/progression will be evaluated using RECIST v1.1 (see 
Section 8.2.15 for details on imaging/radiologic evaluation and Appendix B for details on 
RECIST v1.1). In addition, radiographic disease response/progression in subjects receiving 
PEGCISGEMATEZO will also be evaluated using Immune-Modified RECIST (refer to 
Appendix D for further details on Immune-Modified RECIST) due to the possibility of 
pseudoprogression (an initial increase in tumor burden caused by immune cell infiltration in the 
setting of a T-cell response with atezolizumab treatment). In the absence of unacceptable 
toxicity, subjects who meet criteria for disease progression per RECIST v1.1 while receiving 
atezolizumab will be permitted to continue treatment if they meet all of the following criteria: 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Evidence of clinical benefit, as determined by the Investigator following a review of 
all available data 
• Absence of symptoms and signs (including laboratory values, such as new or 
worsening hypercalcemia) indicating unequivocal progression of disease 
• Absence of decline in Eastern Cooperative Oncology Group (ECOG) Performance 
Status that can be attributed to disease progression 
• Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by protocol-allowed medical interventions 
• Subject's written consent to acknowledge deferring other treatment options in favor of 
continuing study treatment at the time of initial disease progression 
Dose modifications for chemotherapy are permitted in the Run-in portion and Expansion portion 
of the study. Dose interruptions are allowed for atezolizumab in both the Run-in portion and 
Expansion portion of the study. No dose modifications of atezolizumab are allowed in this study. 
PEGPH20 dose interruption and dose reductions are allowed in both portions of the study. Dose 
reduction of PEGPH20 to lower doses of 2.2 µg/kg and 1.6 µg/kg will be recommended if 
necessary based on toxicities in the Run-in portion and the Expansion portion. After dose 
reduction, the dose of PEGPH20 may be re-escalated to the prior dose utilized, at the 
Investigator's discretion, following a discussion with the Sponsor, provided there are no safety 
concerns. Dose modification guidelines are provided in Section 8.3 for PEGPH20, CIS and 
GEM. Guidance on atezolizumab dose interruption and discontinuation due to AEs are provided 
in the atezolizumab Investigator’s Brochure. Guidance on the allowed dose reduction levels for 
PEGPH20 are provided in Section 8.3.1.3. Additional dose modification guidelines for CIS and 
GEM are provided in the Prescribing Information of these chemotherapeutic agents. 
In single-agent studies of PEGPH20 and in a Phase 1 combination study of PEGPH20 with 
GEM, the DLTs were MSEs myalgia and muscle cramping. In clinical studies HALO-109-102, 
HALO-109-201, and HALO-109-202, dexamethasone was administered per protocol to attenuate 
the severity of MSEs. Since this study (HALO-110-101) uses an immunotherapeutic agent 
(atezolizumab) and dexamethasone and other steroids may suppress an immune response, 
steroids should only be used to treat AEs in some exceptional circumstances or at the 
Investigator’s discretion as detailed in Section 10.12.3.  
PEGPH20 and atezolizumab administration must be held if steroids are administered to treat AEs 
and can only be restarted once the steroid is discontinued. The only exceptions are topical, 
inhaled, intranasal or intra-articular steroids, thyroid-replacement hormone, and 
mineralocorticoids, which are allowed as described in Section 7.2 and Section 10.12.3, and 
low-dose steroids as described in Section 10.12.3. 
In addition to study medication, all subjects in the PEGCISGEM and PEGCISGEMATEZO arms 
will also be administered piroxicam to reduce potential musculoskeletal symptoms often 
associated with PEGPH20 administration. Piroxicam (20 mg) will be administered at least 1 hour 
prior to PEGPH20 administration on the day of dosing (timing will be at the Investigator’s 
discretion based on the piroxicam manufacturer’s Prescribing Information, institutional practices, 
and subject’s convenience) to minimize the severity of MSEs. A non-steroidal analgesic agent (at 
a dose equivalent to 20 mg of piroxicam) may be administered instead of piroxicam to reduce 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
potential MSEs, at the discretion of the Investigator. Prophylactic use of a proton pump inhibitor 
is mandated for all subjects while receiving PEGPH20 (e.g., 20 mg omeprazole daily or 
over-the-counter [OTC] equivalent). 
Toradol may be given for severe pain as recommended in the Toradol Prescribing Information. 
Toradol should not be administered concurrently with piroxicam as per the Prescribing 
Information, as it is contraindicated to administer Toradol simultaneously with other nonsteroidal 
anti-inflammatory drugs (NSAIDs) because of the cumulative risk of inducing serious 
NSAID-related side effects. 
To help minimize MSEs, prescribed medication such as narcotics, muscle relaxants and other 
analgesics, OTC drugs and physical therapy can also be used at the Investigator’s discretion.  
To decrease the risk of TE events, an identified risk of PEGPH20, and based on the incidence of 
TE events observed in this study to date, prophylactic enoxaparin will be administered 
subcutaneously at 1 mg/kg/day to all subjects receiving PEGPH20 including subjects in the 
PEGCISGEM and PEGCISGEMATEZO arms enrolled through Protocol Amendment 2 and the 
additional cohort of 15 subjects enrolled under Protocol Amendment 3 receiving 
PEGCISGEMATEZO (details in Section 10.1.1). The dosage of enoxaparin of 1 mg/kg/day is 
the same as that administered in trials of PEGPH20 in combination with GEM and NAB in PDA 
(completed Study HALO-109-202 and ongoing Study HALO-109-301).  
If enoxaparin is discontinued for any reason in subjects receiving PEGPH20, PEGPH20 will also 
be discontinued. Treatment with other drugs, however, may continue at the Investigator’s 
discretion. 
Subjects who discontinue treatment with all study drugs 
(PEGCISGEM/PEGCISGEMATEZO/CISGEM) will have an End of Treatment Visit and enter 
long-term follow-up for survival. 
Subjects will be assessed for AEs and clinical laboratory evaluations as graded by the National 
Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 4.03. 
An independent DMC will periodically review safety data to protect subject welfare and identify 
potential safety signals in the Run-in and Expansion portions of the study. 
In both portions of the study, tumor response will be assessed by a local reviewer after every 
3 cycles based on RECIST v1.1 criteria and Immune-Modified RECIST. Scans for RECIST v1.1 
and Immune-Modified RECIST may be obtained any time on or after Day 15 to allow enough 
time for the scan to be reviewed locally prior to the subject’s next scheduled dosing visit.  
A confirmatory scan is required in both portions of the study for subjects with CR or PR for 
confirmation of response. This confirmatory scan may be performed at the earliest 28 days after 
the date of the first documented response (per RECIST v1.1) (preferred) or at the next scheduled 
imaging timepoint, whichever is clinically indicated (details in Section 8.2.15).  
A confirmatory scan is also required for subjects receiving PEGCISGEMATEZO to confirm 
radiological disease progression, per Immune-Modified RECIST. This confirmatory scan should 
be obtained no sooner than 28 days after the initial scan that showed progression (this can be the 
next scheduled tumor assessment scan).  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
All scans for tumor assessments performed during the study should be archived in accordance 
with the standard local practice. The scans will be submitted to a central imaging vendor (CIV) 
selected by the Sponsor for potential central review at a later time. 
After the End of Treatment Visit, subjects will enter long-term follow-up during which 
information on the subject’s survival and subsequent anticancer therapy will be obtained by the 
site every 12 weeks until the subject dies, is lost to follow-up, or withdraws consent. Subjects 
may be contacted more frequently to collect information on survival and subsequent anticancer 
therapy, as required, prior to important study timepoints, including DMC meetings and database 
locks.

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Figure 1: 
Study Design - Phase 1b Run-in and Expansion (HALO-110-101) 
~6 subjectsa 
PEGPH20 (3.0 μg/kgb) + 
CIS (25 mg/m2) + GEM 
(1000 mg/m2). 
PEGPH20 once/week 
(Days 1, 8 and 15) of all 
cycles. 
CIS and GEM on Days 2 
and 9 of all cycles.
~6 subjectsa 
PEGPH20 (3.0 μg/kgb) + 
CIS (25 mg/m2) + GEM 
(1000 mg/m2) + 
atezolizumab (1200 mg). 
PEGPH20 once/week 
(Days 1, 8 and 15) of all 
cycles. 
Atezolizumab on Day 1. 
CIS and GEM on Days 2 
and 9 of all cycles.
Subjects with Previously Untreated,Unresectable, 
Locally Advanced or Metastatic Intrahepatic and 
Extrahepatic Cholangiocarcinoma and Gallbladder 
Adenocarcinoma
Confirm the 
safety and 
tolerability of 
PEGCISGEM 
treatment
Confirm the safety 
and tolerability of 
PEGCISGEMATEZO 
treatment 
 21-day Cycles
Phase 1b Run-in Portion
 21-day Cycles
Phase 1b Expansion Portion
Randomization
 Decision to 
initiate expansion
~10 subjects 
CIS (25 mg/m2) + GEM  (1000 mg/m2) on Days 1 
and 8 of all cycles.
~20 subjects 
PEGPH20 (3.0 μg/kgc) + CIS (25 mg/m2) + GEM 
(1000 mg/m2). 
PEGPH20 once/week (Days 1, 8 and 15) of all 
cycles. 
CIS and GEM on Days 2 and 9 of all cycles.
~20 subjects 
PEGPH20 (3.0 μg/kgd) + CIS (25 mg/m2) +  GEM 
(1000 mg/m2) + atezolizumab (1200 mg). 
PEGPH20 once/week  (Days 1, 8 and 15) of all 
cycles. 
Atezolizumab on Day 1. CIS and GEM on Days 2 
and 9 of all cycles.
Tumor 
Assessment 
End C3, C6, C9 
and beyond 
until PD
Then Survival 
Follow-up 
every 3 monthsf
PEGCISGEM Arm
PEGCISGEMATEZO 
Arm
CISGEM Arm
~15 subjects
PEGPH20 (3.0 μg/kg) + CIS (25 mg/m2) + GEM 
(1000 mg/m2) + atezolizumab (1200 mg). 
PEGPH20 twice/week in Cycle 1 (Days 1, 4, 8, 11, 
15 and 18), and once/week in Cycles 2+ (Days 1, 
8 and 15).  
Atezolizumab on Day 1. 
CIS and GEM on Days 2 and 9 of all cycles.
PEGCISGEMATEZO Cohorte
 
Abbreviations: CIS = cisplatin; GEM = gemcitabine; PEGPH20 = PEGylated recombinant human hyaluronidase;  
a An additional 8 subjects may be enrolled in the Run-in portion to further assess the tolerability of either combination arm with PEGPH20 in order to establish 
an acceptable safety profile prior to the Expansion portion of the study. 
b Dose reduction of PEGPH20 to lower doses of 2.2 µg/kg and 1.6 µg/kg will be recommended if necessary based on toxicities. 
c The highest PEGPH20 dose level found to be safe and tolerable in PEGCISGEM arm of the Run-in portion will be utilized in the PEGCISGEM arm of the 
Dose Expansion portion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
d The highest PEGPH20 dose level found to be safe and tolerable in PEGCISGEMATEZO arm of the Run-in portion will be utilized in the 
PEGCISGEMATEZO arm of the Dose Expansion portion. 
e Per Protocol Amendment 3. 
f Subjects may be contacted more frequently to collect information on survival and subsequent anticancer therapy, as required, prior to important study 
timepoints, including DMC meetings and database locks. 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
6.1.1. 
Phase 1b Run-in 
In the Run-in portion, approximately 6 subjects will receive 3.0 µg/kg PEGPH20 on Day 1, Day 
8, and Day 15 and 25 mg/m2 of CIS and 1000 mg/m2 of GEM administered on Day 2 and Day 9 
of each 21-day cycle.  
After the 6 subjects are treated for at least 1 cycle without significant toxicities, the 
PEGCISGEMATEZO arm will open and subjects in this arm will receive 3.0 µg/kg PEGPH20 
on Day 1, Day 8, and Day 15 in combination with 1200 mg atezolizumab on Day 1 and 25 
mg/m2 of CIS and 1000 mg/m2 of GEM administered on Day 2 and Day 9 of each 21-day cycle. 
PEGPH20 dose reduction to a lower dose of 2.2 µg/kg or 1.6 µg/kg will be performed if 
necessary. 
An additional 8 subjects may be enrolled in the Run-in portion to further assess the tolerability of 
either combination arm with PEGPH20 in order to establish an acceptable safety profile prior to 
the Expansion portion of the study. 
The Sponsor in collaboration with the treating investigators will review all available safety data 
from all subjects in the Run-in portion, and the Sponsor will determine if the doses/tolerability 
profile is acceptable.  
DLT evaluation of PEGCISGEM or PEGCISGEMATEZO treatments at a given PEGPH20 dose 
level will be carried out during DLT evaluation period (i.e., Cycle 1) as follows: 
Initially 3 subjects will be enrolled: 
• If ≤1 subjects experiences a DLT then 3 additional subjects will be enrolled. 
− If ≤1 subject experiences a DLT among the 6 enrolled subjects then the 
combination evaluated (PEGCISGEM or PEGCISGEMATEZO) will be 
considered safe. 
− If ≥2 subjects experience DLTs then PEGPH20 dose will be de-escalated to the 
next lower dose level (see Table 6) and additional subjects (up to a total of 6) will 
be enrolled and evaluated. 
• If ≥2 subjects experience a DLT, then PEGPH20 dose will be de-escalated to the next 
lower dose level and additional subjects (up to a total of 6) will be enrolled and 
evaluated. 
• If the combination of PEGCISGEM is found to be safe and tolerable, the 
PEGCISGEMATEZO arm will be opened at the same PEGPH20 dose level found to 
be safe and tolerable in the PEGCISGEM arm, and the tolerability of this 
combination will be evaluated following the steps outlined earlier. 
• The highest PEGPH20 dose level found to be safe and tolerable in PEGCISGEM arm 
of the Run-in portion will be utilized in the PEGCISGEM arm of the Dose Expansion 
portion. The highest PEGPH20 dose level found to be safe and tolerable in 
PEGCISGEMATEZO arm of the Run-in portion will be utilized in the 
PEGCISGEMATEZO arm of the Dose Expansion portion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Subjects who drop out during the initial 21 days of treatment without experiencing a 
DLT will be replaced. 
• Safety evaluation will be initiated at PEGPH20 3.0 μg/kg dose level for the 
PEGCISGEM combination.  
• Subjects who experience DLTs during Cycle 1 will be permanently discontinued 
from all study treatments.  
Table 6: 
Dose Allocation and Cohort Schedule - Run-in Portion (PEGCISGEM and 
PEGCISGEMATEZO treatments) 
Cohort 
PEGPH20 µg/kg 
CIS mg/m2 
GEM mg/m2 
ATEZOLIZUMAB mg 
-2 
1.6 
25 
1000 
1200 
-1 
2.2 
25 
1000 
1200 
1 
3.0 
25 
1000 
1200 
Abbreviations: PEGPH20 = PEGylated recombinant human hyaluronidase; CIS = cisplatin; GEM = gemcitabine 
Note: Each treatment cycle is 21 days. Dose interruption and modifications are permitted (See Section 8.3 for further 
details). 
Definition of DLT 
Treatment-related AEs that limit the dose of PEGPH20 or the combination 
(PEGCISGEM/PEGCISGEMATEZO) may be considered as DLTs. DLTs will be assessed for 
each subject during the 21 days following their first PEGPH20 dose and will be defined as any of 
the following: 
• Treatment-emergent Grade ≥3 toxicity that is considered related to either PEGPH20 
or the combination (PEGCISGEM/PEGCISGEMATEZO)  
- 
MSEs, colitis, and immune-related toxicities, infections will be considered as 
DLTs only if they reach Grade ≥3 severity despite adequate supportive care 
measures. 
- 
Grade 3 nausea, vomiting, and diarrhea will be considered as DLTs if they persist 
for >72 hours despite optimal supportive care.  
- 
Grade 4 nausea, vomiting, and diarrhea will be considered as DLTs if they reach 
Grade 4 severity despite optimal supportive care, irrespective of duration. 
• Treatment-emergent Grade ≥3 symptomatic hepatic toxicity that is considered related 
to either PEGPH20 or the combination that does not resolve to Grade ≤2 
within 48 hours or Grade ≥3 asymptomatic hepatic toxicity that is considered related 
to either PEGPH20 or the combination that does not resolve to Grade ≤1 within 
3 weeks of onset with the following exception: 
- 
For patients with Grade 2 alkaline phosphatase abnormality at baseline, 
an increase to >8 × the upper limit of normal (ULN) that does not resolve 
to Grade ≤2 within 48 hours (if symptomatic) or that does not resolve to Grade ≤1 
within 3 weeks of onset (if asymptomatic) will be considered a DLT. 
• Grade 4 hepatic toxicity of any duration will be considered as a DLT. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: 
- 
Grade 3 immune-related AE that resolves to Grade ≤1 with immunosuppressant 
therapy within 3 weeks of its onset  
- 
Grade 3 autoimmune thyroiditis or other endocrine abnormality that can be 
managed by endocrine therapy or hormonal replacement 
• Grade 3 neutropenia (asymptomatic) will not be considered a DLT; however Grade 4 
neutropenia lasting 7 days or longer will be considered a DLT. 
• Febrile neutropenia (defined below) will be considered as a DLT. 
Febrile Neutropenia - Fever is present, defined as an oral temperature of at least 
38.0°C on at least 2 occasions within 24 hours, or a single oral temperature of at least 
38.3°C, in the presence of neutropenia, defined as an absolute neutrophil count 
(ANC) of less than 500 cells/μl. Fever may also be defined as a rectal temperature of 
38.6°C on at least 2 occasions within 24 hours, or a single rectal temperature of 39°C 
(FDA Guidance for Industry: Empiric Therapy of Febrile Neutropenia - Developing 
Antimicrobial Drugs for Treatment 1998). 
• Grade 3 MSEs are considered DLTs only if they do not reduce to Grade ≤2 within 
48 hours despite therapeutic intervention. 
• Hypersensitivity/infusion reactions related to PEGPH20 or the combination dosing 
(PEGCISGEM/PEGCISGEMATEZO) will not be considered DLTs (hypersensitivity 
reactions are generally not related to the dose level of a drug since they can occur 
even upon a low level of exposure). 
To be considered evaluable for DLT assessment, subjects in the PEGCISGEM arm must receive 
1 of the 3 full planned doses of PEGPH20 and 1 complete dose each of CIS and GEM in 
Cycle 1. 
To be considered evaluable for DLT assessment, subjects in the PEGCISGEMATEZO arm must 
receive 1 of the 3 full planned doses of PEGPH20 and 1 complete dose each of atezolizumab, 
CIS, and GEM in Cycle 1. 
Subjects who experience a DLT within the first 21 days of treatment and withdraw from the 
study treatment will be considered evaluable for DLT and will not be replaced. Subjects who 
withdraw within the first 21 days for reasons other than a DLT will be considered not evaluable 
and will be replaced. Subjects who experience DLTs in the Run-in portion will be permanently 
discontinued from all study treatments. 
6.1.2. 
Phase 1b Dose Expansion 
Approximately 50 previously untreated subjects will be randomized in a 2:2:1 ratio into 1 of 3 
treatment arms as follows: 
• PEGCISGEM arm: PEGPH20 (3.0 µg/kg) + CIS (25 mg/m2) + GEM (1000 mg/m2) 
• PEGCISGEMATEZO arm: PEGPH20 (3.0 µg/kg) + atezolizumab (1200 mg) + CIS 
(25 mg/m2) + GEM (1000 mg/m2) 
• CISGEM (control) arm: CIS (25 mg/m2) + GEM (1000 mg/m2) 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Randomization will be stratified by geographical region (North America and Asia) and cancer 
type (cholangiocarcinoma and gallbladder). 
An additional cohort of approximately 15 subjects will be enrolled in the Expansion portion 
under Protocol Amendment 3 and receive PEGCISGEMATEZO treatment: PEGPH20 
(3.0 µg/kg) + Atezolizumab (1200 mg) + CIS (25 mg/m2) + GEM (1000 mg/m2). 
The study medication dosing and treatment schedule are shown in Table 7. 
Table 7: 
Study Medication Dosing and Treatment Schedule 
Timepoint 
PEGCISGEM Treatment 
All cycles (21-day cycles) 
Week 1 
Day 1 
PEGPH20  
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20)  
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Week 3 
Day 15  
PEGPH20 
 
 
 
Timepoint 
PEGCISGEMATEZO Treatment 
Cycle 1 (21-day cycles) 
Week 1 
Day 1 
PEGPH20  
Atezolizumab (1 to 3 hours after PEGPH20) 
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20) 
Day 4a 
PEGPH20 
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Day 11a 
PEGPH20 
Week 3 
Day 15 
PEGPH20 
Day 18a 
PEGPH20 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 7: 
Study Medication Dosing and Treatment Schedule (Continued) 
Cycle 2 and Beyond 
Week 1 
Day 1 
PEGPH20 
Atezolizumab (1 to 3 hours after PEGPH20) 
Day 2 
CIS + GEM (24 ± 4 hours after Day 1 dose of PEGPH20) 
Week 2 
Day 8 
PEGPH20 
Day 9 
CIS + GEM (24 ± 4 hours after Day 8 dose of PEGPH20) 
Week 3 
Day 15 
PEGPH20 
 
Timepoint 
CISGEM Treatment 
All cycles (21-day cycles) 
Week 1 
Day 1 
CIS + GEM  
Week 2 
Day 8 
CIS + GEM  
Abbreviations: PEGPH20 = PEGylated recombinant human hyaluronidase; GEM = gemcitabine; CIS = cisplatin 
Note: Dose interruption and modifications are permitted (See Section 8.3 for further details). 
a This visit is applicable to the ~15 subjects enrolled under Protocol Amendment 3 only. 
6.1.3. 
Study Duration 
The study will consist of a screening period of up to 28 days, a treatment period (21-day cycles), 
a 30-day post-treatment period (after last dose) for collection of AEs and a long-term follow-up. 
Subjects will be allowed to continue treatment on study until radiologic disease progression or 
clinical progression or unacceptable toxicity is documented. 
Due to the possibility of “pseudoprogression” in immunotherapy trials, subjects who meet the 
criteria for disease progression, per RECIST v1.1, while receiving atezolizumab will be 
permitted to continue treatment if they meet all of the following criteria: 
• Evidence of clinical benefit, as determined by the investigator following a review of 
all available data 
• Absence of symptoms and signs (including laboratory values, such as new or 
worsening hypercalcemia) indicating unequivocal progression of disease 
• Absence of decline in ECOG Performance Status that can be attributed to disease 
progression 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by protocol-allowed medical interventions 
• Subject's written consent to acknowledge deferring other treatment options in favor of 
continuing study treatment at the time of initial disease progression 
Investigators may also discontinue study treatment if it is no longer in the best interest of the 
subject.  
Subjects who discontinue treatment with all study drugs will be followed every 12 weeks for 
survival until death, withdrawal of consent, or lost to follow-up. Subjects may be contacted more 
frequently to collect information on survival and subsequent anticancer therapy, as required, prior 
to important study timepoints, including DMC meetings and database locks. 
6.1.4. 
Disease Progression 
Disease progression will be defined by the presence of the following, based on the Investigator’s 
radiology reviewer’s assessment: 
• Disease progression documented by CT scan/Magnetic resonance imaging (MRI) 
scan based on RECIST v1.1 (Appendix B) 
• Per Immune-Modified RECIST, disease progression for subjects receiving 
PEGCISGEMATEZO requires confirmation of progression with an additional scan 
obtained no sooner than 28 days after the initial scan that showed progression based 
on RECIST v1.1. 
Radiographic disease progression is based on the analysis of CT/MRI scans by the Investigator. 
Investigators should continue study treatment until disease progression (as defined above and 
described in Section 6.1) has occurred, but may discontinue study treatment if there is 
documented clinical disease progression and/or unacceptable toxicity and/or study treatment is 
no longer in the best interest of the subject. Subjects who discontinue treatment with all study 
drugs will be followed every 12 weeks for survival until death, withdrawal of consent, or lost to 
follow-up. Subjects may be contacted more frequently to collect information on survival and 
subsequent anticancer therapy, as required, prior to important study timepoints, including DMC 
meetings and database locks. 
7. 
SELECTION AND WITHDRAWAL OF SUBJECTS AND STUDY 
TERMINATION 
Males and females aged 18 years and older with previously untreated, locally advanced or 
metastatic ICC, ECC, and gallbladder adenocarcinoma who meet the inclusion/exclusion criteria 
will be enrolled in both portions of the study. 
7.1. 
Inclusion Criteria 
For both portions of the study, subjects must satisfy all of the following inclusion criteria to be 
enrolled in the study: 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
1. Written Institutional Review Board/Ethics Committee-approved informed consent form 
(ICF), signed by subject or legally authorized representative. 
2. Subjects must be determined to have histologically confirmed unresectable, locally 
advanced or metastatic adenocarcinoma of the intra- and/or extra-hepatic bile ducts 
and/or gallbladder. Prior to enrollment, confirmation of shipment of tissue sample to the 
central laboratory must be obtained. Subjects must have sufficient tissue with 
architectural integrity, including tumor and associated stroma, available for retrospective 
PD-L1 and HA testing (details will be included in a separate Laboratory Manual). 
Note: Tumor biopsies must be collected on or after the date that locally advanced or 
metastatic disease is documented. 
3. One or more lesions measurable on CT scan/MRI scan per RECIST v1.1. 
4. Subjects having ECOG Performance Status of 0 to 1. 
5. Life expectancy ≥3 months. 
6. Males and females aged ≥18 years. 
7. Screening clinical laboratory values as follows: 
• Total bilirubin ≤1.5 × ULN, except for Gilbert’s syndrome 
• Aspartate aminotransferase and alanine aminotransferase ≤2.5 × ULN (<5 × ULN is 
allowed if liver metastases or liver involvement are present) 
• Serum creatinine ≤1.5 mg/dL 
• Serum albumin ≥2.5 g/dL 
• Hemoglobin ≥9 g/dL (transfusion and erythropoietic agents allowed) 
• Absolute neutrophil count ≥1500 cells/mm3 
• Platelet count ≥100,000/mm3 
8. Female participants of childbearing potential (WOCBP) must have a negative urine or 
serum pregnancy test within 7 days before Day 1 (first dose of study medication). 
9. For WOCBP and for men, agreement to use a highly effective contraceptive method from 
the time of screening throughout the study until 5 months (WOCBP) or 6 months (men) 
after administration of the last dose of any study medication. Highly effective 
contraceptive methods consist of prior sterilization, intrauterine device (IUD), 
intrauterine hormone releasing system (IUS), oral or injectable contraceptives, barrier 
methods, and/or true sexual abstinence.  
7.2. 
Exclusion Criteria 
Subjects are ineligible for enrollment if they meet any of the following exclusion criteria: 
1. Clinical evidence of deep vein thrombosis or pulmonary embolism present during the 
screening period. 
• Subject with superficial vein thrombosis are eligible. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Subjects with visceral/splanchnic vein thrombosis, that in the opinion of the Principal 
Investigator are primarily associated with the anatomic location of the underlying 
disease of metastatic biliary tract cancer, are eligible. 
2. New York Heart Association Class III or IV (Appendix C) cardiac disease, atrial 
fibrillation, unstable angina, or myocardial infarction within the past 12 months before 
screening. 
3. Subjects with known brain metastases 
4. History of cerebrovascular accident or transient ischemic attack 
5. History of active bleeding within the last 3 months prior to screening requiring 
transfusion. 
6. Contraindication to heparin as per institutional guidelines. 
7. Subjects must have received no previous radiotherapy, surgery, chemotherapy or 
investigational therapy for treatment of metastatic or locally advanced disease. 
8. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including 
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death 
protein 1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies 
9. Prior treatment with 5-fluorouracil (FU) or GEM administered as a radiation sensitizer in 
the neoadjuvant and adjuvant settings surrounding surgery, during and up to 4 weeks 
after radiation therapy, is allowed if all toxicities have returned to baseline or ≤ Grade 1. 
10. If a subject received therapy in the adjuvant setting, tumor recurrence or disease 
progression must have occurred no sooner than 6 months after completing the last dose of 
the adjuvant therapy. 
11. Clinically significant pre-existing carotid artery disease. 
12. Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 
13. Known allergy to hyaluronidase. 
14. Intolerance to NSAIDs. 
15. Current use of megestrol acetate or megestrol acetate-containing drugs (within 10 days of 
Day 1). 
16. Women currently pregnant or breastfeeding. 
17. Positive human immunodeficiency virus (HIV) test 
18. Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface 
antigen (HBsAg) test at screening 
• Subjects with a past or resolved HBV infection, defined as having a negative HBsAg 
test and a positive total hepatitis B core antibody (HBcAb) test at screening, are 
eligible for the study if active HBV infection is ruled out on the basis of HBV 
ribonucleic acid (RNA)/deoxyribonucleic acid (DNA) viral load per local guidelines. 
19. Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test 
at screening 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Subjects who have a positive HCV antibody test are eligible for the study if a 
polymerase chain reaction assay is negative for HCV RNA. 
20. Active tuberculosis. 
21. History of: 
a. Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest CT scan. History of radiation pneumonitis in the 
radiation field (fibrosis) is permitted. 
b. Or known cases of hepatobiliary diseases (e.g., primary biliary cholangitis, primary 
sclerosing cholangitis, history of immune-mediated cholangitis);  
i. 
Subjects with cholangitis attributed to infectious etiology (e.g., ascending 
cholangitis, bacterial cholangitis) are eligible if the infection has been fully 
resolved prior to the screening visit.  
c. Or known cases of drug-induced hepatobiliary toxicities.  
22. Known clinically significant liver disease, including active viral, alcoholic, or other 
hepatitis, cirrhosis, fatty liver, and inherited liver disease. 
23. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells. 
24. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or 
humanized antibodies or fusion proteins. 
25. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of 
study treatment 
• Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or 
chronic obstructive pulmonary disease exacerbation) are eligible for the study. 
26. Signs or symptoms of infection within 2 weeks prior to initiation of study treatment. 
27. Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of 
study treatment, or anticipation of need for a major surgical procedure during the course 
of the study 
• Placement of central venous access catheter(s) (e.g., port or similar) is not considered 
a major surgical procedure and is therefore permitted. 
28. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study 
treatment, or anticipation of need for such a vaccine during the course of the study 
• Influenza vaccination should be given during influenza season only (approximately 
October to March in the Northern Hemisphere and approximately April through 
September in the Southern Hemisphere). Subjects must agree not to receive live, 
attenuated influenza vaccine (e.g., FluMist) within 28 days prior to the start of study 
treatment, during treatment, or within 5 months after the last dose of atezolizumab. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
29. Treatment with systemic immunostimulatory agents (including, but not limited to, 
interferon and interleukin-2) within 6 weeks or 5 half-lives of the drug, whichever is 
longer, prior to initiation of study treatment. 
30. Treatment with systemic immunosuppressive medication (including, but not limited to, 
prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor 
necrosis factor alpha [anti-TNF-α] agents) within 2 weeks prior to initiation of study 
treatment, or anticipation of need for systemic immunosuppressive medication during the 
course of the study 
• Subjects who have received acute, low-dose, systemic immunosuppressant 
medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in 
the study after discussion with and approval by the Medical Monitor. 
• The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for 
subjects with orthostatic hypotension, chronic obstructive pulmonary disease, or 
adrenocortical insufficiency is allowed. 
• Subjects with a history of allergic reaction to IV contrast requiring steroid 
pre-treatment should have baseline and subsequent tumor assessments performed 
using MRI. 
31. Active or history of autoimmune disease, including, but not limited to, colitis, Crohn’s 
disease, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, Wegener 
granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, 
vasculitis, or glomerulonephritis.* 
• Subjects with a history of autoimmune-related hypothyroidism on a stable dose of 
thyroid-replacement hormone may be eligible for this study after discussion with and 
approval by the Medical Monitor. 
• Subjects with controlled Type 1 diabetes mellitus on a stable insulin regimen may be 
eligible for this study after discussion with and approval by the Medical Monitor. 
32. Subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., subjects with psoriatic arthritis) are permitted provided that 
they meet the following conditions: 
• Subjects with psoriasis must have a baseline ophthalmologic exam to rule out ocular 
manifestations 
• Rash must cover less than 10% of body surface area (BSA) 
• Disease is well controlled at baseline and only requiring low potency topical steroids 
(e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, 
desonide 0.05%, alclometasone dipropionate 0.05%) 
• No acute exacerbations of underlying condition within the last 12 months (not 
requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, high potency or oral steroids) 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
33. Uncontrolled tumor-related pain 
• Subjects requiring narcotic pain medication must be on a stable regimen at study 
entry. 
• Symptomatic lesions (e.g., bone metastases or metastases causing nerve 
impingement) amenable to palliative radiotherapy should be treated prior to start of 
study treatment. Subjects should be recovered from the effects of radiation. There is 
no required minimum recovery period. 
• Asymptomatic metastatic lesions whose further growth would likely cause functional 
deficits or intractable pain (e.g., epidural metastasis that is not presently associated 
with spinal cord compression) should be considered for loco-regional therapy if 
appropriate prior to the start of study treatment. 
34. Uncontrolled hypercalcemia (>1.5 mmol/L ionized calcium or calcium >12 mg/dL or 
corrected serum calcium >ULN) or symptomatic hypercalcemia requiring continued use 
of bisphosphonate therapy (unless bisphosphonate is used to prevent skeletal events). 
35. Prior allogeneic stem cell or solid organ transplantation. 
36. History of another primary cancer within the last 3 years that required treatment, with the 
exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated 
cervical carcinoma in situ. 
37. Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that lead to reasonable suspicion of a disease or condition that 
contraindicates the use of an investigational drug, may affect the interpretation of the 
results, or may render the subject at high risk for treatment complications. 
38. Subject inability to comply with study and follow-up procedures, as judged by the 
Investigator. 
* Any relevant diseases that are not listed as examples of exclusionary diseases are to be 
discussed with the Sponsor. 
7.3. 
Subject Withdrawal Criteria 
7.3.1. 
Discontinuation of Treatment 
The Investigator must guard the subject’s welfare and may discontinue study drug treatment at 
any time when this action appears to be in the subject’s best interest. The reason for the subject’s 
withdrawal must be recorded in the subject’s electronic case report form (eCRF). Possible 
reasons for such actions may include, but are not limited to, the following: 
• Disease progression (defined in Section 6.1.4). 
• AE. 
• Any significant protocol violation (e.g., demonstrated lack of treatment compliance, 
subject starts taking any concomitant anti-cancer therapy). 
• Withdrawal of consent by an enrolled subject, either for study treatment itself (and 
subsequent follow-up) or for participation in follow-up.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Other reasons as determined by the Investigator or Sponsor: a subject may have study 
treatment discontinued if, in the opinion of the Investigator or Sponsor, it is not in the 
subject’s best interest to continue 
• The subject becomes pregnant and/or begins breast feeding (treatment must be 
discontinued immediately). 
• Subjects for whom enoxaparin is discontinued for any reason (PEGPH20 will be 
discontinued if administered, treatment with other study drugs may continue as 
deemed appropriate by the Investigator). 
Subjects who discontinue treatment with all study drugs should enter long-term follow-up unless 
they withdraw consent, die, or are lost to follow-up. 
7.3.2. 
Discontinuation from Study 
After discontinuing study treatment (PEGPH20, CIS, GEM, and atezolizumab [if applicable] 
treatments), the subject will enter long-term follow-up for assessment of survival and subsequent 
anti-cancer therapies (Section 8.1.2.5). Long-term follow-up will continue until the subject 
discontinues from the study. The reason for the subject’s discontinuation from the study should 
be documented in the subject’s eCRF. Possible reasons for study discontinuation include the 
following: 
• Death. 
• DLT during the Run-in portion of the study. 
• Adverse event. 
• Withdrawal of consent. 
• Lost to follow-up. 
• Sponsor termination of the study. 
• Other. 
7.4. 
Sponsor Study Stopping Rules 
Halozyme may terminate this study after informing Investigators at any time. Investigators will 
be notified by Halozyme (or designee) if the study is placed on hold, completed, or closed. 
Conditions that may warrant termination of the study include but are not limited to the following: 
• The discovery of unexpected, serious, or unacceptable risk to the subjects in the 
study. 
• A decision on the part of the Sponsor to suspend or discontinue testing, evaluation, or 
development of the product. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8. 
STUDY PROCEDURES AND ASSESSMENTS 
Study procedures for each portion of the study are provided in the tables in Section 3. This 
section describes evaluations to be done before, during, and after treatment. Section 8.2 provides 
information on individual study assessments. 
When duplicate evaluations are performed before study commencement, the data from the 
evaluation closest in time to study entry will be recorded. When duplicate evaluations are 
performed in a given time window, the worst case value will be recorded for safety evaluations, 
unless otherwise stipulated. Unless otherwise specified, clinical laboratory tests may be 
performed 1 day earlier than specified in the relevant Study Schedule of Events. 
Scheduled clinic attendance should occur within ±2 days of the specified dates, as long as doses 
are separated by the appropriate amount of time. Where this is not possible because of 
extenuating circumstances (e.g., holidays), the reason should be noted and the doses should be 
separated by at least 45 hours. 
8.1. 
Study Procedures by Visit 
8.1.1. 
Screening 
If the following procedures were done as per the standard-of-care prior to the subject signing the 
ICF, the results may be used for this study provided they were within the screening window 
(≤28 days before Day 1): physical examination, vital sign measurements, height, weight/BSA, 
and CT/MRI scan. 
Note: Plasma samples are required for PEGPH20 PK, CIS PK, GEM PK, HA, biomarker, and 
PEGPH20 immunogenicity analysis. Serum samples are required for atezolizumab PK, 
atezolizumab immunogenicity, CA19-9, and CEA analysis. All subjects will be monitored for 
study procedure-associated serious adverse events (SAEs) starting from the time of ICF signature 
as described in Section 10.2. 
8.1.1.1. 
Within 28 Days Prior to Day 1 (Unless Otherwise Indicated) 
• Sign and date ICF.  
• Review inclusion/exclusion criteria. 
• Collect medical and prior medication history. 
• Collect history of bile duct adenocarcinoma (intrahepatic, extrahepatic, and 
gallbladder). 
• Confirm availability of and retrieve tumor tissue (refer to Inclusion Criterion #2 for 
more details). Tumor tissue must be sent to central laboratory for retrospective testing 
of HA levels.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Obtain CT/MRI scan (baseline scan) for disease assessment and eligibility review by 
a local reviewer and send to CIV for storage. In addition, chest CT scans should be 
read locally to evaluate for the presence of PE. If subject has signs or symptoms of 
PE after the initial scan was completed, the chest scan should be repeated prior to 
enrollment (in Run-in)/randomization (in Expansion) to assess for the presence of PE. 
If a PE is present, the subject will not be enrolled/randomized. 
• Obtain Doppler ultrasound of lower extremities. 
• Perform the following assessments: 12-lead ECG, physical examination, vital signs, 
ECOG Performance Status, height and weight/BSA within 28 days before Day 1 (first 
dose of study medication), and urine or serum pregnancy test within 7 days before 
Day 1 (WOCBP; local laboratory). 
• Obtain samples for the following tests and send to the central laboratory: CA19-9 and 
CEA analysis, plasma HA levels and exploratory biomarkers, thyroid hormones, 
hematology, blood chemistry, coagulation, viral serology, and urinalysis. 
• Register subjects into an Interactive Web Response System (IWRS) for screening. 
• Enroll subjects (and randomize if in Expansion portion). 
8.1.2. 
Treatment Period 
AEs and concomitant medications will be obtained throughout the study and at every visit. 
Note: Hydration and electrolyte supplementation with potassium and magnesium must be given 
prior to CIS infusion per individual institutional standards. Premedication with antiemetics will 
be administered as standard-of-care to all subjects prior to chemotherapy (CIS and GEM) 
infusion. The use of steroids during treatment in the study should be avoided unless emesis is not 
controlled with other antiemetics. 
Also note that the translational medicine and PK samples are not listed below and should be 
obtained at the timepoints mentioned in Table 4 for subjects receiving PEGCISGEM and 
PEGCISGEMATEZO treatment and in Table 5 for subjects receiving CISGEM treatment in both 
portions of the study. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.1.2.1. 
Subjects Receiving PEGCISGEM Treatment (Run-in and Expansion) 
8.1.2.1.1. Treatment Cycle 1 
8.1.2.1.1.1. Cycle 1 Day 1 
Before PEGPH20 Infusion 
• Confirm subjects’ eligibility based on inclusion and exclusion criteria. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status, and 
weight/BSA. 
- 
Obtain samples for the following tests and send to the central laboratory: 
hematology, blood chemistry, and urinalysis. 
• Obtain samples for PEGPH20 immunogenicity testing and send to the central 
laboratory. 
• Obtain samples for CA19-9 and CEA testing and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.1.2. Cycle 1 Day 9 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
8.1.2.1.2. Treatment Cycle 2 and Beyond (Repeats Every 3 weeks) 
8.1.2.1.2.1. Cycle 2 and Beyond Day 1 
Before PEGPH20 Infusion 
• Perform urine/serum pregnancy test (WOCBP) at a local laboratory. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status, and 
weight/BSA. 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
CA19-9, CEA, blood chemistry, and urinalysis. 
• Obtain samples for PEGPH20 immunogenicity testing and send to the central 
laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: An analgesic 
non-steroidal agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.2.2. Cycle 2 and Beyond, Day 9 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
8.1.2.1.2.3. All Cycles Day 2 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
8.1.2.1.2.4. All Cycles Day 8 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain samples for the following tests and send to the central laboratory: hematology 
and blood chemistry. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information and subject’s convenience) to 
minimize the severity of MSEs. Note: A non-steroidal analgesic agent (at a dose 
equivalent to 20 mg of piroxicam) may be administered instead of piroxicam to 
reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.2.5. All Cycles Day 15 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain hematology sample and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.1.3. Selected Cycles from Cycle 3 Onwards, Day 15 
• Obtain CT/MRI scans for tumor assessment (based on RECIST v1.1) at the end of 
Cycles 3 and then at the end of every third cycle thereafter (i.e., end of Week 3 of 
Cycles 6, 9, and beyond). Scans may be obtained any time on or after Day 15 (of 
Cycles 3, 6, 9, and every third treatment cycle thereafter) to allow enough time for the 
scan to be reviewed locally prior to the subject’s next scheduled dosing visit. The 
results should be interpreted before dosing in the next cycle begins. The tumor 
assessments scans obtained during the study should be archived in accordance with 
the standard local practice. The scans will be submitted to a CIV selected by the 
Sponsor for potential central review at a later timepoint. For subjects who are 
withdrawn from the study due to clinical disease progression, a CT/MRI scan should 
be requested as soon as possible after clinical progression is determined. 
• Note: A confirmatory scan is required for subjects with CR or PR to confirm response 
per RECIST v1.1 (details in Section 8.2.15). 
8.1.2.2. 
Subjects Receiving PEGCISGEMATEZO Treatment (Run-in and Expansion) 
8.1.2.2.1. Treatment Cycle 1 
8.1.2.2.1.1. Cycle 1 Day 1 
Before PEGPH20 and Atezolizumab Infusion 
• Confirm subjects’ eligibility based on inclusion and exclusion criteria. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status, and 
weight/BSA. 
• Obtain samples for the following tests and send to the central laboratory:  
- 
Hematology. 
- 
Blood chemistry. Note: Measurements of total bilirubin, aspartate 
aminotransferase (AST), and alanine aminotransferase (ALT) (as part of blood 
chemistry) must be obtained prior to dosing (within 48 hours is acceptable). Local 
laboratories may be used for these measurements. Dosing can only take place if 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
AST and ALT values are within the ranges specified in the Inclusion Criterion. 
For total bilirubin, dosing can take place only if the total bilirubin is ≤3.0 × ULN. 
- 
Urinalysis. 
- 
Thyroid. 
• Obtain samples for PEGPH20 and atezolizumab immunogenicity testing and send to 
the central laboratory. 
• Obtain samples for CA19-9 and CEA testing and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 and Atezolizumab Infusion  
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
• Atezolizumab IV infusion over 60 minutes, 1 to 3 hours after completion of 
PEGPH20 infusion. 
8.1.2.2.1.2. Cycle 1 Day 4 (Subjects Enrolled Under Protocol Amendment 3 Only) 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.1.3. Cycle 1 Day 8 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain samples for the following tests and send to the central laboratory:  
- 
Hematology 
- 
Blood chemistry. Note: Measurements of total bilirubin, AST, and ALT (as part 
of blood chemistry) must be obtained prior to dosing (within 48 hours is 
acceptable). Local laboratories may be used for these measurements. Dosing can 
only take place if AST and ALT values are within the ranges specified in the 
Inclusion Criterion. For total bilirubin, dosing can take place only if the total 
bilirubin is ≤3.0 × ULN. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin.  
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.1.4. Cycle 1 Day 9 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole daily or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin . 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.1.2.2.1.5. Cycle 1 Day 11 (Subjects Enrolled Under Protocol Amendment 3 Only) 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A nonsteroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg/day of enoxaparin.  
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.1.6. Cycle 1 Day 15 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain hematology sample and send to the central laboratory. 
• Obtain blood chemistry sample and send to the central laboratory. Note: 
Measurements of total bilirubin, AST, and ALT (as part of blood chemistry) must be 
obtained prior to dosing (within 48 hours is acceptable). Local laboratories may be 
used for these measurements. Dosing can only take place if AST and ALT values are 
within the ranges specified in the Inclusion Criterion. For total bilirubin, dosing can 
take place only if the total bilirubin is ≤3.0 × ULN. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.1.7. Cycle 1 Day 18 (Subjects Enrolled Under Protocol Amendment 3 Only) 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg/day of enoxaparin.  
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.2. Treatment Cycle 2 and Beyond (Repeats Every 3 weeks) 
8.1.2.2.2.1. Cycle 2 and Beyond Day 1 
Before PEGPH20 and Atezolizumab Infusion 
• Perform urine/serum pregnancy test (WOCBP) at a local laboratory. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status, and 
weight/BSA. 
− Obtain samples for the following tests and send to the central laboratory: 
hematology, urinalysis, CA19-9, CEA, and blood chemistry. Note that for Cycle 2 
Day 1 only: Measurements of total bilirubin, AST, and ALT (as part of blood 
chemistry) must be obtained prior to dosing (within 48 hours is acceptable). Local 
laboratories may be used for these measurements. Dosing can only take place if 
AST and ALT values are within the ranges specified in the Inclusion Criterion. 
For total bilirubin, dosing can take place only if the total bilirubin is ≤3.0 × ULN. 
If a subject has any of the values outside the specified ranges for ALT, AST and 
total bilirubin on Day 1 of Cycle 2, the Investigator should discuss further dosing 
plans for the subject with the Sponsor. 
• Obtain samples for PEGPH20 and atezolizumab immunogenicity testing and send to 
the central laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 and Atezolizumab Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
• Atezolizumab IV infusion over 60 minutes, 1 to 3 hours after completion of 
PEGPH20 infusion. Atezolizumab may be administered over 30 minutes instead of 
60 minutes if the first infusion in Cycle 1 is tolerated. 
8.1.2.2.2.2. Cycle 2 and Beyond, Day 8 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
blood chemistry.  
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin.  
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.2.3. Cycle 2 and Beyond, Day 9 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole daily or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
8.1.2.2.2.4. Cycle 2 and Beyond, Day 15 
Before PEGPH20 Infusion 
• Assess vital signs. 
• Obtain hematology sample and send to the central laboratory. 
• Obtain blood chemistry sample and send to the central laboratory. 
• Administer piroxicam (20 mg) at least 1 hour prior to the start of the PEGPH20 
infusion on the day of dosing (timing will be at the Investigator’s discretion based on 
the piroxicam manufacturer’s Prescribing Information, institutional practices, and 
subject’s convenience) to minimize the severity of MSEs. Note: A non-steroidal 
analgesic agent (at a dose equivalent to 20 mg of piroxicam) may be administered 
instead of piroxicam to reduce potential MSEs, at the discretion of the Investigator. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
PEGPH20 Infusion 
• PEGPH20 IV infusion over 10 to 12 minutes (approximately 1 mL/min). 
8.1.2.2.2.5. All Cycles Day 2 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole daily or OTC equivalent). 
• Administer 1 mg/kg of enoxaparin. 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
• GEM IV infusion over 30 minutes, 24 hours (±4 hours) after completion of PEGPH20 
infusion. 
8.1.2.2.3. Selected Cycles from Cycle 3 Onwards, Day 1 
• Obtain blood sample for testing of thyroid hormones (to be collected on Day 1 of 
Cycle 3 and every third cycle thereafter (i.e., Day 1 of Cycles 6, 9, etc.). 
8.1.2.2.4. Selected Cycles from Cycle 3 Onwards, Day 15 
• Obtain CT/MRI scans for tumor assessment (based on RECIST v1.1 and 
Immune-Modified RECIST) at the end of Cycles 3 and then at the end of every third 
cycle thereafter (i.e., end of Week 3 of Cycles 6, 9, and beyond). Scans may be 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
obtained any time on or after Day 15 (of Cycles 3, 6, 9, and every third treatment 
cycle thereafter) to allow enough time for the scan to be reviewed locally prior to the 
subject’s next scheduled dosing visit. The results should be interpreted before dosing 
in the next cycle begins. The tumor assessments scans obtained during the study 
should be archived in accordance with the standard local practice. The scans will be 
submitted to a CIV selected by the Sponsor for potential central review at a later 
timepoint. For subjects who are withdrawn from the study due to clinical disease 
progression, a CT/MRI scan should be requested as soon as possible after clinical 
progression is determined. 
Note: A confirmatory scan is required to confirm disease progression based on 
Immune-Modified RECIST; and a confirmatory scan is required for subjects with CR 
or PR to confirm response per RECIST v1.1 (details in Section 8.2.15).  
8.1.2.3. 
Subjects Receiving CISGEM (Expansion only) 
8.1.2.3.1. Treatment Cycle 1 
8.1.2.3.1.1. Cycle 1 Day 1 
Before CIS and GEM Infusion 
• Confirm subjects’ eligibility based on inclusion and exclusion criteria. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status and 
weight/BSA. 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
urinalysis, blood chemistry, CA19-9 and CEA. 
CIS and GEM Infusion 
• CIS IV infusion over 1 hour. 
• GEM IV infusion over 30 minutes. 
8.1.2.3.2. Treatment Cycle 2 and Beyond (Repeats Every 3 weeks) 
8.1.2.3.2.1. Cycle 2 and Beyond Day 1 
Before CIS and GEM Infusion 
• Perform urine/serum pregnancy test (WOCBP) at a local laboratory. 
• Perform physical examination. 
• Perform the following assessments: vital signs, ECOG Performance Status and 
weight/BSA. 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
blood chemistry, CA19-9, CEA, and urinalysis. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
CIS and GEM Infusion  
• CIS IV infusion over 1 hour. 
• GEM IV infusion over 30 minutes. 
8.1.2.3.2.2. All Cycles Day 8 
Before CIS and GEM Infusion 
• Assess vital signs. 
• Obtain samples for the following tests and send to the central laboratory: hematology 
and blood chemistry.  
CIS and GEM Infusion  
• CIS IV infusion over 1 hour. 
• GEM IV infusion over 30 minutes. 
8.1.2.3.3. Selected Cycles from Cycle 3 Onwards, Day 15 
• Obtain CT/MRI scans for tumor assessment (based on RECIST v1.1) at the end of 
Cycles 3 and then at the end of every third cycle thereafter (i.e., end of Week 3 of 
Cycles 6, 9, and beyond). Scans may be obtained any time on or after Day 15 (of 
Cycles 3, 6, 9, and every third treatment cycle thereafter) to allow enough time for the 
scan to be reviewed locally prior to the subject’s next scheduled dosing visit. The 
results should be interpreted before dosing in the next cycle begins. The tumor 
assessments scans obtained during the study should be archived in accordance with 
the standard local practice. The scans will be submitted to a CIV selected by the 
Sponsor for potential central review at a later timepoint. For subjects who are 
withdrawn from the study due to clinical disease progression, a CT/MRI scan should 
be requested as soon as possible after clinical progression is determined. 
• Note: A confirmatory scan is required for subjects with CR or PR to confirm response 
per RECIST v1.1 (details in Section 8.2.15).  
8.1.2.4. 
End of Treatment Visit 
The End of Treatment Visit procedures described below will be the same for all subjects, 
regardless of the study portion or the treatment, unless otherwise specified. Subjects should 
return to the study site for an End of Treatment Visit within approximately 7 days after 
determination of disease progression or within 7 days after treatment discontinuation for other 
reasons. AEs and concomitant medications will be obtained and the following procedures should 
be performed: 
• Perform the following assessments: physical examination, vital signs, measure 
weight/calculate BSA, ECOG Performance Status, and 12-lead ECG. 
• Obtain CT/MRI scan and send to CIV for storage - CT/MRI should only be done if 
radiographic disease progression was not documented in the previous CT/MRI scan, 
unless the latter was performed within the last 14 days. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Administer proton pump inhibitor (e.g., 20 mg omeprazole daily or OTC equivalent) 
for subjects receiving PEGCISGEM and PEGCISGEMATEZO treatment. 
• Obtain samples for the following tests and send to the central laboratory: hematology, 
blood chemistry, coagulation, and urinalysis. 
• Obtain sample for PEGPH20 and atezolizumab immunogenicity testing (subjects 
receiving PEGCISGEM and PEGCISGEM ATEZO only) and testing of serum 
CA19-9 and CEA levels and send to the central laboratory. 
• Obtain an End of Treatment tumor biopsy if deemed clinically feasible by the 
Investigator, at the time of disease progression per RECIST v1.1 (subjects receiving 
PEGCISGEM, PEGCISGEMATEZO, and CISGEM), loss of clinical benefit as 
determined by the Investigator (subjects receiving PEGCISGEM and 
PEGCISGEMATEZO), or unacceptable toxicity (subjects receiving PEGCISGEM, 
PEGCISGEMATEZO, and CISGEM). 
8.1.2.5. 
Long-Term Follow-Up 
After the End of Treatment Visit, all subjects will enter long-term follow-up during which 
information on the subject’s survival status and subsequent anti-cancer therapies (i.e., therapies 
received, responses) will be obtained by the site once every 12 weeks (or more frequently, if, 
required, prior to important study timepoints, including DMC meetings and database locks). 
Long-term follow-up will continue until the subject dies, is lost to follow-up, or withdraws 
consent. 
8.1.3. 
Procedures for Study Treatment Discontinuation 
In the event of study treatment discontinuation, the subject should be instructed to report to the 
clinic as early as possible after the decision to discontinue study treatment has been made or for 
the next scheduled clinic visit. When the subject returns to the clinic, all End of Treatment 
procedures should be conducted (see Section 8.1.2.4). The Investigator will make his or her best 
efforts to perform these procedures. 
8.2. 
Study Assessments 
8.2.1. 
Informed Consent 
The Investigator or designee must present and explain the study protocol to prospective study 
subjects before screening. The Investigator or designee must be available to answer any 
questions the subject may have regarding the study protocol and procedures. The Investigator or 
designee must explain that the subject is not obliged to enter the study and is free to withdraw 
from it at any time for any reason. If new safety information becomes available and results in 
significant changes in risk/benefit assessment, the ICF should be reviewed and updated if 
necessary. Under this circumstance, all subjects, including those already being treated, should be 
given the new information, given a copy of the revised ICF, and allowed to re-evaluate their 
consent to continue in the study. 
A copy of the signed and dated ICF will be provided to the subject. The original ICF will be 
retained by the Investigator. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.2.2. 
Inclusion/Exclusion Criteria 
The inclusion/exclusion criteria (Sections 7.1 and 7.2) must be reviewed at screening to ensure 
that the subject qualifies for the study. Subjects may be enrolled into the study if all selection 
criteria are met. 
8.2.3. 
Medical History (including bile duct adenocarcinoma history) 
A complete medical history (significant past and ongoing conditions), tobacco/nicotine usage 
history and demographic information will be obtained at screening. Previous history of 
allergies/allergic reactions (allergy to bee stings, anaphylaxis, etc.) should also be captured on 
the Medical History eCRF page. 
A complete medical history of bile duct adenocarcinoma (intrahepatic, extrahepatic, gallbladder) 
will be obtained at screening and captured on the Medical History eCRF page. 
8.2.4. 
Concomitant Medications 
Information regarding collection of concomitant medications is provided in Section 10.12. 
8.2.5. 
Adverse Events 
AEs will be collected as defined in Section 10. 
8.2.6. 
Physical Examination 
Physical examination, including head/ears/eyes/nose/throat, respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, central and peripheral nervous system, and dermatologic 
assessments, will be performed when required by protocol. 
8.2.7. 
Height and Weight 
Height will be recorded in cm, and weight will be recorded in kg. Body surface area (BSA) will 
be calculated from the height and weight. 
8.2.8. 
ECOG Performance Status 
The subject’s ECOG Performance Status will be assessed (see Appendix A). 
8.2.9. 
Vital Signs 
Assessment of vital signs includes the measurement of blood pressure (systolic and diastolic), 
pulse, respiratory rate, and body temperature. Blood pressure and pulse will be measured with 
the subject at rest and in a sitting position for at least 5 minutes. 
8.2.10. 
12-lead ECG 
ECGs including clinical significance will be evaluated by the Investigator and recorded in the 
eCRF. 
8.2.11. 
Central Laboratory Tests  
Hematology, blood chemistry, thyroid hormones, coagulation parameters, viral serology, and 
urinalysis will all be analyzed by the central laboratory. Central laboratory testing is mandatory 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
and must be performed; however, if central laboratory results cannot be obtained within the 
required timeframe, then local laboratory results may be used to for the purposes of eligibility 
determination at Screening and for measurement of liver function, including total bilirubin, AST, 
and ALT prior to dosing (within 48 hours is acceptable) during Cycle 1 through Day 1 of Cycle 2 
(Table 2 and Section 8.1.2). In such cases, results and reference ranges of the local laboratory 
will take precedence over those of the central laboratory (e.g., if a subject is eligible according to 
the local laboratory but ineligible according to the central laboratory, then that subject would still 
be considered qualified for study enrollment as per protocol). For study analysis and reporting 
purposes, only values derived from the central laboratories will be utilized. 
The Investigator must evaluate all results outside the reference range and determine the clinical 
significance (clinically significant or not clinically significant). 
• Hematology: hemoglobin, hematocrit, red blood cell count, white blood cell (WBC) 
count, neutrophils (ANC), lymphocytes (absolute), monocytes (absolute), eosinophils 
(absolute), basophils (absolute), granulocytes (absolute), mean corpuscular 
hemoglobin, mean corpuscular volume, and platelet count. 
• Blood chemistry: glucose, blood urea nitrogen (BUN), albumin, total bilirubin, 
alkaline phosphatase, AST, ALT, electrolytes (including sodium, potassium, calcium, 
magnesium, chloride, and bicarbonate), and creatinine. 
• Since the atezolizumab US Prescribing Information (TECENTRIQ® US Prescribing 
Information 2018) advises monitoring of patients for changes in thyroid function at 
the start of treatment and periodically during treatment, the thyroid hormones free 
triiodothyronine (T3; or total T3 for sites where free T3 is not performed), free total 
thyroxine (T4), and thyroid stimulating hormone (TSH) will be monitored throughout 
the study (see Schedule of Events Table 1 and Table 2). 
• Coagulation: international normalized ratio (INR), prothrombin time (PT), and partial 
thromboplastin time (PTT). 
• Viral serology: HIV, HBsAg, HBsAb, total HBcAb, HCV antibody; HBV DNA (for 
subjects with negative HBsAg result and positive total HBcAb result); HCV RNA 
(for subjects with positive HCV antibody result). 
• Urinalysis: protein, glucose, ketones, blood, specific gravity, nitrite, pH, and 
leukocytes. 
8.2.12. 
Pregnancy Test 
A serum or urine human chorionic gonadotropin test to determine whether a female subject is 
pregnant should be collected for all WOCBP. A woman is considered of childbearing potential, 
i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile. 
A postmenopausal state is defined as no menses for 12 months without an alternative medical 
cause. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and 
bilateral oophorectomy. The pregnancy test will be done by the local laboratory within 7 days 
before Day 1 (first dose of study medication). Pregnancy tests will be performed approximately 
every month at the beginning of each treatment cycle (Cycles 2 and beyond) during the study. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.2.13. 
Contraception 
Highly effective methods of contraception for participating WOCBP should be used during the 
study treatment and up to 5 months following the last dose of any study medication, and include 
the following: 
• Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation (oral, intravaginal, transdermal). 
• Progestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable). 
• IUD. 
• IUS. 
• Bilateral tubal occlusion. 
• Vasectomized partner. 
• True sexual abstinence (defined as refraining from heterosexual intercourse if this is 
aligned with the preferred and usual lifestyle of the subject). Periodic abstinence, 
declaration of abstinence for the duration of the trial or withdrawal should not be 
considered as a highly effective method of contraception and therefore are not 
acceptable methods of contraception. 
Participating men can be fertile or vasectomized. Fertile men are advised to use highly effective 
methods of contraception during the study and until 6 months after administration of the last 
dose of any study medication. 
8.2.14. 
Immunogenicity 
A blood sample will be collected from all subjects who receive PEGPH20 and analyzed to 
determine if PEGPH20 is eliciting a humoral immune response. Initial anti-drug antibodies 
(ADA) testing will be done using a multi-tiered approach per the Guidance, and 
immunocompetition will be performed to confirm an initial positive response in the screening 
assay. Any samples confirmed as positive in the ADA assay will then be assayed for neutralizing 
antibodies. 
A serum sample will also be collected from all subjects receiving PEGCISGEMATEZO and 
analyzed to determine if atezolizumab is eliciting a humoral immune response. Initial ADA 
testing will be done using a multi-tiered approach per the Guidance, and immunocompetition 
will be performed to confirm an initial positive response in the screening assay.  
Refer to the current US Prescribing Information of atezolizumab for information related to 
immunogenicity of atezolizumab. 
Refer to the current US Prescribing Information of CIS and GEM for information related to 
immunogenicity of CIS and GEM. 
8.2.15. 
Imaging/Radiologic Evaluation 
CT/MRI with contrast evaluations will be performed for all subjects in accordance with each 
site’s Standard-of-Care Bile Duct Adenocarcinoma CT/MRI imaging protocols (include chest, 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
abdomen, pelvis contrast-enhanced CT/MRI). CT/MRI scans of other areas of known or newly 
suspected disease must also be obtained. In the event that the subject is intolerant to any contrast 
agents needed for imaging, local/institutional guidelines should be followed for imaging 
evaluation. 
All scans, including those obtained at Screening (baseline), will be evaluated locally for disease 
assessment using RECIST v1.1 and Immune-Modified RECIST.  
For study eligibility, the Investigator must determine the presence of 1 or more tumors on 
CT/MRI scans performed within 28 days of Day 1. For subject eligibility in both portions of the 
study measurable disease must be determined using RECIST v1.1 (Appendix B). During the 
study, CT/MRI scans for objective tumor assessment (based on RECIST v1.1 and 
Immune-Modified RECIST) will be performed at the end of Cycle 3, and at the end of every 
third treatment cycle thereafter (i.e., end of Week 3 of Cycles 6, 9, and beyond). CT/MRI scans 
for RECIST v1.1 and Immune-Modified RECIST should be performed after the last dose in each 
cycle to allow time for reading of the scans by the local reviewer prior to start of subsequent 
cycles.  
Per RECIST v1.1, a response of PR and CR should be confirmed by a repeat tumor imaging 
assessment no less than 28 days from the date the response was first documented. A 
confirmatory scan is required in both portions of the study for subjects with CR or PR for 
confirmation of response. This confirmatory scan may be performed at the earliest 28 days after 
the date of the first documented response (preferred) or at the next scheduled imaging timepoint, 
whichever is clinically indicated. Subjects who have a confirmatory scan need not undergo the 
next scheduled tumor imaging if the latter is less than 4 weeks after the confirmatory scan, unless 
clinically indicated. Subjects will return to regular scheduled imaging starting with the next 
scheduled imaging timepoint.  
A confirmatory scan is required for subjects receiving PEGCISGEMATEZO treatment to 
confirm radiological disease progression, per Immune-Modified RECIST. This confirmatory 
scan should be obtained no sooner than 28 days after the initial scan that showed progression 
based on RECIST v1.1 (this can be the next scheduled tumor assessment scan).  
For subjects who are withdrawn from the study due to clinical disease progression, a CT/MRI 
scan should be requested as soon as possible. At the End of Treatment Visit, a CT/MRI scan is 
only required if radiographic disease progression was not documented in the previous CT/MRI 
scan, unless the latter was performed within the last 14 days. 
Note: For disease assessment, if a CT/MRI scan is taken at screening then the same modality of 
scanning must be used for the subject throughout the course of the study. 
8.2.15.1. Chest Computed Tomography to Exclude Pulmonary Embolism 
The chest CT obtained during the screening period should be read locally to assess for the 
presence of PE. If a subject has signs and symptoms of PE after the initial screening scan was 
obtained, the scan should be repeated prior to enrollment (in Run-in)/randomization (in 
Expansion) (refer to Section 8.1.1). 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.2.16. 
Doppler Ultrasound Scanning for Assessment of Deep Vein Thrombosis 
Doppler ultrasound will be performed as per Section 10.1. Bilateral Doppler ultrasound scanning 
of the proximal and distal veins is the current standard for routine clinical assessment of possible 
lower extremity DVT. 
8.2.17. 
Pharmacokinetic Assessments 
Plasma samples will be collected to assess the potential effects of atezolizumab, CIS and GEM 
on the PK of PEGPH20 (as specified in Table 4 and Table 5). Additionally, plasma samples will 
also be collected to assess the PK of CIS and GEM. Serum samples will be collected to assess 
the PK of atezolizumab. Post-dose PK timepoints will be specified relative to PEGPH20, 
atezolizumab, CIS, and GEM infusions. If samples are collected from a central line, the line 
should be flushed with saline prior to collecting the PK samples. Samples should not be collected 
from the same line used to administer PEGPH20. Actual sampling times must be recorded. Initial 
testing will be done during the study; however, samples will be stored for possible re-analysis if 
deemed necessary and for potential future testing of other biomarkers that may be found to be 
relevant. 
If a subject discontinues PEGPH20 therapy, PEGPH20 PK samples will not be collected from 
that subject. However, if that subject continues therapy with any of the other study drugs, at the 
discretion of the Investigator, PK samples of those drugs must be collected. 
8.2.18. 
CA19-9 
CA19-9 is a blood test from the tumor marker category. Serum samples will be collected from all 
subjects to assess the effect of treatment on CA19-9 levels and sent to the central laboratory for 
analysis. 
8.2.19. 
CEA 
The CEA test is a blood test from the tumor marker category. Serum samples will be collected 
from all subjects to assess the effect of treatment on CEA levels and sent to the central laboratory 
for analysis. 
8.2.20. 
Pharmacodynamic and Biomarker Assessments 
This study will collect samples for pharmacodynamic and biomarker assessments in all subjects 
(where not prohibited by local regulations). Sample types collected include tumor, blood, and 
plasma samples. Any sample or derivatives (such as DNA, RNA, and protein) may be stored for 
up to 15 years after study completion to assist in any research related to PEGPH20 or cancer, and 
for potential diagnostic development. 
In addition, biomarkers identified in other clinical studies may also be assessed in the biomarker 
samples collected from subjects enrolled in this study. The decision to perform other biomarker 
assessments may be based on the clinical outcome of this study and/or the signals observed in 
other clinical studies or other information available at that time. 
Refer to the Laboratory Manual for detailed instructions on the processing, storage, and shipping 
of samples. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.2.20.1. Tumor Biopsies 
Tumor tissue needs to meet specific tissue sample requirements (see Laboratory Manual). 
Tumor tissue will be sent to a central laboratory and tested for HA levels retrospectively using an 
exploratory investigational diagnostic assay. This assay uses an affinity-histochemistry-based 
staining method to evaluate HA levels in tumor biopsies. PD-L1 expression levels will also be 
tested in the tumor tissue retrospectively. Exploratory biomarkers may also be assessed. 
If deemed clinically feasible by the Investigator, an End of Treatment biopsy will be collected at 
the time of disease progression per RECIST v1.1, loss of clinical benefit as determined by the 
Investigator, or unacceptable toxicity, in subjects receiving PEGCISGEM and 
PEGCISGEMATEZO. In the CISGEM control arm, tumor tissue will be collected at the time of 
disease progression per RECIST v1.1 or unacceptable toxicity. The samples will be analyzed for 
tumor HA, PD-L1 expression, and other exploratory biomarkers in comparison with the pre-dose 
sample to evaluate PEGPH20 and/or chemotherapy effects and to potentially identify resistance 
mechanisms. 
8.2.20.2. Blood Samples 
Blood samples will be collected according to timepoints listed in Table 4 and Table 5.  
8.2.20.2.1. Plasma Samples 
Plasma HA is a pharmacodynamic marker of PEGPH20 pharmacological activity. Baseline and 
post-dose HA levels in plasma samples will be analyzed to evaluate the PEGPH20 treatment 
effect, and assess drug exposure. 
In addition, plasma samples will be analyzed for exploratory biomarkers (such as protein, 
circulating tumor DNA) to assess their potential prognostic or predictive value. 
8.2.20.2.2. Pharmacogenetic Samples 
One blood sample will be collected from all subjects predose in Cycle 1 Day 1 to correlate 
individual subject DNA sequence variation (e.g., exploratory single nucleotide polymorphism 
genotyping) with safety, tolerability, and potential clinical benefit. 
The information obtained is solely used to further characterize drug effects and does not have 
clinical diagnostic or therapeutic implications for the individual subject. The Sponsor will be 
blinded as to the subject’s identity and since the analysis is done for research purposes only, 
individual results will not be shared with the Investigator and/or subject or the subject’s relatives. 
Any information obtained is not intended for inclusion in the medical record. This research will 
not change the care the subject receives in this study. 
8.3. 
Study Drug Administration 
Each treatment cycle is 21 days (3 weeks). 
PEGPH20, CIS, GEM, and atezolizumab will be administered as specified in the Schedule of 
Events Table 2 and Table 3. 
Treatment in both portions of the study will continue until disease progression or unacceptable 
toxicity, death, or withdrawal of consent from the study. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
This section provides guidance for dose interruptions and modifications of study treatment. Dose 
modifications for chemotherapy are permitted in the Run-in and Expansion portions of the study. 
Dose interruptions are allowed for atezolizumab in both the Run-in and Expansion portions of 
the study. PEGPH20 dose interruption and dose reduction is allowed in both the Run-in and 
Expansion portions of the study. No dose modifications of atezolizumab are allowed in this 
study. Dose modification guidelines are provided in Section 8.3 for PEGPH20, CIS and GEM. 
Guidance for atezolizumab dose interruption and discontinuation due to AEs are provided in the 
atezolizumab Investigator’s Brochure. Dose reduction levels of PEGPH20 are provided in 
Table 10 of Section 8.3.1.3 . Additional dose modification guidelines for CIS and GEM are 
provided in the Prescribing Information of these chemotherapeutic agents. 
Missed or Held Doses of Study Drugs 
Subjects receiving PEGCISGEM: 
Cycle 1 does not begin until PEGPH20 is administered. 
If PEGPH20 is permanently discontinued, the dosing of CIS and GEM should continue per study 
protocol schedule.  
If both CIS and GEM are anticipated to be missed or held on Day 2 of Cycle 2+, PEGPH20 must 
also be held until chemotherapy can be restarted. 
If both CIS and GEM are anticipated to be missed or held on Day 9, dosing with PEGPH20 
should continue per protocol schedule. 
If CIS is missed, held, or permanently discontinued, dosing with GEM and PEGPH20 should 
continue per protocol schedule. If GEM is anticipated to be missed, held, or permanently 
discontinued, CIS should not be administered. 
If both GEM and CIS are permanently discontinued, PEGH20 must also be permanently 
discontinued.  
Subjects receiving PEGCISGEMATEZO: 
Cycle 1 does not begin until PEGPH20 is administered. 
If PEGPH20 is permanently discontinued, the dosing of CIS, GEM, and atezolizumab should 
continue per protocol schedule.  
If both CIS and GEM are anticipated to be missed or held on Day 2 of Cycle 2+, PEGPH20 and 
atezolizumab should also be held until chemotherapy can be restarted. 
If both CIS and GEM are anticipated to be missed or held for Day 9, dosing with PEGPH20 
should continue per protocol schedule.  
If CIS is missed, held, or permanently discontinued, dosing with GEM, PEGPH20, and 
atezolizumab should continue per protocol schedule. If GEM is anticipated to be missed, held, or 
permanently discontinued CIS should not be administered. 
If both GEM and CIS are permanently discontinued, PEGH20 and atezolizumab dosing should 
continue per protocol schedule.  
If atezolizumab, GEM, and CIS are permanently discontinued then PEGPH20 (all study 
treatment) must also be permanently discontinued. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
If GEM, CIS, and PEGPH20 are permanently discontinued, atezolizumab dosing should continue 
per protocol schedule. 
Subjects receiving CISGEM (Control): 
If CIS is missed, held, or permanently discontinued, dosing with GEM should continue per 
protocol. If GEM is missed, held, or permanently discontinued CIS should not be administered. 
8.3.1. 
PEGPH20 
8.3.1.1. 
PEGPH20 Administration 
The PEGPH20 dose will be individually calculated for all dosing visits according to the subject’s 
screening weight. In calculating the dose, there will be no downward adjustment to “ideal” body 
weight. Doses should be re-adjusted if the subject’s weight changes by >10%. If the subject’s 
weight changes by ≤10%, no adjustment is necessary unless the site has a standard procedure to 
adjust doses based upon current weight. The dispensing pharmacist will verify the dose accuracy 
with a qualified study staff member. The appropriate dose will be diluted as per the instructions 
provided in a separate pharmacy manual. 
After completion of pre-dose activities, PEGPH20 will be administered as an IV infusion over 
10 minutes, approximately 1 mL/minute (a window of +2 minutes is allowed, i.e., infusion can 
be 10 to 12 minutes), under observation by qualified clinic staff and as per institutional 
guidelines. The volume and/or duration of PEGPH20 administration may change at the 
discretion of the Sponsor, based upon safety information. The study nurse or alternate designee 
by the Investigator will record the time the infusion was started and stopped. A saline flush 
should follow IV delivery of the complete PEGPH20 dose as per standard-of-care for flushing IV 
lines. Only a peripheral line should be used for the administration of PEGPH20 (heparin flushes 
should not be used on the same line as PEGPH20), but heparin flushes may be used for central 
lines as per standard-of-care. In the event that peripheral venous access cannot be obtained, the 
central line may be used. If this happens, ensure the line is flushed with saline (minimum of 10 
mL) prior to administering PEGPH20 and after administering PEGPH20. Ensure the PEGPH20 
administration is not done immediately before or after the central line has been flushed with a 
heparin flush (i.e., ensure the line is flushed with a heparin flush no earlier than 1 hour before or 
after the PEGPH20 administration). 
8.3.1.2. 
Hypersensitivity Reactions 
In the event of a hypersensitivity reaction, the PEGPH20 and atezolizumab infusion should be 
managed per Table 8 below and the symptoms should be treated as necessary. Blood should be 
drawn and analyzed per the Sponsor’s instructions to confirm the reaction (e.g., 
PEGPH20-specific immunoglobulin E and serum tryptase levels). Halozyme should be contacted 
immediately (see study manual for contact information) so that current knowledge of laboratory 
testing can be provided to the site.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 8: 
Guidelines for Management of PEGPH20 or atezolizumab infusion-related 
reactions 
Event 
Action to Be Taken 
IRR and anaphylaxis 
• 
For anaphylaxis precautions, refer to Appendix E.  
IRR, Grade 1  
• 
Reduce infusion rate to half the rate being given at the time 
of event onset. 
• 
After the event has resolved, the Investigator should wait for 
30 minutes while delivering the infusion at the reduced rate. 
• 
If the infusion is tolerated at the reduced rate for 30 minutes 
after symptoms have resolved, the infusion rate may be 
increased to the original rate. 
 IRR, Grade 2 
• 
Interrupt infusion. 
• 
Administer aggressive symptomatic treatment (e.g., oral or 
IV antihistamine, anti-pyretic, glucocorticoids, epinephrine, 
bronchodilators, oxygen). 
• 
After symptoms have resolved to baseline, resume infusion 
at half the rate being given at the time of event onset. 
• 
For subsequent infusions, administer oral premedication with 
antihistamine and anti-pyretic and monitor closely for IRRs. 
IRR, Grade 3 or 4 
• 
Stop infusion. 
• 
Administer aggressive symptomatic treatment (e.g., oral or 
IV antihistamine, anti-pyretic, glucocorticoids, epinephrine, 
bronchodilators, oxygen). 
• 
Permanently discontinue treatment and contact Medical 
Monitor.a 
Abbreviations: IRR = infusion-related reaction; IV = intravenous 
a Resumption of treatment may be considered in subjects who are deriving benefit and have fully recovered 
from the immune-related event. Subjects can be rechallenged only after approval has been documented by 
both the Investigator (or an appropriate delegate) and the Medical Monitor. 
 
8.3.1.3. 
PEGPH20 Dose Modification Guidelines 
PEGPH20 dose adjustments are allowed based on toxicities that are deemed related, possibly 
related, or probably related to PEGPH20. See Table 9 for guidelines. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 9: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines 
Event 
Management/Action 
Musculoskeletal  
Any Grade 1 MSEs 
• 
No change in PEGPH20 dose or frequency. Prescribed 
medication such as narcotics, muscle relaxants and other 
analgesics (with the exception of high-dose steroids), 
OTC drugs, and physical therapy can be used at the 
Investigator’s discretion. 
Any Grade 2 MSEs 
• 
Based on Investigator’s discretion use prescribed 
medication such as narcotics, muscle relaxants and other 
analgesics (with the exception of high-dose steroids), 
OTC drugs, and physical therapy. 
• 
If the MSEs resolve or decrease to Grade 1 with 
administration of prescribed medication, such as 
narcotics, muscle relaxants and other analgesics (with 
the exception of high-dose steroids), OTC drugs, and 
physical therapy, PEGPH20 can be continued. 
• 
If the MSEs persist at Grade 2 despite administration of 
prescribed medication, such as narcotics, muscle 
relaxants and other analgesics (with the exception of 
high-dose steroids), OTC drugs, and physical therapy, 
the Investigator must discuss any further PEGPH20 
treatment with the Sponsor’s Medical Monitor. 
Any Grade 3 or 4 MSEs  
• 
Hold PEGPH20 treatment. 
• 
Based on Investigator’s discretion use prescribed 
medication, such as narcotics, muscle relaxants and other 
analgesics (with the exceptions of steroidsa), OTC drugs, 
and physical therapy. 
• 
If the MSEs decrease to ≤ Grade 2, the Investigator must 
discuss any PEGPH20 treatment reinitiation with the 
Sponsor’s Medical Monitor.  
• 
If the MSEs persist at Grade 3 or 4 levels, PEGPH20 
should not be resumed. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 9: 
PEGPH20 Dose Adjustment and Toxicity Management Guidelines 
(Continued) 
Event 
Management/Action 
All non-MSE Events (Except TE Events) Potentially Related to PEGPH20 
Grade 1 or 2 
• 
No change in PEGPH20 treatment. 
Grade 3 
• 
Hold PEGPH20 treatment. 
• 
If toxicity is resolved to baseline within 14 days, 
treatment may resume at the same dose level. 
• 
If toxicity is reduced to ≤ Grade 2 within 14 days, 
treatment may resume but at next lower dose but must 
be discussed and decided upon mutual agreement with 
the Sponsor’s Medical Monitor (refer to Table 10 
below). 
• 
If toxicity persists at Grade 3, any consideration to 
resume PEGPH20 treatment must be discussed with the 
Sponsor’s Medical Monitor. 
Grade 4 
• 
Hold PEGPH20 treatment. 
• 
If toxicity is resolved or reduced to ≤ Grade 2, any 
PEGPH20 treatment reinitiation must be discussed with 
the Sponsor’s Medical Monitor. 
Thromboembolic Events (Regardless of Relatedness to PEGPH20) 
Grade 1 visceral/splanchnic vein 
thrombosis (associated with underlying 
disease of CCA and gallbladder 
adenocarcinoma) 
No change. 
Any Grade TE event (except superficial 
vein thrombosis; Grade 1 
visceral/splanchnic vein thrombosis 
[associated with underlying disease of 
CCA and gallbladder adenocarcinoma]) 
• 
Discontinue PEGPH20 treatment permanently and treat 
event per current NCCN guidelines until documented 
resolution of event. Treatment with the other drugs may 
continue as deemed appropriate by the Investigator. 
Abbreviations: CCA = cholangiocarcinoma; MSE = musculoskeletal event; NCCN = National Comprehensive 
Cancer Network; OTC = over-the-counter; PEGPH20 = PEGylated recombinant human hyaluronidase;  
 TE = thromboembolic. 
aSince this study uses an immunotherapeutic agent and steroids may suppress an immune response, steroids may be 
used at the Investigator’s discretion to treat ≥ Grade 3 MSEs that are refractory to non-steroid management only.  
 
For details on administration of piroxicam and Toradol for the management of MSEs, refer to 
Section 10.12.1; for information on administration of prophylactic enoxaparin for management 
of TE events, refer to Section 10.1.1. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 10: 
PEGPH20 Dose Reduction Guidelines 
Starting PEGPH20 
Dose 
First Allowed Dose 
Reduction 
Second Allowed Dose 
Reduction 
Third Allowed Dose 
Reduction 
3.0 μg/kg 
2.2 μg/kg 
1.6 μg/kg 
Discontinue PEGPH20 
treatment 
2.2 μg/kg 
1.6 μg/kg 
Discontinue PEGPH20 
treatment 
- 
1.6 μg/kg 
Discontinue PEGPH20 
treatment 
- 
- 
The lowest dose level for dose reduction will be 1.6 μg/kg of PEGPH20. Re-escalations of 
PEGPH20 are allowed in both portions of the study at the Investigator’s discretion with written 
permission by a Halozyme medical monitor. 
8.3.2. 
Atezolizumab  
8.3.2.1. 
Atezolizumab Administration 
Atezolizumab will be administered per the US Prescribing Information (as an IV infusion at a 
fixed dose of 1200 mg over 60 minutes on Day 1 of each 21-day cycle, 1 to 3 hours after 
PEGPH20. Note that in Cycle 2 and beyond, atezolizumab may be administered as an IV 
infusion over 30 minutes instead of 60 minutes if the first infusion in Cycle 1 is tolerated 
(TECENTRIQ® US Prescribing Information 2018). 
All Cycle Day 1 administrations of atezolizumab should occur 1 to 3 hours after PEGPH20 
administration. 
8.3.2.2. 
Identified Risks of Atezolizumab Treatment 
Refer to the current Atezolizumab US Prescribing Information for the identified risks associated 
with atezolizumab treatment. 
8.3.2.3. 
Atezolizumab Dose Adjustment and Toxicity Management 
Dose adjustments (interruption, and discontinuation) and toxicity management should be 
undertaken per the current US Atezolizumab Prescribing Information, Appendix F, and the 
current Atezolizumab Investigator’s Brochure. 
8.3.3. 
Cisplatin and Gemcitabine 
Premedication with antiemetics will be administered as standard-of-care prior to CIS and GEM 
infusions. The use of steroids during treatment in the study should be avoided unless emesis is 
not controlled with other antiemetics. 
8.3.3.1. 
Cisplatin Administration 
CIS will be administered as an IV infusion at 25 mg/m2 over 1 hour with prior hydration and 
electrolyte supplementation with potassium and magnesium per individual institutional standard 
on Day 2 and Day 9 of each 21-day cycle to subjects receiving PEGCISGEM and 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
PEGCISGEMATEZO. In the Control arm, CIS will be administered as an IV infusion at 25 
mg/m2 over 1 hour with prior hydration and electrolyte supplementation with potassium and 
magnesium per individual institutional standard on Day 1 and Day 8 of each 21-day cycle. 
Please refer to the current package insert for the description and composition of this drug. 
The CIS dose will be individually calculated for all infusion visits according to the subject’s 
screening BSA. In calculating the dose, there will be no downward adjustment to “ideal” body 
weight unless institution policy requires it. Doses should be re-adjusted if the subject’s BSA 
changes by >10%. If the subject’s BSA changes by ≤10%, no adjustment is necessary unless the 
site has a standard procedure to adjust doses based upon current BSA. 
8.3.3.2. 
Gemcitabine Administration 
After completion of the CIS infusion, GEM will be administered as an IV infusion at 
1000 mg/m2 over 30 minutes per institutional standard on Day 2 and Day 9 of each 21-day cycle 
to subjects treated with PEGCISGEM and PEGCISGEMATEZO. In the Control arm, GEM will 
be administered as an IV infusion at 1000 mg/m2 over 30 minutes per institutional standard on 
Day 1 and Day 8 of each 21-day cycle. 
Please refer to the current Prescribing Information for the description and composition of this 
drug. 
The GEM dose will be individually calculated for all infusion visits according to the subject’s 
screening BSA. In calculating the dose, there will be no downward adjustment to “ideal” body 
weight unless institution policy requires it. Doses should be re-adjusted if the subject’s BSA 
changes by >10%. If the subject’s BSA changes by ≤10%, no adjustment is necessary unless the 
site has a standard procedure to adjust doses based upon current BSA. 
8.3.3.3. 
Identified Risks of CIS and GEM Treatment 
Refer to the current CIS package insert and GEM Prescribing Information for the identified risks 
associated with CIS and GEM treatments. 
8.3.3.4. 
Cisplatin and Gemcitabine Dose Adjustment and Toxicity Management 
CIS and GEM regimen is usually well tolerated and most dose modifications will be due to 
hematological toxicity and assessment of renal function. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Hematological toxicity 
GEM will be dose-reduced if hematological toxicity occurs. CIS can be dose-reduced for cases 
of hematological toxicity if it is standard practice for the site. The dose to be administered will 
depend on the complete blood count (CBC) result on the day of treatment. 
WBC 
(x109/L) 
And 
/or 
ANC 
(x109/L) 
And/
or 
Platelets 
(x1000/mm3) 
Gemcitabine 
Dose 
Cisplatin 
Dose 
≥2 
≥1 
≥100 
Full 
Full 
1-1.9 
0.5-0.9 
50-99 
75% dose 
Full** 
<1 
<0.5 
<50 
Delay* 
Delay 
* If delay is >3 weeks for hematological toxicity, the patient will be withdrawn from treatment. 
Abbreviations: ANC = absolute neutrophil count; WBC = white blood cell. 
** CIS can be reduced to 75% of the standard dose for cases of hematological toxicity, if it is standard practice for 
the site. 
Note: the dose of CIS and GEM will be re-escalated to full dose upon recovery of hematological 
toxicity in order to maintain the dose intensity of therapy. 
Renal toxicity 
CIS dosage will depend on renal function, (Cockcroft Gault formula): 
 
Cisplatin 
Gemcitabine 
Estimated GFR ≥45 mL/min 
Full dose 
Full dose 
Estimated GFR <45 mL/min* 
Omit 
Full dose 
Abbreviations: GFR = Glomerular Filtration Rate 
*Repeat the creatinine clearance assessment (consider using the more accurate isotope GFR method, if not available 
24 hour urine creatinine clearance could be used) ensuring the patient is adequately hydrated prior to this test and 
further cisplatin administration. Proceed with cisplatin if the repeated reading is ≥45ml/min, otherwise cisplatin is to 
be omitted until recovery of renal function. If cisplatin has to be omitted, continue with gemcitabine dosing 
according to CBC. If a sudden increase in creatinine occurs, hemolytic uraemic syndrome should be ruled out. 
Other toxicity 
No dose reduction/modification is required for: 
Alopecia (any grade)  
 
Lethargy (grade 1-2)  
 
Nausea/vomiting (grade 1-2) 
May have been reduced from grade 3-4 by 
appropriate use of antiemetics 
Edema (grade 1-2) 
Give postural advice, consider appropriate 
diuretics 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Consider dose-modifications* for: 
Lethargy (grade 3-4)  
Reduce gemcitabine by 25%  
Nausea/vomiting (grade 3-4)  
Ensure optimal use of antiemetics (according to 
local policy). 
Delay until recovery to baseline, then: 
Omit cisplatin first. If no improvement reduce 
gemcitabine by 25%.  
Peripheral neuropathy 
(grade 1-2)  
Delay cisplatin until recovery to baseline, then 
continue at full dose. If no recovery, treat as for 
grade 3-4. Continue with gemcitabine (full dose).  
Peripheral neuropathy 
(grade 3-4)  
Omit cisplatin from further treatment. Continue 
with gemcitabine (full dose).  
Edema (grade 3-4)  
Dipstick urine test for protein followed by full 
24-hour urinary protein estimation if result ≥+ 
Delay until recovery to baseline (with use of 
appropriate diuretics). Then reduce gemcitabine 
by 25%.  
Tinnitus  
No dose modification required if full recovery 
between cycles. 
Omit cisplatin if no recovery between cycles. 
Continue gemcitabine (full dose).  
Stop allocated treatment for: 
Lethargy (grade 3-4)**  
Which has not responded to dose modification  
Nausea/vomiting (grade 3-4)**  
Which has not responded to optimal antiemetics 
or dose reduction  
Edema (grade 3-4) 
Which has not responded to dose modification 
and use of appropriate diuretics 
Pulmonary toxicity (grade 2-4) 
Supportive therapy (high dose steroids) should be 
initiated immediately 
* Clinician discretion as to whether a particular non-hematological toxicity requires a dose reduction or treatment 
delay 
** If delay is >3 weeks for non-hematological toxicity (excluding biliary tract obstruction) 
Biliary tract obstruction during treatment  
In the event of the development of obstructive jaundice due to biliary tract obstruction, 
appropriate measures will be undertaken to diagnose (e.g., by ultrasound and/or CT scan) and 
relieve the obstruction (e.g., by endoscopic retrograde cholangiopancreatography/ percutaneous 
transhepatic cholangiography +/- stent insertion/drainage). All study treatments will be deferred 
until the Liver Function Tests have improved to the pre-treatment eligibility levels (i.e., total 
bilirubin ≤1.5 × ULN; ALT, AST, and alkaline phosphatase ≤2.5 × ULN). All study treatments 
may then resume at the start of the next treatment cycle. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
8.4. 
Excluded Concomitant Medications and Study Restrictions 
Concurrent chronic use of IV heparin is prohibited; however, for acute TE events, IV heparin 
may be used. PEGPH20 administration must be stopped during this period. Use of megestrol 
acetate and any megestrol acetate-containing drugs is prohibited. 
Any other anti-cancer agents or investigational agents are prohibited while the subject is on 
study. After treatment is discontinued and a subject enters long-term follow-up, the subject will 
not have any restrictions. 
The use of systemic corticosteroids or immunosuppressants before starting atezolizumab should 
be avoided because of their potential interference with the efficacy of atezolizumab. However, 
systemic corticosteroids are recommended, at the discretion of the Investigator, for the treatment 
of specific AEs when associated with atezolizumab therapy (refer to the current US Prescribing 
Information for details). With the exception of inhaled, intranasal or intra-articular steroids, and 
low-dose steroids administered to treat AEs, PEGPH20 and atezolizumab administration must be 
held when any other systemic steroids are administered for management of an AE and may be 
restarted when the steroids have been discontinued. 
Live attenuated vaccines should not be administered throughout the study period and for 5 
months after the last dose of atezolizumab.  
Systemic immunostimulatory agents are also prohibited during the treatment period. 
8.5. 
Treatment Compliance 
Trained medical personnel are to administer the IV study treatments. Treatment compliance will 
be monitored by the review of drug accountability records and study treatment administration 
data, which will be recorded in the subject’s medical record and eCRFs. 
9. 
STUDY DRUG AND MATERIALS 
9.1. 
Study Drug Description 
9.1.1. 
PEGPH20 
The investigational material in PEGPH20 is a PEGylated, neutral-pH-active human 
hyaluronidase PH20 produced by recombinant DNA technology. rHuPH20 degrades HA under 
physiologic conditions and acts as a spreading factor in vivo. 
PEGPH20 is a multi-site PEGylated enzyme generated by conjugating 30 kDa PEG and 
rHuPH20.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Chemical Name 
PEGPH20 (PEGylated recombinant human hyaluronidase: 36-482-hyaluronoglucosaminidase 
PH20 [human]) 
Structural Formula 
The structure of PEGPH20 is represented in Figure 2. 
Figure 2: 
Structure of PEGPH20 
 
The empirical formula for PEGPH20 is rHuPH20: C2327H3565N589O667S20 and PEG: 
C1371H2737NO686. PEGPH20 is a multi-site PEGylated enzyme. Its average molecular weight is 
approximately 220,000 Da (range of approximately 90,000 to 320,000 Da). 
9.1.2. 
Atezolizumab 
Atezolizumab is a PD-L1 antibody indicated for the treatment of patients with: 
• Locally advanced or metastatic urothelial carcinoma who: 
− Are not eligible for cisplatin-containing chemotherapy, or 
− Have disease progression during or following any platinum-containing 
chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy. 
This indication is approved under accelerated approval based on tumor response rate and 
duration of response. Continued approval for the indication may be contingent upon verification 
and description of clinical benefit in confirmatory trials. 
• Metastatic NSCLC who have disease progression during or following 
platinum-containing chemotherapy. Patients with epidermal growth factor receptor 
(EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should 
have disease progression on Food and Drug Administration (FDA) approved therapy 
for these aberrations prior to receiving atezolizumab. 
Atezolizumab will be considered investigational for the purpose of this study since the 
combination of atezolizumab with PEGPH20, CIS and GEM has not been indicated as yet for the 
treatment of the populations studied in this trial. 
Refer to the current Atezolizumab Prescribing Information for a thorough description and 
diagram of the structure of atezolizumab. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
9.1.3. 
Cisplatin 
CIS is a cytotoxic chemotherapeutic drug that triggers apoptosis or programmed cell death by 
binding to and causing crosslinking of DNA. It is indicated as therapy to be employed for the 
following: 
• Metastatic Testicular Tumors - In established combination therapy with other 
approved chemotherapeutic agents in patients with metastatic testicular tumors who 
have already received appropriate surgical and/or radiotherapeutic procedures. 
• Metastatic Ovarian Tumors - In established combination therapy with other approved 
chemotherapeutic agents in patients with metastatic ovarian tumors who have already 
received appropriate surgical and/or radiotherapeutic procedures. An established 
combination consists of CIS and cyclophosphamide. CIS as a single agent, is 
indicated as secondary therapy in patients with metastatic ovarian tumors refractory 
to standard chemotherapy who have not previously received CIS therapy. 
• Advanced Bladder Cancer - CIS is indicated as a single agent for patients with 
transitional cell bladder cancer which is no longer amenable to local treatments, such 
as surgery and/or radiotherapy. 
Although CIS is not indicated for the treatment of biliary tract cancers it is considered the 
non-label standard-of-care therapy for biliary tract cancers in combination with GEM. 
Refer to the current CIS package insert for a thorough description and diagram of the structure of 
CIS. 
9.1.4. 
Gemcitabine 
GEM is a nucleoside metabolic inhibitor indicated: 
• In combination with carboplatin, for the treatment of advanced ovarian cancer that 
has relapsed at least 6 months after completion of platinum-based therapy. 
• In combination with paclitaxel, for first-line treatment of metastatic breast cancer 
after failure of prior anthracycline-containing adjuvant chemotherapy, unless 
anthracyclines were clinically contraindicated. 
• In combination with cisplatin for the treatment of NSCLC. 
• As a single agent for the treatment of pancreatic cancer. 
Although GEM is not indicated for the treatment of biliary tract cancers it is considered the 
non-label standard-of-care therapy for biliary tract cancers in combination with CIS. 
Refer to the current GEM Prescribing Information for a thorough description and diagram of 
GEM. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
9.2. 
Study Drug Packaging and Labeling 
9.2.1. 
PEGPH20 
PEGPH20 drug product is supplied as a refrigerated, sterile, single-use, injectable liquid. The 
PEGPH20 drug product is an aqueous solution containing 300 mcg/mL PEGPH20 with 10 mM 
succinic acid, 130 mM NaCl, and 10 mM L-methionine at a pH of 6.2. Each vial contains 1.0 mL 
(0.30 mg) of PEGPH20 drug product. PEGPH20 drug product will be packaged in clear, Type 1 
borosilicate glass vials with a 13 mm FluroTec®-coated chlorobutyl rubber stopper and a 13 mm 
aluminum overseal with light blue plastic flip-off cap. This drug product is provided as a 
refrigerated formulation and should be stored at 2°C to 8°C before use. Label information is 
provided in the Pharmacy Manual. 
9.2.2. 
Atezolizumab 
Atezolizumab injection is a sterile, preservative-free, and colorless to slightly yellow solution for 
IV infusion supplied as a carton containing one 1200 mg/20 mL single-dose vial. 
Label information is provided in the Pharmacy Manual. 
9.2.3. 
Cisplatin 
CIS lyophilized powder or concentrate for solution for infusion may be utilized. 
Cisplatin Lyophilized Powder 
CIS for injection, USP is a white to light yellow lyophilized powder. Each amber vial of 
Plantinol® contains 50 mg CIS, 450 mg sodium chloride, USP, and 500 mg mannitol, USP. 
Label information is provided in the Pharmacy Manual. 
Cisplatin Concentrate Solution for Injection 
CIS Injection is a clear, light-yellow, sterile aqueous solution available in amber vials containing 
1 mg/mL of CIS. One mL of infusion concentrate 1 mg/mL contains: 1 mg CIS (USP), 9 mg 
sodium chloride, hydrochloric acid and/or sodium hydroxide to pH of 3.2 to 4.4, and water for 
injection. CIS Injection, 1 mg/mL, is supplied in multiple dose vials containing 50 mL and 
100 mL. 
Label information is provided in the Pharmacy Manual. 
9.2.4. 
Gemcitabine 
GEM lyophilized powder or concentrate for solution for infusion may be utilized. 
Gemcitabine Lyophilized Powder  
GEM is a white to off-white lyophilized powder for reconstitution with 0.9% sodium chloride 
injection without preservatives. GEM is supplied in sterile single-use vials as follows: 1 g white 
to off-white, lyophilized powder in 50 mL vials. 
Label information is provided in the Pharmacy Manual. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Gemcitabine Concentrate for Solution for Injection 
GEM is a sterile concentrate for solution for infusion that must be diluted before use. This is a 
sterile, clear, colorless or light straw-colored solution, practically free from visible particles. 
Presentation: 1 g/26.3 mL. Strength: 38 mg/mL, Quantity of GEM: 1g. Volume of Solution: 
26.3 mL. 
Label information is provided in the Pharmacy Manual. 
9.3. 
Study Drug Storage 
9.3.1. 
PEGPH20 
PEGPH20 drug product, supplied at a concentration of 0.30 mg/mL, is a liquid formulation and 
should be stored at 2°C to 8°C before use. Stability testing of this PEGPH20 drug product was 
initiated following general International Conference on Harmonisation (ICH) guidelines at 
5°C ±3°C, and concurrent stability evaluation is ongoing. The Sponsor will monitor drug 
stability and provide updates on an ongoing basis. 
9.3.2. 
Atezolizumab 
Atezolizumab should be stored under refrigeration at 2°C to 8°C (36°F to 46°F) in original 
carton to protect from light. It should not be frozen or shaken. 
Atezolizumab does not contain a preservative and should be administered immediately once 
prepared.  
If diluted atezolizumab infusion solution is not used immediately, it can be stored either: 
• At room temperature for no more than 6 hours from the time of preparation. This 
includes room temperature storage of the infusion in the infusion bag and time for 
administration for infusion.  
• Under refrigeration at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. 
9.3.3. 
Cisplatin 
Cisplatin Lyophilized Powder 
Unopened vials of dry powder are stable for the lot life indicated on the package when stored at 
room temperature (25°C, 77°F). The reconstituted solution is stable for 20 hours at room 
temperature (25°C, 77°F). Solution removed from the amber vial should be protected from light 
if it is not to be used within six hours. 
Important Note: Once reconstituted, the solution should be kept at room temperature (25°C, 
77°F). If the reconstituted solution is refrigerated a precipitate will form. 
Cisplatin Concentrate Solution for Injection 
CIS concentrate solution for injection should be stored at 20°C to 25°C (68°F to 77°F) [refer to 
USP Controlled Room Temperature] and not refrigerated. The unopened container must be 
protected from light. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
9.3.4. 
Gemcitabine 
Gemcitabine Lyophilized Powder 
Unopened vials of GEM lyophilized powder are stable until the expiration date indicated on the 
package insert when stored at controlled room temperature 20°C to 25°C (68°F to 77°F), 
however, as also noted in the package insert, there is allowance for excursions between 15°C and 
30°C (59°F and 86°F) [refer to USP Controlled Room Temperature]. 
GEM lyophilized powder must be retained in the original package to protect from bright light. 
Refer to the package insert for storage conditions after preparation. 
Gemcitabine Concentrate for Solution for Injection 
Unopened vials of GEM Concentrate for Solution are stable until the expiration date indicated on 
the package when stored at 2°C to 8°C (36°F to 46°F). GEM Concentrate for Solution must not 
be frozen. 
Refer to the package insert for storage conditions after preparation. 
9.4. 
Study Drug Preparation 
9.4.1. 
PEGPH20 
Instructions for preparing PEGPH20 can be found in the Pharmacy Manual. 
9.4.2. 
Atezolizumab 
Atezolizumab will be prepared and administered according to local site standard-of-care and the 
appropriate package insert. 
9.4.3. 
Cisplatin 
CIS will be prepared and administered according to local site standard-of-care and the 
appropriate package insert.  
9.4.4. 
Gemcitabine 
GEM will be prepared and administered according to local site standard-of-care and the 
appropriate package insert.  
9.5. 
Study Drug Accountability 
The Investigator, pharmacist, or qualified designee is responsible for making an inventory of 
study drug(s) upon their receipt. All used and unused study drug supplies should be retained until 
final reconciliation or as indicated by the Sponsor, or as per Institution policy. The study drugs 
are to be administered/prescribed by the Principal Investigator (PI) or appropriately qualified site 
personnel named on the delegation of authority log. Under no circumstances will the Investigator 
allow the study drugs to be used other than as directed by this protocol. Although appropriate 
personnel may be designated to administer/dispense drug and maintain drug accountability 
records, the PI is ultimately responsible for all drug accountability. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
The Investigator or designee must maintain accurate records of the receipt and disposition of 
study drug supplies. Documentation of drug disposition should identify the subject receiving the 
drug, the amount and date of the dose, and any unused drug. This documentation is required in 
addition to drug accountability information recorded on eCRFs. A copy of the reconciled drug 
inventory record will be provided to Halozyme or its designee, and the study site will retain the 
original record. 
After study drug is reconciled by the study monitor, drug may be destroyed as per institutional 
policy, or returned to the country specific drug depot as per country regulations. If used study 
medications cannot be stored until drug accountability has been performed as per clinic/institution 
policy, the Sponsor should be notified in advance, and reconciliation procedures will be agreed 
upon. 
10. 
SAFETY ASSESSMENTS 
Safety parameters monitored and recorded during this study include AEs; dose modifications 
(e.g., interruptions and delays); medical history; concomitant medications; immunogenicity 
(PEGPH20 and atezolizumab ADA), hematology, blood chemistry, thyroid hormone levels, 
coagulation, and urinalysis results; physical examination findings; vital signs; ECG results; 
pregnancy test results; and ECOG Performance Status. 
10.1. 
Management of Thromboembolic Events 
TE events have been identified in the pancreatic cancer clinical studies with PEGPH20. While 
pancreatic cancer is considered to be one of the most thrombogenic malignancies, it is necessary 
to manage any potential risks in subjects with ICC, ECC, and gallbladder adenocarcinoma. 
Subjects will be screened for TE events during the screening visit. Doppler ultrasound of both 
legs (Section 8.2.16) and chest CT (Section 8.2.15.1) will be performed during screening to 
exclude subjects with DVT and PE. 
If a DVT or PE is detected before study treatment begins on Cycle 1 Day 1, the subject will be 
taken off study and will enter long-term follow-up. If a DVT or PE is detected during treatment, 
PEPGH20 will be held. Subjects should be treated with therapeutic doses of low molecular 
weight heparin and continue with chemotherapy and immunotherapy (if applicable) and be 
monitored per standard practice (i.e., routine Doppler ultrasound or chest CT scans and other 
routine laboratory testing). 
To minimize the occurrence of TE events, prophylaxis for TE events will be given. Prophylactic 
enoxaparin will be administered at 1 mg/kg/day to all subjects receiving PEGPH20 (see 
Section 10.1.1 for additional details). If enoxaparin is discontinued for any reason, PEGPH20 
will also be discontinued. Treatment with other drugs, however, may continue as deemed 
appropriate by the Investigator.  
TE events should be managed per institutional guideline. PEGPH20 must be permanently 
discontinued for any TE event (with the exception of superficial venous thrombosis and Grade 1 
visceral/splanchnic vein thrombosis [associated with underlying disease of CCA and gallbladder 
adenocarcinoma]). 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Any anticoagulation therapy received by the subjects must be documented in the applicable 
eCRF pages. 
10.1.1. 
Enoxaparin Management 
All subjects receiving PEGPH20, including subjects in the PEGCISGEM and 
PEGCISGEMATEZO arms enrolled through Protocol Amendment 2 and the additional cohort of 
subjects enrolled under Protocol Amendment 3 receiving PEGCISGEMATEZO, will be 
administered prophylactic enoxaparin subcutaneously at a dose of 1 mg/kg/day. This is the same 
dosage administered to subjects with metastatic PDA in completed Phase 2 Study 
HALO-109-202 and ongoing Phase 3 Study HALO-109-301 of PEGPH20 in combination with 
GEM and NAB.  
The change in enoxaparin dosage from a fixed dose of 40 mg/day to a weight-adjusted dose in 
subjects receiving PEGPH20 in the current study follows an ongoing review of safety data 
which, to date, identified in the PEGCISGEMATEZO arm a total of 5 TE events (16.7% of 
subjects dosed) vs. no TE events in the PEGCISGEM arm and 1 TE event (10% of subjects 
dosed) in the CISGEM arm, as communicated in a letter to Investigators dated 22 March 2019. 
The reported incidence of venous TE events in patients with biliary tract cancer is 11.5% 
(Larsen 2015). In Stage 2 of Study HALO-109-202, prophylaxis with enoxaparin 40 mg/day 
reduced the incidence of TE events in the PAG arm from 43% in Stage 1 (no enoxaparin 
prophylaxis) to 28%. A subsequent increase in the enoxaparin dose to 1 mg/kg/day in Stage 2 
reduced the incidence further to 10% (Halozyme Clinical Study Report HALO-109-202 and 
Section 4.4.7.2).  
Enoxaparin will be administered prior to the infusion of PEGPH20.  
The dosage of enoxaparin of 1 mg/kg/day will be based on the subject’s screening weight and 
should be modified if the subject’s weight changes by 10%, or per institution’s policy. 
Institution’s rounding practices may be used when calculating the dose of enoxaparin. Efforts 
should be made to administer the calculated 1 mg/kg dose (± 10%); however, if prefilled 
syringes are used, rounding may be performed. If the difference between the rounded dose and 
the expected dose based on weight is greater than 20%, the Sponsor should be consulted. Refer 
to Table 11 for examples of rounding based on the expected enoxaparin dose. 
Table 11: 
Enoxaparin 1 mg/kg/day Dosage 
Expected Enoxaparin Dose 
(mg) 
Rounded Enoxaparin Dose 
(mg) 
Syringes Dispensed 
35-49 
40 
40 mg × 1 
50-69 
60 
60 mg × 1 
70-89 
80 
80 mg × 1 
90-109 
100 
100 mg × 1 
110-134 
120 
120 mg × 1 
135-164 
150 
150 mg × 1 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Enoxaparin dosing should be held or reduced per standard institutional guidelines for 
thrombocytopenia. Enoxaparin dosing for an acute TE event on study should also be managed 
per institutional guidelines. 
In situations when enoxaparin is held, administration of PEGPH20 should be stopped during the 
holding period. All other study treatments may continue according to the dose modification 
sections for the respective therapy (See Section 8.3.3.4). 
Enoxaparin treatment should be managed per institutional guidelines when the subject is 
permanently removed from PEGPH20 treatment. 
10.2. 
Adverse Event Definitions 
An AE is any unfavorable or unintended sign, symptom, or disease temporally associated with 
the use of a pharmaceutical product (i.e., study drug), whether or not considered related to the 
pharmaceutical product. 
The recording of AEs (except for procedure-associated SAEs) will begin at the start of the 
administration of the first dose of a study drug and continue until 30 days after the last dose of 
study drug or until initiation of new systemic anti-cancer therapy, whichever occurs first, and 
SAEs and AEs of special interest will continue to be reported until 90 days after the last dose of 
study drug or until initiation of new systemic anti-cancer therapy, whichever occurs first. AEs 
related to disease progression should not be collected or recorded, unless the Investigator 
considers the AE to be at least possibly related to study medication. Procedure-associated SAEs, 
will be recorded starting after the subject signs the informed consent for the study. AEs should 
include the development or increased severity of an undesirable medical condition or the 
worsening of a pre-existing medical condition during or following exposure to study drug, 
regardless of relationship to study drug. Only the highest severity will be recorded for a single 
AE in the eCRF. 
An SAE is any AE that: 
• Results in death. 
• Is life-threatening. 
A life-threatening SAE is any AE that places the subject at immediate risk of death 
from the reaction as it occurred, as assessed by the Investigator. This definition does 
not include a reaction that might have caused death if it occurred in a more severe 
form. 
• Requires inpatient hospitalization or prolongs existing hospitalization. 
• For the purposes of this protocol, any hospital admission except for disease 
progression (see Section 10.4.3 for details) will be considered inpatient 
hospitalization, regardless of duration. An emergency room visit without hospital 
admission will not be recorded as a SAE under this criterion, nor will cases of 
elective hospitalization for administration of chemotherapy, hospitalization for social 
admissions, or hospitalization for a procedure scheduled before study enrollment. 
However, unexpected complications that occur during elective surgery should be 
recorded as AEs and assessed for seriousness. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Results in persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
• Results in a congenital anomaly or birth defect. 
• Is any other important medical event. 
Other medical events may be considered SAEs when, based on appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical intervention 
to prevent one of the other outcomes in the SAE definition. Examples include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in hospitalization of the subject, or the 
development of drug dependency or drug abuse. 
10.3. 
Reporting Serious Adverse Events 
Report all SAEs to the designated safety contact IMMEDIATELY AND NO LATER THAN 
24 HOURS OF AWARENESS, i.e., knowledge, discovery or notification of the SAE. Enter the 
study-specific SAE into the study specific SAE form and send any other available pertinent 
information (e.g., hospital records, laboratory results) to the designated safety contact (contact 
information is provided in the study reference binder). 
If additional follow-up information is required or becomes available for a previously reported 
SAE, entry of the new information into the electronic data capture (EDC) should be completed 
and submitted IMMEDIATELY AND NO LATER THAN 24 HOURS OF AWARENESS. 
For hospitalizations, all attempts to obtain the hospital record should be documented in the study 
file. 
10.4. 
Reporting Adverse Events of Special Interest 
10.4.1. 
Thromboembolic Events 
TE events are considered AEs of special interest in the current trial. All TE events, regardless of 
type of event, severity, or seriousness, must be reported to the Sponsor IMMEDIATELY AND 
NO LATER THAN 24 HOURS OF AWARENESS. Details regarding timelines for the 
reporting of such events are available on the AE of Special Interest form (guidance regarding 
completion of associated eCRF pages will be provided to the study sites). Complete the 
study-specific AE of Special Interest form and send to the designated safety contact (contact 
information is provided in the study reference binder). 
The current version of the NCI CTCAE (Version 4.03 [14 June 2010]) should be utilized when 
grading TE events. Table 12 denotes the most commonly reported TE events and the associated 
grading scale per CTCAE Version 4.03 (14 June 2010). If the CTCAE is updated during the 
study, the current version of the CTCAE (Version 4.03 [14 June 2010]) should be used. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 12: 
CTCAE Version 4.03 Grading for Thromboembolic Events 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Acute coronary 
syndrome 
- 
Symptomatic, 
progressive 
angina; cardiac 
enzymes normal; 
hemodynamically 
stable 
Symptomatic, 
unstable angina 
and/or acute 
myocardial 
infarction, 
cardiac enzymes 
abnormal, 
hemodynamically 
stable 
Symptomatic, 
unstable angina 
and/or acute 
myocardial 
infarction, 
cardiac enzymes 
abnormal, 
hemodynamically 
unstable 
Death 
Definition: A disorder characterized by signs and symptoms related to acute ischemia of the myocardium secondary 
to coronary artery disease. The clinical presentation covers a spectrum of heart diseases from unstable angina to 
myocardial infarction. 
Ischemia 
cerebrovascular 
Asymptomatic; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicated 
Moderate 
symptoms 
- 
- 
- 
Definition: A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction 
(thrombosis or embolism) of an artery resulting in neurological damage. 
Myocardial 
infarction 
- 
Asymptomatic 
and cardiac 
enzymes 
minimally 
abnormal and no 
evidence of 
ischemic ECG 
changes 
Severe 
symptoms; 
cardiac enzymes 
abnormal; 
hemodynamically 
stable; ECG 
changes 
consistent with 
infarction 
Life-threatening 
consequences; 
hemodynamically 
unstable 
Death 
Definition: A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood 
supply to the area. 
Portal Vein 
Thrombosis 
- 
Intervention not 
indicated 
Medical 
intervention 
indicated 
Life-threatening 
consequences; 
urgent 
intervention 
indicated 
Death 
Definition: A disorder characterized by the formation of a thrombus (blood clot) in the portal vein. 
Superficial 
thrombophlebitis 
- 
Present 
- 
- 
- 
Definition: A disorder characterized by a blood clot and inflammation involving a superficial vein of the 
extremities. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 12: 
CTCAE Version 4.03 Grading for Thromboembolic Events (Continued) 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Thromboembolic 
event 
Venous 
thrombosis 
(e.g., superficial 
thrombosis) 
Venous 
thrombosis (e.g., 
uncomplicated 
deep vein 
thrombosis), 
medical 
intervention 
indicated 
Thrombosis (e.g., 
uncomplicated 
pulmonary 
embolism 
[venous], non-
embolic cardiac 
mural [arterial] 
thrombus), 
medical 
intervention 
indicated 
Life-threatening 
(e.g., pulmonary 
embolism, 
cerebrovascular 
event, arterial 
insufficiency); 
hemodynamic or 
neurologic 
instability; urgent 
intervention 
indicated 
Death 
Definition: A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via 
the blood stream. 
Vascular access 
complication 
- 
Device 
dislodgement, 
blockage, leak, or 
malposition; 
device 
replacement 
indicated 
Deep vein or 
cardiac 
thrombosis; 
intervention 
indicated (e.g., 
anticoagulation, 
lysis, filter, 
invasive 
procedure) 
Embolic event 
including 
pulmonary 
embolism or life 
threatening 
thrombus 
Death 
Definition: A finding of a previously undocumented problem related to the vascular access site. 
Source: NCI CTCAE 4.03 June 14, 2010. 
10.4.2. 
Adverse Events of Special Interest for Atezolizumab (Immediately Reportable 
to the Sponsor) 
AEs of special interest are required to be reported by the Investigator to the Sponsor 
IMMEDIATELY AND NO LATER THAN 24 HOURS OF AWARENESS. Details 
regarding timelines for the reporting of such events are available on the AE of Special Interest 
form (guidance regarding completion of associated eCRF pages will be provided to the study 
sites). Complete the study-specific AE of Special Interest form and send to the designated safety 
contact (contact information is provided in the study reference binder). 
AEs of special interest for atezolizumab include the following: 
• Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's 
Law, based on the following criteria: 
− Treatment-emergent ALT or AST >3 × baseline value in combination with total 
bilirubin >2 × ULN, of which ≥35% is direct bilirubin 
− Treatment-emergent ALT or AST >3 × baseline value in combination with 
clinical jaundice 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Suspected transmission of an infectious agent by the study treatment, as defined 
below: 
− Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent. A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an infection 
in a patient exposed to a medicinal product. This term applies only when a 
contamination of study treatment is suspected. 
• Pneumonitis 
• Colitis 
• Vasculitis 
• Endocrinopathies: diabetes mellitus, pancreatitis, adrenal insufficiency, 
hyperthyroidism, and hypophysitis 
• Hepatitis, including AST or ALT >10 × ULN 
• Systemic lupus erythematosus 
• Neurological disorders: Guillain-Barré syndrome, myasthenic syndrome or 
myasthenia gravis, and meningoencephalitis 
• Events suggestive of hypersensitivity, infusion-related reactions, cytokine-release 
syndrome, influenza-like illness, systemic inflammatory response syndrome, and 
systemic immune activation 
• Nephritis 
• Ocular toxicities (e.g., uveitis, retinitis) 
• Myositis 
• Myopathies, including rhabdomyolysis 
• Grade ≥2 cardiac disorders (e.g., atrial fibrillation, myocarditis, pericarditis) 
• Autoimmune hemolytic anemia 
• Severe cutaneous reactions (e.g., Stevens-Johnson syndrome, dermatitis bullous, toxic 
epidermal necrolysis) 
10.4.3. 
Disease-Related Events That Are Endpoints 
For the purposes of this study in subjects with ICC, ECC, and gallbladder adenocarcinoma, 
progression of the subject’s underlying disease (“disease progression”) is an efficacy assessment 
and should generally not be reported as an AE or SAE. However, if the Investigator determines 
that there is evidence suggesting a causal relationship between the event and the study 
medication, immediately report the event to the safety contact and record as an AE or SAE. 
Death resulting from disease progression is a study endpoint, and generally should not be 
reported as a SAE. This event must be recorded in the eCRF and will be reviewed by the 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Sponsor periodically for increased frequency by treatment. However, if the Investigator 
determines that there is evidence suggesting a causal relationship between the event and the 
study medication, immediately report the event as an SAE. 
10.5. 
Adverse Events 
Events that occur before the first administration of study drug are not considered AEs, by 
definition (Section 10.2); record these events on the Medical History eCRF. However, as noted 
in Section 10.2, any study procedure-associated events occurring after the subject’s signing of 
the informed consent for the study (including prior to the administration of study drug) should be 
recorded if the event qualifies as an SAE. 
The Investigator or a qualified designee will question and examine subjects for evidence of AEs. 
Subjects should not be asked about specific AEs. Instead, they should be asked general questions 
(e.g., “How have you been feeling since your last visit?”). Record all AEs in the eCRF. 
For an event to be recorded as an AE, the onset must occur during or after the subject’s first 
exposure to study drug (except for study procedure-associated SAEs), and no later than 30 days 
after the last study drug dose. However, there is no limit on reporting SAEs considered 
reasonably related to study drugs (i.e., assessed as “Yes, Related,” “Probably Related,” or 
“Possibly Related,” Section 10.5.2); these should be submitted as SAEs per Section 10.3, even if 
they are first identified during the long-term follow-up period. The Investigator should follow all 
AEs that are considered reasonably related to study drug until resolution or stabilization. All 
other AEs should be followed until resolution or stabilization or until the End of Treatment Visit, 
whichever occurs first. 
Wherever possible, record syndromes rather than individual signs or symptoms to avoid 
duplication and to facilitate meaningful interpretation of data. For example, a subject presenting 
with rhinitis, fever, and headache should be reported as having “flu-like symptoms,” without 
independently recording each accompanying sign. When no clearly recognizable clinical 
syndrome can be described, record individual clinical signs and symptoms. In addition, “disease 
progression” or “death” should not be reported as an AE or SAE term; instead the underlying 
cause of the disease progression or death should be reported. 
All AEs that occur during the study should be treated appropriately to protect and ensure the 
subject’s well-being. If such treatment constitutes a deviation from this protocol, Halozyme must 
be notified and the Investigator should comply with applicable Institutional Review Board 
(IRB)/Ethics Committee (EC) reporting requirements. 
The Investigator is responsible for determining whether or not an AE is severe enough to require 
the subject’s removal from treatment. A subject may also voluntarily withdraw from treatment 
because of an AE. If either occurs, the subject must receive appropriate medical care, and the 
Investigator must strongly encourage the subject to return to the study site for the final protocol-
specified visit and assessments, and to continue returning to the study site for follow-up 
evaluations until the AE resolves or stabilizes. All AEs, serious or not, that result in permanent 
withdrawal from study treatment should be immediately reported to Halozyme (Section 10.3). 
Halozyme will conduct reviews of all available AEs at the end of the PEGCISGEM and 
PEGCISGEMATEZO Run-in portions and at a minimum of once every 12 weeks during 
Expansion.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
10.5.1. 
Classification of Adverse Events by Severity 
The Investigator must categorize the severity of each AE using the NCI CTCAE v4.03 (Table 9). 
It is important to distinguish between AE seriousness and severity; these terms are not 
interchangeable. Severity is a measure of intensity, whereas seriousness is defined by the criteria 
in Section 10.2. 
10.5.2. 
Classification of Adverse Events by Relationship to Study Drug 
For each AE, the Investigator must document whether there is a reasonable possibility that the 
event was caused by administration of PEGPH20 or atezolizumab or CIS or GEM. The 
Investigator should make this decision after careful consideration of the following questions: 
• Does the AE follow a reasonable temporal sequence from administration of study 
drug? 
• Can the AE be reasonably explained by the known characteristics of the subject’s 
clinical state, environmental or toxic factors, or other therapy? 
• Do the AE symptoms disappear or decrease on cessation of study drug or reduction in 
study drug dose? (There are exceptions when an AE does not disappear on 
discontinuation of the drug, yet drug relatedness clearly exists [e.g., bone marrow 
depression, fixed drug eruptions, tardive dyskinesia]) 
• Does the AE reappear or worsen when the study drug is re-administered? 
• Does the AE follow an expected response pattern based on the established 
pharmacologic and toxicologic effects of the study drug? 
• Does the AE follow an expected response pattern based on the known effects of other 
products in the same class? 
For this assessment, the Investigator will classify each AE as one of the following: 
• Yes, Related: The AE is definitely related to study drug administration. 
• Probably Related: There is a high degree of certainty that the AE is related to study 
drug administration. 
• Possibly Related: The AE could be related either to study drug administration or to 
concurrent disease/medication. 
• Unlikely Related: There is a high degree of certainty that the AE is NOT related to 
study drug administration. 
• Not Related: The AE is clearly due to other causes (e.g., concurrent medication, 
underlying disease, etc.). 
For the purposes of expedited reporting to regulatory authorities, AEs assessed as “Yes, 
Related,” “Probably Related,” or “Possibly Related” will be considered suspected adverse 
reactions. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
10.6. 
Abnormal Laboratory Results 
Abnormal laboratory results may occur in the context of an AE that is a clinical syndrome (e.g., 
elevated BUN and creatinine in the setting of an AE of renal failure, or elevated AST/ALT in the 
setting of an AE of hepatitis). In these cases, do not record the abnormality itself as an AE. 
However, in the absence of an AE that encompasses an observed abnormal laboratory result, 
report the abnormality as an AE if the Investigator judges it to be clinically significant for the 
subject. Changes in trial dosing or study discontinuation resulting from an abnormal laboratory 
value not associated with an AE should also be captured as an AE. 
If test results lead to a change in trial dosing or discontinuation from the trial, significant 
additional concomitant drug treatment, or other therapy, and/or requires medical/surgical 
intervention and/or is considered to be an AE by the Investigator or Sponsor as an abnormal 
objective test finding, it should be reported as an AE. 
10.7. 
Pregnancy 
Pregnancy itself is not regarded as an AE unless there is suspicion that the study drug may have 
interfered with the effectiveness of the contraceptive medication. Refer to the current Prescribing 
Information for atezolizumab, CIS, and/or GEM for the summary of risks in this specific 
population. Based on its mechanism of action, atezolizumab, CIS and GEM can cause fetal harm 
when administered to a pregnant woman. WOCBP should therefore use highly effective 
contraception during treatment with the study drugs and refrain from breast feeding for 5 months 
after the last dose of the last study drug is administered in in all subjects receiving their same 
treatment. Pregnancy within 150 days of study drug discontinuation in a subject must be reported 
to the designated safety contact (contact information is provided in the study reference binder) 
IMMEDIATELY AND NO LATER THAN 24 HOURS OF AWARENESS. Complete the 
study-specific Pregnancy Report Form with all available information and submit the form with 
pregnancy test results and any other pertinent information. Also, within 24 hours, complete the 
eCRF with all available AE, demographic, medical history, concomitant medication, and study 
drug administration information. As additional information on a previously reported pregnancy 
becomes available, a follow-up Pregnancy Report Form should be prepared with the new 
information and submitted to the safety contact. 
Subjects who become pregnant during the study will not receive any additional study drug and 
will be withdrawn from the study. The Investigator must strongly encourage these subjects to 
return to the study site for the final protocol-specified visit and assessments. In addition, the 
Investigator will monitor the pregnancies of subjects exposed to study drug or the partner of a 
male subject who may become pregnant while that subject is on study until final resolution 
(delivery, miscarriage, or early termination of the pregnancy). Follow-up should occur monthly 
and should be documented in the study file. A follow-up Pregnancy Report Form must be 
completed for each follow-up contact with the subject or the partner of a male subject who 
became pregnant while that subject is on study and submitted to the Sponsor’s designated safety 
contact. Report a spontaneous miscarriage, therapeutic abortion, stillbirth, or congenital anomaly 
as an SAE (Section 10.3). 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
10.8. 
Overdose 
PEGPH20, atezolizumab, CIS, and GEM will be administered by IV infusion at a qualified and 
experienced clinical study site. The potential for drug overdose is therefore minimal. However, 
should an overdose occur, the infusion should be stopped immediately. A blood PK plasma 
sample should be taken as soon as possible, with a notation of the time of sampling relative to 
the time of cessation of the infusion. The Investigator should also monitor the subject with 
appropriate blood counts and blood chemistry tests, and should also provide supportive therapy, 
as necessary. Contact the Halozyme Medical Monitor, or designee, WITHIN 24 HOURS. 
There are no data regarding PEGPH20 overdose in humans. However, the likelihood of 
significant MSEs (such as pain, spasms, and weakness) increases with increasing PEGPH20 
dose. An overdose and AEs should be treated as per standard medical practice. There is no 
known antidote for PEGPH20. 
Overdose of atezolizumab, CIS, and GEM should be managed per the current respective 
Prescribing Information. 
Dosing details should be captured in the eCRF. If the subject receives a dose of a study drug that 
exceeds protocol specifications and the subject is symptomatic, then the symptom(s) should be 
documented as AEs in the eCRF and, if serious, submitted to the Sponsor’s designated safety 
contact on an SAE Report Form. Do not record the overdose as an AE if the subject is not 
symptomatic. 
10.9. 
Data Monitoring Committee 
A DMC will periodically review safety data in the Run-in and Expansion portions of the study to 
protect subject welfare and identify potential safety signals. 
10.10. 
Unblinding 
No part of the study is blinded. 
10.11. 
Reporting Safety Information to the Regulatory Authorities and to 
the Institutional Review Board 
The Sponsor will determine if SAEs are suspected unexpected serious adverse reactions 
(SUSARs), and if so will expedite reporting to Regulatory Authorities according to applicable 
Clinical Trials Regulations. 
The Sponsor and/or a designated agent may provide written safety reports or other safety-related 
communications to the Investigator. The Investigator will ensure that these reports are reviewed 
and processed in accordance with regulatory and IRB/EC requirements and archived in the site’s 
study file. 
At the completion or early termination of the study, the Investigator will submit a final report to 
the IRB/EC within the applicable time frame. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
10.12. 
Concomitant Medications 
Any medication received during the study, other than a designated study drug (PEGPH20 or CIS 
or GEM or atezolizumab), is regarded as concomitant medication. Record concomitant 
medications taken after the subject signs the ICF during the Screening period (≤28 days prior to 
Study Day 1) through 30 days after the last dose of study drug on the Concomitant Medications 
eCRF. Only those concomitant medications administered for ongoing AEs during the 30 days 
post the last dose of study drug are required to be recorded in the Adverse Event eCRF. 
Anti-cancer medications administered within 30 days post the last dose of study drug will be 
captured separately and should not be recorded as concomitant medications on the concomitant 
medication eCRF. 
Update information on concomitant medications, including medication used to treat an AE, at 
each visit according to the study schedule of events. At each visit, ask subjects if there have been 
any changes in their prescription or non-prescription medications since their last visit. 
Subjects may receive medications during the study including, but not limited to, antibiotics, 
analgesics, antipyretics, etc., when clinically indicated. Prohibited medications are identified in 
Section 8.4. 
Piroxicam and Toradol used to decrease the severity of musculoskeletal symptoms should be 
documented and recorded in the eCRF. Prescribed medication such as narcotics, muscle 
relaxants, and other analgesics, OTC drugs and physical therapy can also be used at the 
Investigator’s discretion and should be documented and recorded in the eCRF.  
Since this study uses an immunotherapeutic agent (atezolizumab) and dexamethasone and other 
steroids may suppress an immune response, steroids can only be used in some exceptional 
circumstances as detailed in Section 10.12.3.  
Steroid usage must be documented and recorded in the eCRF. 
Enoxaparin and any other anticoagulants should be documented and recorded in the eCRF. 
Antiemetics administered prior to CIS and GEM infusions should be documented and recorded 
in the eCRF. 
10.12.1. 
Piroxicam and Toradol 
Refer to the respective current piroxicam and Toradol Prescribing Information for prescribing 
information and toxicity profile. 
Piroxicam (20 mg) will be administered at least 1 hour prior to PEGPH20 administration on the 
day of dosing (timing will be at the Investigator’s discretion based on the piroxicam 
manufacturer’s Prescribing Information, institutional practices, and subject’s convenience) to 
minimize the severity of MSEs. Note that a non-steroidal analgesic agent (at a dose equivalent to 
20 mg of piroxicam) may be administered instead of piroxicam to reduce potential MSEs, at the 
discretion of the Investigator. The prophylactic use of a proton pump inhibitor is mandated for all 
subjects while receiving the study drug (e.g., 20 mg omeprazole daily or OTC equivalent). 
Toradol should not be administered concurrently with piroxicam as it is contraindicated in the 
Toradol Prescribing Information to administer Toradol simultaneously with other NSAIDs 
because of the cumulative risk of inducing serious NSAID-related side effects. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
If side effects are observed following administration of NSAIDs, the dosing of piroxicam may be 
adjusted at the Investigator’s discretion. The Investigator may also choose alternative analgesic 
agents if NSAIDs are not tolerated. 
10.12.2. 
Enoxaparin 
Refer to the current enoxaparin Prescribing Information for prescribing information and toxicity 
profile. 
All subjects receiving PEGPH20 will be given enoxaparin 1 mg/kg/day for prophylaxis of TE 
events (details in Section 10.1.1). 
If enoxaparin is discontinued for any reason, PEGPH20 will also be discontinued. Treatment 
with the other drugs, however, may continue as deemed appropriate by the Investigator. 
10.12.3. 
Steroids 
Since this study uses an immunotherapeutic agent (atezolizumab) and dexamethasone and other 
steroids may suppress an immune response, steroids should only be used in the following 
exceptional circumstances: 
• When prescribed by the Investigator to treat ≥ Grade 3 MSEs that are refractory to 
non-steroid management (refer to Section  8.3.1.3, Table 9 for further details) 
• For management of specific AEs as listed in Section 8.3.1.2, Section 8.3.3.4 and/or 
the current atezolizumab US Prescribing Information and Investigator’s Brochure  
• To treat emesis or other AEs that are not controlled with non-steroidal medications  
• Low-dose steroids may be administered at the discretion of the Investigator to treat 
other AEs. 
The following steroids are allowed (see also Section 7.2):  
• Inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for subjects with 
orthostatic hypotension, chronic obstructive pulmonary disease, or adrenocortical 
insufficiency 
• Thyroid-replacement hormone  
• Low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 
0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) for 
subjects with eczema, psoriasis, lichen simplex chronicus, or vitiligo with 
dermatologic manifestations only (e.g., subjects with psoriatic arthritis) 
With the exception of the allowed steroids listed above and low-dose steroids to treat AEs, 
PEGPH20 and atezolizumab administration must be held if steroids are administered to treat AEs 
and can only be restarted once the steroid is discontinued.  
10.12.4. 
Hydration and Electrolyte Supplementation 
Hydration and electrolyte supplementation with potassium and magnesium must be given prior 
to CIS infusion per individual institutional standards. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
10.12.5. 
Antiemetics 
Premedication with antiemetics will be administered as standard-of-care to all subjects prior to 
chemotherapy (CIS and GEM infusions). The use of steroids during treatment in the study will 
be avoided unless emesis is not controlled with other antiemetics. 
11. 
STATISTICS 
11.1. 
Statistical Methods 
In general, continuous variables will be summarized using descriptive statistics (N, mean, 
standard deviation, median, minimum, and maximum). Categorical variables will be presented 
using frequencies and percentages. Data collected during the Run-in portion will be summarized 
by PEGPH20 dose levels tested with each combination. Results in the Expansion portion will be 
summarized for the 3 treatment arms randomized as well as the 3 treatments arms combined 
(total). Data from the non-randomized PEGCISGEMATEZO cohort enrolled under Protocol 
Amendment 3 will be summarized separately. All statistical analyses and data listings will be 
performed using SAS version 9.3 or higher (Cary, NC). 
11.1.1. 
Randomization and Blinding 
This is a multicenter, open-label, randomized study. 
11.1.2. 
Sample Size 
This study is planned to enroll approximately 77 to 85 subjects.  
In the Run-in portion approximately 6 subjects will receive PEGPH20 plus CIS plus GEM, then 
a cohort of 6 subjects will receive PEGPH20, atezolizumab, CIS, and GEM when the 
PEGCISGEM cohort clears the safety evaluation. Additional dosing cohorts may be evaluated in 
the Run-in portion if the initial dose of PEGPH20 utilized in the combinations tested is deemed 
unsafe and/or intolerable. An additional 8 subjects may be enrolled in the Run-in portion to 
further assess the tolerability of PEGPH20 in order to establish an acceptable safety profile prior 
to randomization in the Expansion Portion of the study. 
In the Expansion portion, approximately 50 subjects will be enrolled and randomized in a 2:2:1 
ratio into PEGCISGEMATEZO, PEGCISGEM, and CISGEM treatment arms, stratified by 
geographical region (North America and Asia) and cancer type (CCA and gallbladder).  
For the approximately 50 subjects enrolled in the Expansion portion through Protocol 
Amendment 2, it is assumed that the addition of PEGPH20 and atezolizumab to CIS + GEM 
treatment increases ORR from 26% to 66%. An ORR of 26% was observed in subjects treated 
with CIS + GEM combination treatment in the ABC-02 trial, a Phase 3 trial enrolling 
410 patients with biliary tract cancers (Valle 2010). A total of 50 subjects, 20 each in the 
PEGCISGEM and PEGCISGEMATEZO treatment arms and 10 in the CISGEM arm, are 
required to detect a treatment difference of 40% in ORR between the CISGEM and 
PEGCISGEMATEZO arms with a statistical power of approximately 80% at the one-sided alpha 
level of 0.1. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
For the cohort of approximately 15 additional subjects enrolled in the Expansion portion under 
Protocol Amendment 3 receiving PEGCISGEMATEZO, assuming a more conservative ORR of 
60% for the PEGCISGEMATEZO treatment is observed, the 80% confidence interval is 40%, 
77%. The lower bound of 40% is higher than the ORR of 37% observed in a study of the 
immunotherapy agent nivolumab in combination with CIS and GEM in 30 subjects with 
advanced biliary tract carcinoma (Ikeda 2019). 
11.1.3. 
Analysis Populations 
11.1.3.1. Enrolled Population 
All subjects enrolled in the Run-in portion and the Expansion portion of the study. The Enrolled 
Population will be used for subject disposition, demographics, and baseline characteristics 
summaries. 
11.1.3.2. Treated Population 
All subjects in the Run-in and the Expansion portion of the study who receive any study 
medication. The Treated Population will be used for efficacy and safety analyses. Subjects will 
be analyzed based on the treatment received. 
11.1.3.3. Efficacy Evaluable Population 
Subjects in the Expansion portion who receive any study medication as randomized and have an 
evaluable baseline and post-baseline tumor assessment, unless discontinued from treatment 
because of disease progression or death. Efficacy Evaluable Population will be used as the 
primary analysis population for efficacy. 
11.1.3.4. PK Analysis Population 
All subjects who receive any study medication and have measurable study drug concentrations in 
at least 1 sample collected for PK analysis. PK Analysis Population will be used for PK analysis. 
11.1.4. 
Subject Disposition 
Subject disposition data will be summarized by treatment and overall for all randomized 
subjects. 
Subject disposition will be tabulated for number of subjects enrolled, receiving any study 
treatment, on study treatment, discontinuation from treatment, and reasons for discontinuing 
treatment. 
Enrollment by region and center, major protocol deviations, and the number of subjects 
randomized to each stratum (in Expansion only) will also be summarized. 
11.1.5. 
Analysis of Demographics and Baseline Characteristics 
Demographics and baseline characteristics will be summarized using the Enrolled Population. 
The following demographic and baseline characteristics will be summarized: age, sex, race, 
height, weight, medical history, disease characteristics, and treatment history. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
11.1.6. 
Efficacy Analyses 
All efficacy analyses will be conducted using the Efficacy Evaluable population and treated 
population. The Efficacy Evaluable population will be the primary analysis population for 
efficacy. All statistical tests will be conducted at the 1-sided alpha level of 0.1. No adjustment of 
alpha level will be made for multiple tests. 
ORR will be calculated as the number of subjects with a CR or PR divided by the number of 
subjects in the analysis population. For the approximately 50 subjects enrolled in the Expansion 
portion through Protocol Amendment 2, the treatment difference between each of the 
investigational arms and the control arm will be tested using the 1-sided Fisher’s Exact test. 
Median DOR will be estimated by treatment arm using the Kaplan-Meier method. The DCR will 
be analyzed similarly to the ORR. For the additional cohort of approximately 15 subjects 
enrolled in the Expansion portion under Protocol Amendment 3 receiving PEGCISGEMATEZO, 
the ORR will be presented and its 80% confidence interval will be calculated using the exact 
method. Median DOR, DCR, and PFS in these subjects will be analyzed in a similar manner as 
for subjects enrolled up to Protocol Amendment 2. No statistical comparison of ORR, DOR, 
DCR, and PFS will be made between subjects in this additional cohort and subjects enrolled 
prior to Protocol Amendment 3. 
PFS is defined as time from randomization to radiological disease progression or death. Kaplan-
Meier method will be used to estimate the median PFS and its 80% CI, first and third quartiles, 
and PFS rates at Months 6, 9, and 12 by treatment arm. The PFS comparison between the 
PEGCISGEM and PEGCISGEMATEZO treatment arm versus CISGEM treatment arm will be 
based on a 1-sided log-rank test. The hazard ratio and 80% CI for the treatment effect will be 
estimated using the Cox proportional hazards regression model. Estimated survival curves of 
PFS of the three treatment arms will be displayed graphically. 
OS is defined as time from randomization to death at any time. OS will be analyzed similarly as 
PFS. 
11.1.7. 
Analysis of Treatment Exposure 
The study medication exposure will be summarized using the Treated Population by dose level 
or treatment as applicable. Study medication exposure will include exposure duration, dosing 
cycles, dosing information for study medication, such as number of doses, relative dose intensity, 
and dose changes. 
11.1.7.1. Pharmacokinetic Analyses 
Noncompartmental analysis will be performed where possible/appropriate on PEGPH20, GEM, 
CIS (bound and free), and atezolizumab. The PK parameters AUC, Cmax, Cmin, CL, Vd, kel, and 
t1/2 will be summarized from noncompartmental analysis along with descriptive statistics, when 
applicable. Other PK analyses will be performed when appropriate. 
11.1.7.2. Plasma Hyaluronan 
Descriptive statistics will be used to summarize measured plasma concentrations of HA. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
11.1.7.3. Exploratory Analyses 
Descriptive summaries will be provided for all exploratory endpoints. 
11.1.8. 
Safety Analyses 
All safety parameters will be summarized by treatment using the Treated Population. 
All AEs will be presented in incidence tables coded by the Medical Dictionary for Regulatory 
Activities (MedDRA) v18.0 Preferred Term and System Organ Class. Additionally, separate AE 
incidence tables, coded by MedDRA, will be presented by: 1) toxicity grade (severity) graded by 
the CTCAE and 2) relationship to study medication (PEGPH20, CIS, GEM and atezolizumab). 
In addition, subjects who experienced TE events will be summarized by Standardized MedDRA 
Queries (SMQ) term and MedDRA preferred term by grade. 
All AEs, SAEs, AEs leading to treatment discontinuation, and deaths occurring during the study 
will be summarized. 
Laboratory parameters and vital signs and the corresponding change from baseline over time will 
be summarized.  
11.1.9. 
Interim Analysis 
No interim analysis will be performed for this study. 
12. 
SPONSOR AND INVESTIGATOR RESPONSIBILITIES  
12.1. 
Protocol Compliance 
Except for a change intended to eliminate an apparent immediate hazard to a study subject, the 
study must be conducted as specified. Any such change must be reported immediately to 
Halozyme and to the IRB/EC according to the applicable IRB/EC policy. 
12.1.1. 
Protocol Waivers 
Halozyme, or its designee, will not prospectively authorize any protocol waivers to study 
inclusion/exclusion criteria. 
12.1.2. 
Protocol Deviations 
Written documentation of all major protocol deviations must be kept in the study site file and 
provided to Halozyme. Examples of possible major protocol deviations include, but are not 
limited to: 
• Failure to obtain/maintain IRB/EC approval for the study. 
• Failure to obtain subject’s informed consent. 
• Failure to collect, submit, or file AE reports. 
• Performance of an unapproved study procedure. 
• Performance of the study at an unapproved location.  

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
• Failure to adhere to the approved protocol. 
The Investigator must notify the IRB/EC of all protocol deviations according to applicable 
IRB/EC policy. Halozyme will not authorize any protocol deviations. 
12.2. 
Study Monitoring 
Site visits will be conducted by an authorized Halozyme representative, who will inspect study 
data, subject medical records, and eCRFs according to Good Clinical Practice (GCP) and FDA 
and ICH guidelines. 
In addition to monitoring by Halozyme or its designees, the study may be audited by 
representatives of the FDA, who will also be allowed access to study documents. The 
Investigator should immediately notify Halozyme’s Department of Clinical Development and 
Medical Affairs of any proposed or scheduled audits by regulatory authorities. 
The Investigator will permit authorized representatives of Halozyme and national or local health 
authorities to inspect facilities and records relevant to this study. 
12.3. 
Data Collection and Electronic Case Report Forms 
eCRFs must be completed for each subject enrolled in the study according to GCP and FDA 
guidelines. Data collected for each study subject will be recorded on eCRFs provided or 
approved by Halozyme. 
eCRF completion is the Investigator’s responsibility. eCRF completion may be delegated to 
other study personnel and documented on the log for delegation of authority. The Investigator is 
responsible for ensuring the accuracy, completeness, legibility, and timeliness of all data 
reported on case report forms and all required reports for each study subject. The Investigator is 
also responsible for maintaining any source documentation related to the study (e.g., operative 
reports, laboratory results, radiographic films, tracings, and computer discs or files). 
12.4. 
Financial Disclosure 
The Investigator is required to provide a financial disclosure statement or certification to 
Halozyme before study initiation. In accordance with 21 Code of Federal Regulations (CFR) 54, 
Investigators and all sub-Investigators are required to disclose all financial interests to the study 
Sponsor (Halozyme), to permit complete and accurate certification statements in an application 
for marketing authorization. This disclosure includes compensation affected by the outcome of a 
clinical study, significant equity interest in Halozyme’s parent entity, Halozyme Therapeutics, 
Inc., and proprietary interest in the tested product. Investigators must promptly update this 
information if any relevant changes occur during the study and for 1 year following study 
completion (21 CFR 312.64(d)). 
12.5. 
Investigator’s Final Report 
After completion of the Investigator’s participation in the study, the Investigator will submit a 
written report to Halozyme. This report may be a copy of the Investigator’s end-of-study report 
to the IRB/EC. The report to the IRB/EC will be consistent with applicable IRB/EC regulations 
and time frames. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
12.6. 
Data Disclosure and Publication 
All information concerning this study and which was not previously published is considered 
confidential information. This confidential information shall remain the sole property of 
Halozyme; it shall not be disclosed to others without written consent of Halozyme; and shall not 
be used except in the performance of this study. 
The information compiled during the conduct of this study is also considered confidential and 
may be disclosed and/or used only by Halozyme as it deems necessary. To allow the use of the 
information derived from this study and to ensure compliance to current federal regulations, the 
Investigator is obliged to furnish Halozyme with the complete test results and all data compiled 
in this study. 
This section of the protocol is intended to be a brief, high-level summary of the requirements for 
data disclosure and publication. The Clinical Study Agreement between Halozyme and the 
Investigator/Institution details the specific disclosure and publication requirements. 
13. 
QUALITY CONTROL AND QUALITY ASSURANCE 
In addition to routine monitoring procedures, audits of clinical research activities may be 
performed to evaluate compliance with the principles of GCP. A regulatory authority may also 
wish to conduct an inspection during the study or after its completion. If an audit of this or any 
other study is requested by any regulatory authority, the Investigator must inform Halozyme 
immediately of the request (Section 12.2). The study site will permit access to all necessary 
records. 
The study protocol, each step of the data recording process, and data handling, as well as any 
study report or publication, will be subject to independent review by Halozyme or its 
representatives. 
14. 
ETHICS 
This study will be conducted under a US Investigational New Drug Application according to the 
provisions of the US CFR, FDA regulations and guidelines, GCP guidelines, and the Declaration 
of Helsinki, revised version of Seoul, October, 2008. All applicable US regulations governing 
human subject protection must be followed. All ethical and regulatory requirements are 
necessary to comply with the principles of GCP. This includes inspection by the Sponsor, its 
representatives, health authority representatives, or IRB/EC representatives at any time. The 
Investigator must agree to the inspection of study-related records by the health authority, the 
Sponsor, and/or the Sponsor's representatives. 
To ensure ethical conduct of this study, the Investigator will be expected to adhere to basic 
principles provided by generally recognized guidelines such as the Belmont Report and the 
International Ethical Guidelines for Biomedical Research Involving Human Subjects. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
14.1. 
Institutional Review Board and Approval 
In accordance with 21 CFR Parts 50 and 56, the Investigator agrees to obtain IRB/EC approval 
of all appropriate material, including a copy of the protocol, ICF, Investigator’s Brochure, and 
any proposed advertisement/study material prior to the start of the study and/or prior to its use on 
the study. 
Halozyme must also agree to the proposed ICF and any proposed study advertisements. A copy 
of the IRB/EC approval letter(s) for the protocol and ICF must be supplied to Halozyme before 
subjects are screened. 
The Investigator will supply Halozyme with the names, professions, and affiliations of IRB/EC 
member, to demonstrate compliance with membership requirements. If the Investigator or a 
sub-investigator is a routine voting member of the IRB/EC, Halozyme will be provided with a 
statement from the IRB/EC that the Investigator /sub-investigator did not vote on this study. 
During the study, the Investigator is responsible for satisfying all IRB/EC regulations for 
reporting study progress. Copies of all reports to and correspondence with the IRB/EC must be 
provided to Halozyme. Furthermore, at the completion or early termination of the study, the 
Investigator should make a final report to the IRB/EC. A copy of this report should be provided 
to Halozyme (Section 12.5). 
The Investigator must maintain an IRB/EC correspondence file and make this file available for 
review by Halozyme or its designated representatives as part of the study monitoring process. 
14.2. 
Written Informed Consent 
A copy of the proposed ICF must be submitted to Halozyme for review and comment before 
submission to the IRB/EC. The ICF must be approved by the IRB/EC and contain all elements 
required by all applicable federal, state, local, and institutional regulations or policies including 
subject compensation information (if applicable), before it is used to obtain a subject’s informed 
consent. Authorization to use or disclose personal health information in accordance with 
requirements of the Health Insurance Portability and Accountability Act of 1996 should be 
provided in the ICF, or in a separate document to be signed by the subject. 
Each subject found eligible for the study must have voluntarily provided written informed 
consent, using the IRB/EC-approved ICF, before study screening (i.e., before any protocol-
specified procedures that are not part of normal subject care). 
15. 
DATA HANDLING AND RECORD KEEPING 
15.1. 
Record Inspection  
An audit may be performed at any time after completion of the study by Halozyme personnel or 
their designees, FDA, or other regulatory agencies. All study-related documentation must be 
made available to the designated auditors. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
15.2. 
Study Documentation and Record Retention 
The Investigator must retain all records of this study, including but not limited to, the following. 
• Protocol and all protocol amendments. 
• All signed versions of the Statement of Investigator, Form FDA 1572. 
• All drug accountability records. 
• All IRB/EC approvals, correspondence and reports. 
• Signed and dated ICFs for each subject. 
• Completed eCRFs for each subject. 
• Copies of any other material distributed to subjects. 
• Any advertisements for this study. 
• The Investigator’s final report to the IRB/EC. 
• Source documents pertaining to the study, including but not limited to, any operative 
reports, laboratory results, radiographic films, tracings, and computer discs or files. 
The period for which these documents must be retained is governed by US law and, when 
applicable, non-US regulations. The Investigator must retain all records for at least 2 years after 
the FDA has approved the New Drug Application, or until 2 years after all studies of the drug 
and indication have been discontinued. However, because of international regulatory 
requirements, Halozyme may request retention for a longer period. Halozyme or its designee will 
inform the Investigator when these documents may be destroyed. Halozyme or its designee must 
be notified in writing at least 30 days before the intended date of disposal of study records. The 
Investigator must obtain written approval from Halozyme before destruction of records. 
The Investigator must advise Halozyme in writing if records are to be moved to a location other 
than the study site’s archives. If the Investigator leaves the study site, the records will be 
transferred to an appropriate designee at the site, who will assume responsibility for record 
retention. Notice of this transfer will be documented in writing and provided to Halozyme. 
If any study records are accidentally lost or destroyed, the Investigator will immediately notify 
Halozyme in writing. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
16. 
REFERENCES 
1. American Cancer Society. Cancer Facts and Figures 2016. Atlanta: American Cancer 
Society, 2016. 
2. Anttila MA, Tammi RH, Tammi MI, et al. High levels of stroma hyaluronan predict poor 
disease outcome in epithelial ovarian cancer. Cancer Res 2000;60:150-155. 
3. Auvinen P, Tammi R, Parkkinen J, et al. Hyaluronan in peritumoral stroma and 
malignant cells associates with breast cancer spreading and predicts survival. Am J 
Pathol 2000;156:529-536. 
4. Bang Y, Doi T, De Braud F, et al. Safety and efficacy of pembrolizumab (MK-3475) in 
patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028.  
 EJC. 2015;(51):S112. 
5. Bapat B, Bhurke S, Rosen E, Stokes M, Bhagnani T, Nordstrom B, et al. Risks of 
thromboembolic events among patients diagnosed with metastatic pancreatic ductal 
adenocarcinoma treated with chemotherapy. 2016 Gastrointestinal Cancers Symposium, 
Poster Abstract 380. J Clin Oncol 34, 2016 (suppl 4S; abstr 380).  
6. Baumgartner G, Gomar-Hoss C, Sakr L, et al. The impact of extracellular matrix on the 
chemoresistance of solid tumors – experimental and clinical results of hylauronidase as 
additive to cytostatic chemotherapy. Cancer Lett 1998; 131:85-99. 
7. Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Practice & 
Research Clinical Gastroenterology. 2015;29(2):221-232. 
8. Bharadwaj AG, Kovar JL, Loughman E, et al. Spontaneous metastasis of prostate cancer 
is promoted by excess hyaluronan synthesis and processing. Am J Pathol 
2009 Mar;174(3):1027-36. 
9. Bragazzi MC, Cardinale V, Carpino G, et al. Cholangiocarcinoma: Epidemiology and 
risk factors. Transl Gastrointest Cancer. 2012;1(1):21-32. 
10. Brekken C, de Lange Davies C. Hyaluronidase reduces the interstitial fluid pressure in 
solid tumors in a non-linear concentration-dependent manner. Cancer Lett 
1998;131:65-70. 
11. Chow G, Tauler J, Mulchine JL. Cytokines and growth factors stimulate hyaluronan 
production: role of hyaluronan in epithelia to mesenchymal-like transition in non-small 
cell lung cancer. Journal of Biomedicine and Biotechnology 2010; Article ID 485468, 
11 pages. 
12. Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, 
pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal 
antibody, an immune checkpoint inhibitor. mAbs 2016;8:3:593-603, 
DOI:10.1080/19420862.2015.1136043 
13. Eikenes L, Tari M, Tufto I, et al. Hyaluronidase induces a transcapillary pressure gradient 
and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human 
osteosarcoma xenografts. Br J Cancer 2005;93:81-88. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
14. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer 2009;45:228-247. 
15. Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation 
and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 
2016;122(9):1349-1369. 
16. FDA Center for Drug Evaluation and Research (1998). Guidance for Industry: Empiric 
Therapy of Febrile Neutropenia - Developing Antimicrobial Drugs for Treatment  
17. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients 
with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, 
phase 2 randomised controlled trial. The Lancet. 2016;387(10030):1837-1846. 
18. Halozyme Clinical Study Report HALO-109-201. A Phase 1b/2, multicenter, 
international, randomized, double-blind, placebo-controlled study of gemcitabine 
combined with PEGPH20 (PEGylated recombinant human hyaluronidase) compared to 
gemcitabine combined with placebo in patients with stage IV previously untreated 
pancreatic cancer. 26 May 2015. 
19. Halozyme Clinical Study Report HALO-109-202. A Phase 2, randomized, multicenter 
study of PEGPH20 (PEGylated recombinant human hyaluronidase) combined with 
nab-paclitaxel plus gemcitabine compared with nab-paclitaxel plus gemcitabine in 
subjects with stage IV previously untreated pancreatic cancer. 21 January 2019. 
20. Halozyme Clinical Study Report HALO-104-104. A Phase 1, open-label study to assess 
the safety, tolerability, and pharmacokinetics/pharmacodynamics of recombinant human 
hyaluronidase (rhuph20) administered intravenously in healthy volunteers. 28 July 2014. 
21. Halozyme Report 13036. In vivo efficacy and safety evaluation of PEGPH20 as single 
agent or combination with Taxotere in the treatment of LU0697 Huprime® Non-small 
cell lung cancer (NSCLC) xenograft model in nude mice. 
22. Halozyme Report 18218. Pharmacometric Modeling for the PEGPH20 Development 
Program Study. 20 August 2018. 
23. Halozyme Report 18250. Pharmacokinetic/Pharmacodynamic and Exposure Response 
Modeling for the PEGPH20 Development Program. 04 October 2018. 
24. Hingorani S, Harris WP, Beck JT et al. Final Results of a Phase 1b Study of Gemcitabine 
Plus PEGPH20 in Patients With Stage IV Previously Untreated Pancreatic Cancer. ASCO 
2015 Gastrointestinal Cancers Symposium, Poster Abstract 359. 
25. Hingorani SR, Harris WP, Seery T, et al. Interim results of a randomized phase 2 study of 
PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously 
untreated pancreatic cancer. ASCO 2016 Gastrointestinal Cancers Symposium, Abstract 
439 in press. 
26. Hundal R, Shafer EA. Gallbladder Cancer: Epidemiology and Outcome. Clin. Epidemiol. 
2014;6:99-109. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
27. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug 
delivery in a mouse model of pancreatic cancer. Gut 2013;62(1):112-20. 
28. Jeon HK, Kim DU, Baek DH, et al. Venous thromboembolism in patients with 
cholangiocarcinoma: focus on risk factors and impact on survival. Eur J Gastroenterol 
Hepatol. 2012 Apr;24(4):444-9. 
29. Jiang P, Li X, Thompson CB, et al. Effective targeting of the tumor microenvironment 
for cancer therapy. Anticancer Res 2012;32(4):1203-12. 
30. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 
2004;5:655-663. 
31. Kim H-R, Wheeler MA, Wilson CM, et al. Hyaluronan facilitates invasion of colon 
carcinoma cells in vitro via interaction with CD44. Cancer Res 2004;64:4569-4576. 
32. Klocker J, Sabitzer H, Raunik W, et al. Hyaluronidase as additive to induction 
chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett 
1998;131:113-115. 
33. Kultti A, Li X, Jiang P, Thompson CB, et al. Therapeutic targeting of hyaluronan in the 
tumor stroma. Cancers 2012;4(3):873-903. 
34. Kultti A, Zhao C, Singha NC, Zimmerman S, et al. Accumulation of extracellular 
hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the 
pancreatic cancer microenvironment. Biomed Res Int 2014;2014:817613.  
35. Ikeda M, Ueno M, Morizane C, et al. A multicenter, open-label, phase 1 study of 
nivolumab alone or in combination with gemcitabine plus cisplatin in patients with 
unresectable or recurrent biliary tract cancer. ASCO 2019 Gastrointestinal Cancers 
Symposium, Poster Abstract 306. 
36. Larsen AC, Brøndum Frøkjaer J, Wishwanath Iyer V, et al. Venous thrombosis in 
pancreaticobiliary tract cancer: outcome and prognostic factors. J Thromb Haemost. 2015 
Apr;13(4):555-62. doi: 10.1111/jth.12843. Epub 2015 Feb 24. 
37. Li Y, Li L, Brown TJ, et al. Silencing of hyaluronan synthase 2 suppresses the malignant 
phenotype of invasive breast cancer cells. Int J Cancer 2007;120:2557-2567. 
38. Martin LK, Bekaii-Saab T. Management of Venous Thromboembolism in Patients with 
Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants? 
Thrombosis. 2012;doi:10.1155/2012/758385. 
39. Nishida Y, Knudson W, Knudson CB, et al. Antisense inhibition of hyaluronan synthase-
2 in human osteosarcoma cells inhibits hyaluronan retention and tumorigenicity. Exp Cell 
Res 2005;307:194-203. 
40. Nishino M, Gargano M, Suda M, et al. Optimizing immune-related tumor response 
assessment: does reducing the number of lesions impact response assessment in 
melanoma patients treated with ipilimumab?. J Immunother Cancer. 2014;2:17. 
41. Padrnos L, Kosiorek H, Marella M, et al. Assessment of hyaluronic acid in tumor 
microenvironment (TME) of intrahepatic cholangiocarcinoma (CCA). Poster abstract 248 
presented at: ASCO GI Cancer Symposium; January 21-23, 2016; San Francisco, CA. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
42. Park JO, Oh D, Hsu C, et al. Gemcitabine Plus Cisplatin for Advanced Biliary Tract 
Cancer: A Systematic Review. Cancer Res Treat. 2015;47(3):343-361. 
43. Patel T. Cholangiocarcinoma-controversies and challenges. Nat. Rev. Gastroenterol. 
Hepatol. 2011;8(4):189-200. 
44. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of Prophylactic Low-Molecular Weight 
Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the 
CONKO-004 Trial. J Clin Oncol 2015;1-8. 
45. Pillwein K, Fuiko R, Slavc I, et al. Hyaluronidase additional to standard chemotherapy 
improves outcome for children with malignant brain tumors. Cancer Lett 
1998;131:101-108. 
46. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates 
physical barriers to treatment of pancreatic ductal carcinoma. Cancer Cell 
2012;21:418-29. 
47. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in 
pancreas cancer. Br J Cancer 2013;108:1-8. 
48. Ropponen K, Tammi M, Parkkinen J, et al. Tumor cell-associated hyaluronan as an 
unfavorable prognostic factor in colorectal cancer. Cancer Res 1998;58:342-347. 
49. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma 
Incidence in the U.S.: Intrahepatic Disease on the Rise. The Oncologist. 
2016;21(5):594-599. 
50. Setälä LP, Tammi MI, Tammi RH, et al. Hyaluronan expression in gastric cancer cells is 
associated with local and nodal spread and reduced survival rate. Br J Cancer 
1999;79:1133-1138. 
51. Shaffer EA. Gallbladder Cancer: The Basics. J Gastroenterol Hepatol 
2008;4(10):737-741. 
52. Shepard HM. Breaching the Castle Walls: Hyaluronan Depletion as a Therapeutic 
Approach to Cancer Therapy. Front Oncol. 2015;5:192. 
53. Shuster S, Frost GI, Csoka AB, et al. Hyaluronidase reduces human breast cancer 
xenografts in SCID mice. Int J Cancer 2002;102:192-197. 
54. Simpson MA, Wilson CM, McCarthy JB. Inhibition of prostate tumor cell hyaluronan 
synthesis impairs subcutaneous growth and vascularization in immunocompromised 
mice. Amer J Path 2002;161:849-857. 
55. Sironen RK, Tammi M, Tammi R, et al. Hyaluronan in human malignancies. Exp Cell 
Res 2011;317:383-391. 
56. Spruss T, Bernhardt G, Schonenberger H, et al. Hyaluronidase significantly enhances the 
efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin 
Oncol 1995;121:193-202. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
57. Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor 
hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 
2010;9:3052-3064. 
58. TECENTRIQ® US Prescribing Information, revised March 2018. 
59. Toole BP, Slomiany MG. Hyaluronan: a constitutive regulator of chemoresistance and 
malignancy in cancer cells. Semin Cancer Biol 2008 Aug;18(4):244-50. 
60. Udabage L, Brownlee GR, Waltham M, et al. Antisense-mediated suppression of 
hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. 
Cancer Res 2005;65:6139-6150. 
61. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus Gemcitabine versus Gemcitabine for 
Biliary Tract Cancer. New England Journal of Medicine. 2010;362(14):1273-1281. 
62. Whatcott CJ, Jiang P, Watanabe A, et al. Hyaluronan deposition correlates with poor 
survival in pancreatic cancer Abstract LB-307, AACR National Meeting. Cancer Res 
2011;71 Suppl. 1. 
63. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the 
Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response 
Criteria. Clin Cancer Res 2009;15(23):7412-7420. 
64. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current Management of Gallbladder 
Carcinoma. The Oncologist. 2010;15(2):168-181. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
17. 
APPENDICES 
APPENDIX A. EASTERN COOPERATIVE ONCOLOGY GROUP 
PERFORMANCES STATUS 
Activity Status 
Description 
0 
Asymptomatic, fully active, and able to carry on all predisease performance 
without restrictions. 
1 
Symptomatic, fully ambulatory but restricted in physical strenuous activity and 
able to carry out performance of a light or sedentary nature, e.g., light 
housework, office work. 
2 
Symptomatic, ambulatory and capable of self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours, but not 
bedridden. 
3 
Symptomatic, capable of only limited self-care, confined to a bed/chair more 
than 50% of waking hours, but not bedridden. 
4 
Completely disabled. Cannot carry on self-care. Totally bedridden. 
5 
Dead 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
APPENDIX B. RESPONSE EVALUATION CRITERIA IN SOLID 
TUMORS VERSION 1.1 (RECIST V1.1)  
Selected sections from RECIST v1.1 (Eisenhauer 2009) are presented below, with slight 
modifications from the original publication and the addition of explanatory text as needed for 
clarity. 
Tumor Measurability 
At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as 
described below. All measurable and non-measurable lesions should be assessed at screening and 
at subsequent protocol-specified tumor assessment timepoints. Additional assessments may be 
performed as clinically indicated for suspicion of progression. 
Definition of Measurable Lesions 
Tumor Lesions 
Tumor lesions must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size as follows:  
10 mm by CT or MRI scan (CT/MRI scan slice thickness/interval ≤5 mm) 
Malignant Lymph Nodes 
To be considered pathologically enlarged and measurable, a lymph node must be ≥15 mm in the 
short axis when assessed by CT scan (CT scan slice thickness recommended to be ≤5 mm). 
At baseline and follow-up, only the short axis will be measured and followed. Additional 
information on lymph node measurement is provided below (see "Identification of Target and 
Non-Target Lesions" and "Calculation of Sum of Diameters"). 
Definition of Non-Measurable Lesions 
Non-measurable tumor lesions encompass small lesions (longest diameter <10 mm or 
pathological lymph nodes with short axis ≥10 mm but <15 mm) as well as truly non-measurable 
lesions. Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural 
or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, 
peritoneal spread, and abdominal mass/abdominal organomegaly identified by physical 
examination that is not measurable by reproducible imaging techniques. 
Special Considerations Regarding Lesion Measurability 
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment, as outlined below. 
Bone Lesions: 
Technetium-99m bone scans, sodium fluoride positron emission tomography scans, and plain 
films are not considered adequate imaging techniques for measuring bone lesions. However, 
these techniques can be used to confirm the presence or disappearance of bone lesions. 
Lytic bone lesions or mixed lytic-blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are non-measurable. 
Cystic Lesions: 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
malignant lesions (neither measurable nor non-measurable) because they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered measurable lesions if 
they meet the definition of measurability described above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions. 
Lesions with Prior Local Treatment: 
Tumor lesions situated in a previously irradiated area or in an area subjected to other loco-
regional therapy are usually not considered measurable unless there has been demonstrated 
progression in the lesion. 
Methods for Assessing Lesions 
All measurements should be recorded in metric notation, using calipers if clinically assessed. All 
baseline evaluations should be performed on CT/MRI scans obtained during the screening period 
of the study.  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during the study. Imaging-based evaluation is 
required for this study. 
Chest X-Ray 
Chest CT or Chest MRI assessment of lesions are to be used in this study for radiographic 
response evaluation and not chest X-rays. New lesions seen on chest X-ray should be confirmed 
by CT or MRI (the same modality as was used at baseline/screening). 
CT and MRI Scans 
CT is the best currently available and reproducible method to measure lesions selected for 
response assessment. In this guideline, the definition of measurability of lesions on CT scan is 
based on the assumption that CT slice thickness is ≤5 mm. When CT scans have slice thickness 
of >5 mm, the minimum size for a measurable lesion should be twice the slice thickness. MRI is 
also acceptable.  
If prior to enrollment it is known that a patient is unable to undergo CT scans with IV contrast 
because of allergy or renal insufficiency, the decision as to whether a non-contrast CT or MRI 
(without IV contrast) will be used to evaluate the patient at baseline and during the study should 
be guided by the tumor type under investigation and the anatomic location of the disease. For 
patients who develop contraindications to contrast after baseline contrast CT is done, the 
decision as to whether non-contrast CT or MRI (enhanced or non-enhanced) will be performed 
should also be based on the tumor type and the anatomic location of the disease, and should be 
optimized to allow for comparison with prior studies, if possible. Each case should be discussed 
with the radiologist to determine if substitution of these other approaches is possible and, if not, 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
the patient should be considered not evaluable from that point forward. Care must be taken in 
measurement of target lesions and interpretation of non-target disease or new lesions on a 
different modality, because the same lesion may appear to have a different size using a new 
modality. 
Endoscopy, Laparoscopy, Ultrasound, Tumor Markers, Cytology, Histology 
Endoscopy, laparoscopy, ultrasound, tumor markers, cytology, and histology cannot be utilized 
for objective tumor evaluation. 
Assessment of Tumor Burden 
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at baseline and use this as a comparator for subsequent measurements. 
Identification of Target and Non-Target Lesions 
When more than one measurable lesion is present at baseline, all lesions up to a maximum of 
five lesions total (and a maximum of two lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. This means 
that, for instances in which patients have only one or two organ sites involved, a maximum of 
two lesions (one site) and four lesions (two sites), respectively, will be recorded. Other lesions 
(albeit measurable) in those organs will be considered non-target lesions. 
Target lesions should be selected on the basis of their size (lesions with the longest diameter) and 
be representative of all involved organs, but in addition should lend themselves to reproducible 
repeated measurements. It may be the case that, on occasion, the largest lesion does not lend 
itself to reproducible measurement, in which circumstance the next largest lesion that can be 
measured reproducibly should be selected. 
Lymph nodes merit special mention because they are normal anatomical structures that may be 
visible by imaging even if not involved by tumor. As noted above, pathological nodes that are 
defined as measurable and may be identified as target lesions must meet the criterion of a short 
axis of ≥15 mm by CT scan. Only the short axis of these nodes will contribute to the baseline 
sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is 
involved by solid tumor. Lymph node size is normally reported as two dimensions in the plane in 
which the image is obtained (for CT, this is almost always the axial plane; for MRI, the plane of 
acquisition may be axial, sagittal, or coronal). The smaller of these measures is the short axis. 
For example, an abdominal node that is reported as being 20 mm × 30 mm has a short axis 
of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be 
recorded as the node measurement. All other pathological nodes (those with short axis ≥10 mm 
but <15 mm) should be considered non-target lesions. Nodes that have a short axis of <10 mm 
are considered non-pathological and should not be recorded or followed. 
All lesions (or sites of disease) not selected as target lesions (measurable or non-measurable), 
including pathological lymph nodes, should be identified as non-target lesions and should also be 
recorded at baseline. Measurements are not required. It is possible to record multiple non-target 
lesions involving the same organ as a single item on the CRF (e.g., "multiple enlarged pelvic 
lymph nodes" or "multiple liver metastases"). 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Calculation of Sum of Diameters 
A sum of the diameters (longest diameter for non-lymph node lesions, short axis for lymph node 
lesions) will be calculated for all target lesions at baseline and at each subsequent tumor 
assessment as a measure of tumor burden. 
Measuring Lymph Nodes 
Lymph nodes identified as target lesions should always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline examination), even if the node 
regresses to < 10 mm during the study. Thus, when lymph nodes are included as target lesions, 
the sum of diameters may not be zero even if complete response criteria are met, because a 
normal lymph node is defined as having a short axis of <10 mm. 
Measuring Lesions That Become Too Small to Measure 
During the study, all target lesions (lymph node and non-lymph node) recorded at baseline 
should have their actual measurements recorded at each subsequent evaluation, even when very 
small (e.g., 2 mm). However, sometimes lesions or lymph nodes that are recorded as target 
lesions at baseline become so faint on CT scan that the radiologist may not feel comfortable 
assigning an exact measurement and may report them as being too small to measure. When this 
occurs, it is important that a value be recorded on the CRF, as follows: 
If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement 
should be recorded as 0 mm. 
If the lesion is believed to be present and is faintly seen but too small to measure, a default value 
of 5 mm should be assigned. (Note: It is less likely that this rule will be used for lymph nodes 
because they usually have a definable size when normal and are frequently surrounded by fat 
such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly 
seen but too small to measure, a default value of 5 mm should be assigned). 
To reiterate, however, if the radiologist is able to provide an actual measurement, that should be 
recorded, even if it is <5 mm. 
Measuring Lesions That Split or Coalesce on Treatment 
When non-lymph node lesions fragment, the longest diameters of the fragmented portions should 
be added together to calculate the sum of diameters. Similarly, as lesions coalesce, a plane 
between them may be maintained that would aid in obtaining maximal diameter measurements 
of each individual lesion. If the lesions have truly coalesced such that they are no longer 
separable, the vector of the longest diameter in this instance should be the maximum longest 
diameter for the coalesced lesion. 
Evaluation of Non-Target Lesions 
Measurements are not required for non-target lesions, except that malignant lymph node non-
target lesions should be monitored for reduction to <10 mm in short axis. Non-target lesions 
should be noted at baseline and should be identified as "present" or "absent" and (in rare cases) 
may be noted as "indicative of progression" at subsequent evaluations. In addition, if a lymph 
node lesion shrinks to a non-malignant size (short axis <10 mm), this should be captured on the 
CRF as part of the assessment of non-target lesions. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Response Criteria 
Criteria for Target Lesions 
Definitions of the criteria used to determine objective tumor response for target lesions are 
provided below: 
Complete Response (CR): Disappearance of all target lesions 
Any pathological lymph nodes must have reduction in short axis to <10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of diameters of all target lesions, 
taking as reference the baseline sum of diameters, in the absence of CR 
Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference the smallest sum of diameters on or prior to the current assessment (including 
baseline)  
In addition to the relative increase of 20%, the sum of diameters must also demonstrate an 
absolute increase of ≥5 mm. 
Stable Disease (SD): Neither sufficient shrinkage to qualify for CR or PR nor sufficient increase 
to qualify for PD 
Criteria for Non-Target Lesions 
Definitions of the criteria used to determine the tumor response for the group of non-target 
lesions are provided below. While some non-target lesions may actually be measurable, they 
need not be measured and instead should be assessed only qualitatively at the timepoints 
specified in the schedules of activities. 
CR: Disappearance of all non-target lesions and (if applicable) normalization of tumor marker 
level 
All lymph nodes must be non-pathological in size (<10 mm short axis). 
Non-CR/Non-PD: Persistence of one or more non-target lesions and/or (if applicable) 
maintenance of tumor marker level above the normal limits 
PD: Unequivocal progression of existing non-target lesions 
Special Notes on Assessment of Progression of Non-Target Lesions 
Patients with Measurable and Non-Measurable Disease 
For patients with both measurable and non-measurable disease to achieve unequivocal 
progression on the basis of the non-target lesions, there must be an overall level of substantial 
worsening in non-target lesions even in the presence of SD, PR or CR in target lesions. A modest 
increase in the size of one or more non-target lesions is usually not sufficient to qualify for 
unequivocal progression status. The designation of overall progression solely on the basis of 
changes in non-target lesions in the face of SD, PR or CR in target lesions will be extremely rare. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
New Lesions 
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important. There are no specific criteria for the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal, that is, not attributable to differences in scanning technique, change in imaging 
modality, or findings thought to represent something other than tumor (for example, some "new" 
bone lesions may be simply healing or flare of preexisting lesions). This is particularly important 
when the patient’s baseline lesions show PR or CR. For example, necrosis of a liver lesion may 
be reported on a CT scan report as a "new" cystic lesion, which it is not. All lymph nodes 
considered as new lesions must be pathological in size (≥10 mm short axis). 
A lesion identified during the study in an anatomical location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression. 
If a new lesion is equivocal, for example because of its small size, continued therapy and follow-
up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is 
definitely a new lesion, progression should be declared using the date of the initial scan. 
Criteria for Overall Response at a Single Timepoint 
Table 13 provides a summary of the overall response status calculation at each response 
assessment timepoint for patients who have measurable disease at baseline. 
Table 13: 
Criteria for Overall Response at a Single Timepoint: Patients with Target 
Lesions (With or Without Non-Target Lesions) 
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR/NA 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not all evaluated 
No 
PR 
PR 
Non-PD or not all 
evaluated or NA 
No 
PR 
SD 
Non-PD or not all 
evaluated or NA 
No 
SD 
Not all evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or no 
PD 
Any 
PD 
Yes or no 
PD 
Any 
Any 
Yes 
PD 
Abbreviations: CR = complete response; NA = not applicable (i.e., no non-target lesions identified at baseline); 
NE = not evaluable; PD = progressive disease; PR = partial response; SD = stable disease. 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Missing Assessments and Not-Evaluable Designation 
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint. If measurements are made on only a subset of target lesions at a 
timepoint, usually the case is also considered not evaluable at that timepoint, unless a convincing 
argument can be made that the contribution of the individual missing lesions would not change 
the assigned timepoint response. This would be most likely to happen in the case of PD. For 
example, if a patient had a baseline sum of 50 mm with three measured lesions and during the 
study only two lesions were assessed, but those gave a sum of 80 mm, the patient will have 
achieved PD status, regardless of the contribution of the missing lesion. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
APPENDIX C. NEW YORK HEART ASSOCIATION CLASSIFICATIONS 
1994 Revisions to Classification of Functional Capacity and Objective Assessment of Patients 
with Diseases of the Heart 
Functional Capacity 
Objective Assessment 
Class I. Patients with cardiac disease but without 
resulting limitation of physical activity. Ordinary 
physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain. 
A. No objective evidence of cardiovascular 
disease. 
Class II. Patients with cardiac disease resulting in 
slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal 
pain. 
B. Objective evidence of minimal cardiovascular 
disease. 
Class III. Patients with cardiac disease resulting in 
marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary activity 
causes fatigue, palpitation, dyspnea, or anginal 
pain. 
C. Objective evidence of moderately severe 
cardiovascular disease. 
Class IV. Patients with cardiac disease resulting in 
inability to carry on any physical activity without 
discomfort. Symptoms of heart failure or the 
anginal syndrome may be present even at rest. If 
any physical activity is undertaken, discomfort is 
increased. 
D. Objective evidence of severe cardiovascular 
disease. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
APPENDIX D. IMMUNE-MODIFIED RESPONSE EVALUATION 
CRITERIA IN SOLID TUMORS (IMMUNE-MODIFIED 
RECIST) 
Conventional response criteria (e.g., standard RECIST) may not be adequate to characterize the 
anti-tumor activity of immunotherapeutic agents like atezolizumab, which can produce delayed 
responses that may be preceded by initial apparent radiographic progression, including the 
appearance of new lesions. Therefore, Immune-Modified response criteria (i.e., 
immune-modified RECIST) have been developed to incorporate new lesions into the assessment 
of total tumor burden and allow radiographic progression to be confirmed at a subsequent 
assessment. Immune-Modified response criteria, in addition to standard RECIST v1.1, will be 
used to assess radiographic disease response in subjects receiving PEGCISGEMATEZO 
treatment.  
All criteria for selecting and following target and non-target lesions are per 
standard RECIST v1.1 (Appendix B). The sum of diameters are calculated at baseline and each 
timepoint for target lesions. Tumor burden, which includes the sum of the sum of diameters of all 
target lesions and the sum of diameters of new target lesions (up to 5 new lesions [no more than 
2 per organ]), is calculated at each post-baseline timepoint. Partial Response (PR) and 
progressive disease (PD) determination at each post-baseline timepoint is then based on the 
percent change in tumor burden from baseline (PR) or nadir (PD) as outlined in Table 14. 
Immune-Modified RECIST requires confirmation of PD with an additional scan obtained no 
sooner than 28 days after the initial scan that determined disease progression.  
Immune-Modified RECIST criteria, as described within this appendix, were adapted using 
RECIST v1.1 (Eisenhauer 2009) by Nishino et al. (Nishino 2014), in the same manner that 
Immune-Related Response Criteria were adapted from WHO criteria and RECIST v1.1 by 
Wolchok et al. (Wolchok 2009). When not otherwise specified, RECIST v1.1 conventions will 
apply. Differences between Immune-Modified RECIST and RECIST v1.1 are summarized in 
Table 14. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
Table 14: 
Comparison of RECIST v1.1 and Immune-Modified RECIST 
 
RECIST v1.1 
Immune-Modified RECIST 
Measurable new lesions 
Always represent progression 
Incorporated into the total tumor 
burdena and followed 
Non-measurable new 
lesions 
Always represent progression 
Do not represent progression, but 
preclude CR 
Non-target lesions 
Contribute to defining CR, 
PR, SD, and PD 
Contribute to defining CR only 
CR 
Disappearance of all lesions 
Disappearance of all lesions 
PR 
≥30% decrease in sum of 
diameters of target lesions 
from baseline, in the absence 
of CR, new lesions, and 
unequivocal progression in 
non-target lesions 
≥30% decrease in tumor burdena 
from baseline in the absence of CR 
PD 
≥20% increase in sum of 
diameters of target lesions 
from nadir (smallest sum of 
diameters on or prior to 
current assessment) with at 
least 5 mm absolute increase, 
unequivocal progression in 
non-target lesions, and/or 
appearance of new lesions 
≥20% increase in tumor burdena 
from nadir (smallest tumor burden 
on or prior to current assessment) 
with at least 5 mm absolute 
increase 
SD 
Neither sufficient shrinkage 
to qualify for CR or PR nor 
sufficient increase to qualify 
for PD 
Neither sufficient shrinkage to 
qualify for CR or PR nor sufficient 
increase to qualify for PD 
Abbreviations: CR = complete response; PD = progressive disease; PR = partial response; RECIST = Response 
Evaluation Criteria in Solid Tumors; SD = stable disease. 
a Tumor burden is the sum of diameters of target lesions and measurable new lesions. Up to 5 new measurable 
lesions (no more than 2 per organ) may be selected. Tumor burden at baseline is the sum of diameters of target 
lesions identified at baseline. 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
APPENDIX E. ANAPHYLAXIS PRECAUTIONS 
EQUIPMENT NEEDED 
• Tourniquet 
• Oxygen 
• Epinephrine for subcutaneous, intravenous, and/or endotracheal use in accordance 
with standard practice 
• Antihistamines 
• Corticosteroids 
• Intravenous infusion solutions, tubing, catheters, and tape 
PROCEDURES 
In the event of a suspected anaphylactic reaction during study treatment infusion, the following 
procedures should be performed: 
1. Stop the study treatment infusion. 
2. Apply a tourniquet proximal to the injection site to slow systemic absorption of study 
treatment. Do not obstruct arterial flow in the limb. 
3. Maintain an adequate airway. 
4. Administer antihistamines, epinephrine, or other medications as required by patient status 
and directed by the physician in charge. 
5. Continue to observe the patient and document observations 
 

Halozyme, Inc. 
Protocol HALO-110-101 Amendment 3 
 
APPENDIX F. MANAGEMENT OF ATEZOLIZUMAB-SPECIFIC 
ADVERSE EVENTS